

CITATION REPORT

List of articles citing

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

DOI: 10.1126/science.2470152
Science, 1989, 244, 707-12.

Source: <https://exaly.com/paper-pdf/20724032/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2314	Cancer Drug Target Identification by SAGE, LongSAGE, and Digital Karyotyping. 2005 , 19-30		
2313	The taxonomic status of <i>Serratia Plymuthica</i> (Lehmann and Neumann) Bergey et al. and of <i>Serratia indica</i> (Eisenberg) Bergey et al.. 1960 , 10, 247-254		2
2312	Breast cancer and a proto-oncogene. 1989 , 299, 1061-2		31
2311	Developmental biology and pathobiology: fusion through molecular biology. 1989 , 68, 1790-1		1
2310	Gene signals relapse of breast, ovarian cancers. <i>Science</i> , 1989 , 244, 654-5	33.3	8
2309	Polypeptide composition of normal and neoplastic human breast tissues and cells analyzed by two-dimensional gel electrophoresis. 1989 , 14, 337-48		12
2308	Amplification of c-myc and c-erbB-2 proto-oncogenes in human solid tumors: frequency and clinical significance. 1989 , 44, 802-5		32
2307	Gene amplification associated with the dominant cob-354 cobalt resistance trait in <i>Dictyostelium discoideum</i> . 1989 , 220, 25-32		10
2306	Association of elevated expression of the c-erbB-2 protein with spread of breast cancer. 1989 , 80, 1192-8		34
2305	Epidermal growth factor and related molecules. 1989 , 1, 1243-6		60
2304	A paradigm for oncogene complementation in human breast cancer. 1989 , 140, 571-91		11
2303	Transforming growth factors in human breast cancer. 1989 , 43, 661-7		15
2302	Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. 1989 , 1, 1246-50		92
2301	Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. 1989 , 86, 9193-7		622
2300	Metastatic diversity in human prostatic carcinoma: implications of growth factors and growth factor receptors for the metastatic phenotype. 1989 , 8, 231-49		10
2299	Cancer biology for individualized therapy: correlation of growth fraction index in native-state histoculture with tumor grade and stage. 1990 , 87, 691-5		29
2298	Transformation of NIH 3T3 cells by overexpression of the normal coding sequence of the rat neu gene. 1990 , 10, 3247-52		81

2297	Amplification of the MYCN oncogene and deletion of putative tumour suppressor gene in human neuroblastomas. 1990 , 1, 41-6	25
2296	Molecules, cancer, and the surgeon. A review of molecular biology and its implications for surgical oncology. 1990 , 212, 3-13	8
2295	cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. 1990 , 10, 6316-24	211
2294	Multiple cis- and trans-acting elements involved in regulation of the neu gene. 1990 , 10, 6306-15	53
2293	Oncogene amplification and expression. Importance of methodologic considerations. 1990 , 94, 240-1	12
2292	Ki67 index and S-phase fraction in human breast carcinomas. Comparison and correlations with prognostic factors. 1990 , 94, 681-6	67
2291	Soci�t� de Biochimie Belge Vereninging Voor Biochemie: Part II. 1990 , 98, B70-B163	1
2290	Heterogeneity and natural history of hereditary breast cancer. Surgical implications. 1990 , 70, 753-74	14
2289	Neu (C-erbB-2) oncogene in breast cancer and its possible association with the risk of distant metastases. A retrospective study and review of literature. 1990 , 29, 931-4	20
2288	DNA isolation and Southern analysis: a clinician's view. 1990 , 299, 356-60	3
2287	The Epidermal Growth Factor. 1990 , 11, 229-261	64
2286	Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis. 1990 , 62, 585-90	53
2285	Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer: its correlation with gene amplification and long-term survival of patients. 1990 , 81, 327-32	74
2284	c-erbB-2 and c-erbA-1 (ear-1) gene amplification and c-erbB-2 protein expression in Japanese breast cancers: their relationship to the histology and other disease parameters. 1990 , 81, 620-4	19
2283	Functional immunocytopathology and the diagnosis of bone marrow micrometastases. 1990 , 1, 223-31	3
2282	c-erbB-2 oncoprotein expression in mammary and extramammary Paget's disease: an immunohistochemical study. 1990 , 17, 243-7	63
2281	c-erbB-2 proto-oncogene product. 1990 , 16, 105-6	3
2280	Expression of c-erbB2 and c-myc in squamous epithelia and squamous cell carcinomas of the head and neck and the lower female genital tract. 1990 , 19, 408-13	40

2279	Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression. 1990 , 62, 430-5	49
2278	Expression of c-erbB-2 protein product in bladder cancer. 1990 , 62, 764-5	53
2277	Immunohistochemical analysis of c-erbB-2 oncogene product and epidermal growth factor receptor expression in human urinary bladder carcinomas. 1990 , 40, 322-6	3
2276	c-erbB2 expression in correlation to other biological parameters of breast cancer. 1990 , 116, 15-20	58
2275	Nobel Lecture. Retroviruses and oncogenes II. 1990 , 10, 473-91	16
2274	A monoclonal antibody that inhibits the action of GM-CSF on normal but not leukaemic progenitors. 1990 , 14, 637-44	5
2273	Expression of c-myc and c-fos mRNA in colorectal carcinoma in man. 1990 , 59, 165-71	16
2272	Biological response modifiers in the management of patients with breast cancer. 1990 , 16, 67-87	2
2271	Immunohistochemical investigation and northern blot analysis of c-erbB-2 expression in normal, premalignant and malignant tissues of the corpus and cervix uteri. 1990 , 417, 477-84	40
2270	Intestinal differentiation in ovarian mucinous tumours. 1990 , 417, 197-201	4
2269	Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma--a detailed morphological analysis. 1990 , 161, 7-14	123
2268	In situ distribution of transforming growth factor alpha in normal human tissues and in malignant tumours of the ovary. 1990 , 162, 223-30	49
2267	c-erbB-2 oncogene expression in ovarian cancer. 1990 , 162, 231-7	83
2266	Gynecologic tumor markers. 1990 , 6, 305-13	14
2265	Ovarian cancer. 1990 , 6, 328-38	6
2264	Chromosomal abnormalities in human breast cancer. 1990 , 9, 35-43	31
2263	The gene for 17 beta-hydroxysteroid dehydrogenase maps to human chromosome 17, bands q12-q21, and shows an RFLP with Scal. 1990 , 85, 473-6	21
2262	Retroviren und Onkogene II (Nobel-Vortrag). 1990 , 102, 765-773	

2261	Amplification of cellular oncogenes: a predictor of clinical outcome in human cancer. 1990 , 1, 181-93	172
2260	Cytogenetic and molecular analysis of human male germ cell tumors: chromosome 12 abnormalities and gene amplification. 1990 , 1, 289-300	133
2259	Cytogenetics and DNA amplification in colorectal cancers. 1990 , 2, 63-70	29
2258	Frequent rearrangement of chromosomal bands 1p22 and 11q13 in squamous cell carcinomas of the head and neck. 1990 , 2, 198-204	66
2257	Analysis of c-erbB-2 protein expression in conjunction with DNA content using multiparameter flow cytometry. 1990 , 11, 522-32	11
2256	The neu-oncogene protein as a predictive factor for haematogenous metastases in breast cancer patients. 1990 , 45, 55-8	68
2255	Rat monoclonal antibodies to the external domain of the product of the C-erbB-2 proto-oncogene. 1990 , 45, 320-4	41
2254	The locus of the polymorphic epithelial mucin (PEM) tumour antigen on chromosome 1q21 shows a high frequency of alteration in primary human breast tumours. 1990 , 45, 431-5	71
2253	Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. 1990 , 45, 457-61	198
2252	Over-expression of the epidermal growth factor receptor in human breast cancer cells fails to induce an estrogen-independent phenotype. 1990 , 46, 712-8	30
2251	Mutations in human breast cancer cells: dominantly-acting oncogenes and tumor suppressor genes suggest strategies for targeted interference. 1990 , 5, 40-6	8
2250	Molecular lesions in breast cancer. 1990 , 5, 47-50	10
2249	The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. 1990 , 5, 55-61	102
2248	Regulation by EGF is maintained in an overexpressed chimeric EGFR/neu receptor tyrosine kinase. 1990 , 42, 123-33	11
2247	Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. 1990 , 3, 254-7	93
2246	Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/neu antigen. 1990 , 3, 350-62	86
2245	The role of the pathologist in breast cancer management. 1990 , 66, 1363-72	17
2244	Current concepts in quantitative molecular hybridization. 1990 , 23, 261-6	8

2243	The future anatomic pathology laboratory for molecular diagnosis and prognosis: circa 1990-95. 1990 , 23, 295-9	0
2242	Monoclonal antibodies in cancer diagnosis. 1989 , 2, 697-701	2
2241	Immunohistochemical Expression of c-erbB-2 in Human Breast Cancer by Monoclonal Antibody: Correlation with Lymph Node and Er Status. 1990 , 76, 461-464	8
2240	Neu (c-erbB-2), a tumor marker in carcinoma of the female breast. 1990 , 58, 297-303	18
2239	Biochemical markers as prognostic indices in breast cancer. 1990 , 36, 188-191	17
2238	Cellular and molecular aspects of neurocarcinogenesis. 1990 , 18, 193-203	11
2237	Breast cancer: oncogenes and suppressor genes. 1990 , 1, 242-3	3
2236	c-erbB-2 protein expression in node negative breast cancer. 1990 , 1, 263-8	27
2235	Assessing the risk of recurrence in breast cancer. 1990 , 322, 329-31	9
2234	[Significance of neu-protein for prognosis of breast cancers]. 1990 , 50, 771-6	4
2233	Studies of the HER-2/neu proto-oncogene in human breast cancer. 1990 , 8, 253	40
2232	H-ras activation and ras p21 expression in bladder tumors induced in F344/NCr rats by N-butyl-N-(4-hydroxybutyl)nitrosamine. 1990 , 11, 2233-8	14
2231	How to use prognostic factors in axillary node-negative breast cancer patients. 1990 , 82, 1006-15	266
2230	Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. <i>Science</i> , 1990 , 249, 1552-5	333 266
2229	The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade. 1990 , 87, 6054-7	44
2228	Ultrastructural localization of c-erbB-2 gene product in transitional cell carcinoma of the urinary tract. 1990 , 14, 399-405	8
2227	Polymerase chain reaction based assay to detect allelic loss in human DNA: loss of beta-interferon gene in chronic myelogenous leukemia. 1990 , 18, 993-8	75
2226	The c-erbB-2 protein. 1990 , 14, iii-iv	1

2225	Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. 1990 , 87, 4499-503	131
2224	Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. 1990 , 29, 11024-8	206
2223	Cancer genes: current status, future prospects, and applications in radiotherapy/oncology. 1990 , 19, 197-218	18
2222	Growth factors and oncogenes in human solid tumors: clinical aspects. 1990 , 44, 25-34	4
2221	Oncogenes, antioncogenes, and the regulation of cell growth. 1990 , 1, 248-53	9
2220	Stimulatory and inhibitory growth factors and breast cancer. 1990 , 37, 795-803	21
2219	The role of glutathione in drug resistance. 1990 , 17 Suppl A, 45-50	30
2218	Absence of abnormalities of the c-erbB-1 and c-erbB-2 proto-oncogenes in human thyroid neoplasia. 1990 , 26, 777-9	38
2217	The significance of histology in non-small cell lung cancer. 1990 , 17, 409-25	21
2216	Growth factors and oncogenes in breast cancer. 1990 , 2, 1-13	21
2215	Expression of c-erbB-2 protein detected in adenocarcinoma arising from parotid pleomorphic adenoma. 1990 , 17, 115-20	5
2214	Growth factor-regulated pathways in epithelial cell proliferation. 1990 , 142, S7-10	43
2213	neu oncogene protein and epidermal growth factor receptor are independently expressed in benign and malignant breast tissues. 1990 , 21, 750-8	62
2212	Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. 1990 , 21, 1164-7	145
2211	Protooncogene amplification and tumor ploidy in human ovarian neoplasms. 1990 , 21, 382-91	61
2210	ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids. 1990 , 132, 73-80	32
2209	Oncogene alterations in endometrial carcinoma. 1990 , 38, 364-6	52
2208	Chromosome abnormalities in human epithelial ovarian malignancies. 1990 , 38, 473-7	38

2207	Signal transduction by receptors with tyrosine kinase activity. 1990 , 61, 203-12	5064
2206	Ovarian cancer, part II: Treatment. 1990 , 2, 34-63	
2205	Clinical significance of oncogenes and growth factors in ovarian carcinomas. 1990 , 37, 855-62	33
2204	Regulation of proliferation, invasion and growth factor synthesis in breast cancer by steroids. 1990 , 37, 305-16	90
2203	Oncogenic proteins new targets for chemotherapeutic agents against cancer. 1990 , 4, 401-22	1
2202	Estrogen receptor gene amplification is found in some estrogen receptor-positive human breast tumors. 1990 , 166, 601-7	31
2201	Mammalian gene studies. 1990 , 1, 209-39	
2200	E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. 1991 , 113, 173-85	1328
2199	Enhanced expression of the cellular oncogene MYCN and progression of human neuroblastoma. 1991 , 31, 329-38	7
2198	Tumour markers and oncogenes in lung cancer. 1991 , 27, 1323-7	7
2197	Growth factors and oncogenes. 1991 , 5, 655-69	
2196	Monoclonal antibodies for radioimmunosintigraphy of breast cancer. 1991 , 18, 437-43	1
2195	Systemic adjuvant therapy in women with resected node-negative breast cancer. 1991 , 66, 805-13	1
2194	Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. 1991 , 164, 1038-42; discussion 1042-3	178
2193	Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines. 1991 , 165, 640-6	58
2192	Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. 1991 , 164, 15-21	229
2191	Transformation and amplification of the K-fgf proto-oncogene in NIH-3T3 cells, and induction of metastatic potential. 1991 , 1097, 103-10	7
2190	MDR1 gene expression and prognostic factors in primary breast carcinomas. 1991 , 27, 1352-5	42

2189	Adjuvant systemic therapy of stage I and II breast cancer. 1991 , 7, 175-86	2
2188	Chromosome aberrations and cancer. <i>Science</i> , 1991 , 254, 1153-60	333 495
2187	Multiparameter flow-cytometric quantitation of epidermal growth factor receptor and c-erbB-2 oncoprotein in normal and neoplastic tissues of the female genital tract. 1991 , 42, 256-64	40
2186	Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. 1991 , 64, 327-36	2428
2185	Tyrphostins as molecular tools and potential antiproliferative drugs. 1991 , 12, 171-4	110
2184	Protooncogenes in endometriotic and endometrial tissue. 1991 , 626, 276-83	25
2183	A retrospective analysis of breast cancer based on outcome differences. 1991 , 22, 475-80	12
2182	Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. 1991 , 22, 254-8	79
2181	Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. 1991 , 164, 669-74	182
2180	Les facteurs pronostiques biologiques dans le cancer du sein. 1991 , 6, 23-28	
2179	Molecular and Clinical Advances in Anticancer Drug Resistance. 1991 ,	2
2178	[Expressions of oncogene products in adenoid cystic carcinomas of salivary glands: immunohistochemical study]. 1991 , 58, 696-717	7
2177	Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma.. 1991 , 10, 2077-2086	90
2176	Why should the clonogenic cell assay be prognostically important in ovarian cancer?. 1991 , 9, 368-70	2
2175	Use of immunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder. 1991 , 20, 238-42	42
2174	Molecular determinants of metastatic transformation. 1991 , 93, 91-5	6
2173	c-erbB-2 oncogene as a prognostic marker in breast cancer. 1991 , 63, 328-32	136
2172	DNA, RNA and immunohistochemical characterization of the HER-2/neu oncogene in transitional cell carcinoma of the bladder. 1991 , 146, 1398-401	35

2171	Expression of c-erbB-2 gene product in urinary bladder cancer. 1991 , 145, 423-7	103
2170	The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. 1991 , 63, 444-6	119
2169	Expression of growth factor receptors in human brain tumours. 1991 , 63, 227-33	62
2168	Cloning, expression, and biological effects of erbB-2/neu gene in mammalian cells. 1991 , 198, 272-7	6
2167	Biological effects of monoclonal antireceptor antibodies reactive with neu oncogene product, p185neu. 1991 , 198, 277-90	5
2166	Quantification of erbB-2/neu levels in tissue. 1991 , 198, 290-300	10
2165	Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene. 1991 , 11, 1745-50	84
2164	Identification and characterization of a novel enhancer for the rat neu promoter. 1991 , 11, 1875-82	26
2163	Expression of haptoglobin-related protein in primary and metastatic breast cancers. A longitudinal study of 48 fatal tumors. 1991 , 96, 238-42	17
2162	Expression of c-erbB-2 oncoprotein in mammary and extramammary Paget's disease. 1991 , 96, 243-7	98
2161	Novel DNA sequences at chromosome 10q26 are amplified in human gastric carcinoma cell lines: molecular cloning by competitive DNA reassociation. 1991 , 19, 117-23	13
2160	Expression of c-erbB-2 in human pancreatic adenocarcinomas. 1991 , 59, 46-52	59
2159	Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. 1991 , 11, 979-86	98
2158	Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. 1991 , 88, 8691-5	180
2157	Characterization of a neu/c-erbB-2 protein-specific activating factor. 1991 , 88, 8582-6	65
2156	c-erbB-2 oncoprotein expression in primary and advanced breast cancer. 1991 , 63, 439-43	202
2155	c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. 1991 , 63, 434-8	285
2154	Expression of c-myc, epidermal growth factor receptor and c-erbB-2 in human endometrial carcinoma and cervical adenocarcinoma. 1991 , 165, 137-45	26

2153	The c-erbB-2 protein in primary and metastatic breast carcinomas. 1991 , 15, 281-9	17
2152	[Overexpression of protein kinase-C-isoenzymes in human tumor cell lines]. 1991 , 70, 146-50	2
2151	Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. 1991 , 2, 47-53	34
2150	Practical application of determinants of cell behaviour. 1991 , 47, 324-42	2
2149	New insights into the causes of cancer. 1991 , 38, 201-21	9
2148	Medical management of early-stage breast cancer. 1991 , 15, 157-232	1
2147	Growth factors and receptors in cancer. 1991 , 2, 260-8	2
2146	Oncogenes: a review of their clinical application. 1991 , 11, 209-39	4
2145	Hormonal steroids act as tumour promoters by modulating oncogene expression. 1991 , 117, 96-101	20
2144	Der prognostische Stellenwert der Flowzytometrie beim Mammakarzinom. 1991 , 23, 43-48	1
2143	Anchorage-independent growth and the expression of cellular proto-oncogenes in normal human epidermal keratinocytes and in human squamous cell carcinoma cell lines. 1991 , 71, 303-11	9
2142	The molecular biology of breast cancer. 1991 , 1072, 33-50	20
2141	Diagnostic utility of oncogenes and their products in human cancer. 1991 , 1072, 193-214	8
2140	An immunohistochemical study of the incidence and significance of C-erbB-2 oncoprotein overexpression in ovarian neoplasia. 1991 , 1, 285-289	14
2139	Epidermal growth factor and related growth factors. 1991 , 30, 687-94	34
2138	An evaluation of the putative human mammary tumour retrovirus associated with peripheral blood monocytes. 1991 , 63, 534-40	7
2137	Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. 1991 , 63, 601-8	150
2136	Multiple sequential molecular abnormalities in the evolution of human gliomas. 1991 , 63, 753-7	55

2135	Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. 1991 , 63, 967-70	166
2134	Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. 1991 , 64, 79-83	134
2133	Epithelial ovarian cancer: a cytokine propelled disease?. 1991 , 64, 617-20	49
2132	C-erb B-2 amplification in cystic renal disease. 1991 , 40, 509-13	34
2131	Alterations in copy number of c-erbB-2 and c-myc proto-oncogenes in advanced stage of human breast cancer. 1991 , 41, 19-23	1
2130	Progesterone augments proliferation induced by epidermal growth factor in a feline mammary adenocarcinoma cell line. 1991 , 45, 196-206	25
2129	DNA ploidy and cell-cycle analysis: tools for assessment of cancer prognosis. 1991 , 5, 422-38	5
2128	Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/neu oncogene. 1991 , 47, 66-71	59
2127	c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. 1991 , 47, 833-8	73
2126	Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification. 1991 , 47, 933-7	91
2125	c-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: an immunohistochemical study on archival material. 1991 , 48, 668-71	66
2124	Trisomy 12 and K-ras-2 amplification in human ovarian tumors. 1991 , 48, 678-81	29
2123	Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. 1991 , 49, 44-9	222
2122	The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. 1991 , 49, 323-8	269
2121	Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice. 1991 , 49, 616-23	49
2120	Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. 1991 , 49, 650-5	325
2119	Expression of the ERBB2 protein in benign and malignant salivary gland tumors. 1991 , 3, 128-35	38
2118	Molecular insights into breast cancer from transgenic mouse models. 1991 , 13, 591-6	18

2117	Hereditary ovarian cancer. Heterogeneity in age at diagnosis. 1991 , 67, 1460-6	86
2116	Human neu oncogene is expressed in endometrial but not in ovarian adenocarcinomas. 1991 , 67, 1713	6
2115	Comparative investigation of c-erbB2/neu expression in head and neck tumors and mammary cancer. 1991 , 67, 2142-9	43
2114	C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia. 1991 , 68, 331-4	69
2113	DNA content flow cytometry as a prognostic factor for node-positive breast cancer. The role of multiparameter ploidy analysis and specimen sonication. 1991 , 68, 1781-8	28
2112	Transformation of human breast epithelial cells by c-Ha-ras oncogene. 1991 , 4, 25-35	145
2111	Breast biopsy nuclear pellets are a convenient source of DNA for routine determination of Her-2/neu gene amplification. 1991 , 19, 57-61	2
2110	Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. 1991 , 18, 11-7	92
2109	Human papillomavirus and c-myc/c-erbB2 in uterine and vulvar lesions. 1991 , 419, 479-85	20
2108	How malignant is malignant? A brief review of the microscopic assessment of human neoplasms, and the prediction of whether they will metastasize and kill. 1991 , 9, 127-37	1
2107	Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma. 1991 , 20, 3-10	19
2106	Prognostic potential of flow cytometric S-phase and ploidy prospectively determined in primary breast carcinomas. 1992 , 20, 93-108	27
2105	Insulin-like growth factors in human breast cancer. 1991 , 18 Suppl 1, S55-62	55
2104	Durchflußzytometrische DNA-Analyse bei Mammakarzinomen: Korrelation mit klinischen Prognosefaktoren. 1991 , 250, 209-216	
2103	Expression of c-erbB-2 oncoprotein in salivary gland tumours: an immunohistochemical study. 1991 , 163, 77-80	55
2102	Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. 1991 , 163, 105-10	68
2101	Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. 1991 , 11, 117-27	252
2100	Assignment by in situ hybridization of a fibroblast growth factor receptor gene to human chromosome band 10q26. 1991 , 87, 84-6	27

2099	Biochemical characteristics of cytosolic and particulate forms of protein tyrosine kinases from N-methyl-N-nitrosourea (MNU)-induced rat mammary carcinoma. 1991 , 106, 87-97	5
2098	Expression of activated oncogenes in the murine mammary gland: transgenic models for human breast cancer. 1991 , 10, 217-27	26
2097	Proto-oncogene expression in dermal naevi and melanomas. 1991 , 283, 500-5	18
2096	PCR detection of an Mbol polymorphism in the ERBB2 (HER2; NEU) gene on chromosome 17q11.2-q12. 1991 , 19, 2515	4
2095	c-erbB-2 expression in different histological types of invasive breast carcinoma. 1991 , 44, 211-4	60
2094	Down-regulation of cellular platelet-derived growth factor receptors induced by an activated neu receptor tyrosine kinase. 1991 , 2, 651-61	4
2093	Growth factors and cancer. <i>Science</i> , 1991 , 254, 1146-53	33.3 1044
2092	Diagnostic Applications of Recombinant Nucleic Acid Technology: Neoplastic Disease. 1992 , 23, 19-23	5
2091	Over-expression of cellular oncogenes in cystadenocarcinomas of the ovary. 1992 , 1, 347-52	
2090	Mutations in an alternatively spliced exon of h-ras are not associated with loss of heterozygosity on chromosome 11p15.5 in ovarian tumorigenesis. 1992 , 1, 215-9	
2089	Mechanisms of p185HER2 expression in human non-small cell lung cancer cell lines. 1992 , 6, 359-63	36
2088	Molecular biology in medicine. 1992 , 68, 251-62	
2087	Prognostic value of c-erbB-2 expression in uterine cervical carcinoma. 1992 , 45, 594-6	44
2086	Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. 1992 , 175, 217-25	155
2085	Oncogenes in gynecological tumors. 1992 , 85, 357-72	7
2084	Genes, Oncogenes, and Hormones. 1992 ,	
2083	Oncogenes and tumor suppressor genes: new biochemical tests. 1992 , 29, 269-305	13
2082	The genetics of ovarian cancer. 1992 , 10, 135-41	9

2081	Molecular biology in the diagnosis and prognosis of solid and lymphoid tumors. 1992 , 10, 399-416	6
2080	Tamoxifen prevents induction of hepatic neoplasia by zeranol, an estrogenic food contaminant. 1992 , 89, 1085-9	26
2079	Humanization of an anti-p185HER2 antibody for human cancer therapy. 1992 , 89, 4285-9	1468
2078	The polymerase chain reaction: its use in the molecular characterization and diagnosis of cancers. 1992 , 10, 417-29	7
2077	ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. 1992 , 89, 5321-5	442
2076	A chimeric EGFR/neu receptor in functional analysis of the neu oncoprotein. 1992 , 31, 147-50	7
2075	Mutations in transmembrane domain of c-erbB-2 gene in human malignant tumours of the central nervous system. 1992 , 14, 236-40	3
2074	Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice. 1992 , 34, 517	
2073	Flow cytometric DNA index and S-phase fraction in breast cancer in relation to other prognostic variables and to clinical outcome. 1992 , 31, 157-65	50
2072	p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. 1992 , 147, 496-9	153
2071	Expression of c-erbB-2 protein in papillary thyroid carcinomas. 1992 , 65, 832-7	60
2070	Unsettled questions regarding ovarian cancer. 1992 , 155, 7-18	3
2069	Oncogenesis in ovarian cancer. 1992 , 155, 25-30	18
2068	Chapter 18. Protein Tyrosine Kinases and Cancer. 1992 , 27, 169-178	26
2067	c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis. 1992 , 66, 728-34	25
2066	Protein tyrosine kinase growth factor receptors and their ligands in development, differentiation, and cancer. 1993 , 60, 43-73	27
2065	Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. 1992 , 89, 2287-91	102
2064	Overexpression of the p185erB-2 tyrosine kinase growth factor receptor: control or chaos. 1992 , 6, 357-8	

2063	Isolation and structural analysis of a 1.2-megabase N-myc amplicon from a human neuroblastoma. 1992 , 12, 5563-70	48
2062	Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. 1992 , 89, 5867-71	139
2061	Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myc antisense oligodeoxynucleotides. 1992 , 89, 7031-5	127
2060	Annulate lamellae in a large cell lung carcinoma cell line with high expression of tyrosine kinase receptor and proto-oncogenes. 1992 , 16, 439-49	13
2059	Antiserum raised against a synthetic phosphotyrosine-containing peptide selectively recognizes p185neu/erbB-2 and the epidermal growth factor receptor. 1992 , 89, 11637-41	48
2058	Negative autoregulation of the neu gene is mediated by a novel enhancer. 1992 , 12, 2739-48	26
2057	Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor. 1992 , 89, 10435-9	56
2056	Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. 1992 , 89, 10578-82	954
2055	Elimination of extrachromosomally amplified MYC genes from human tumor cells reduces their tumorigenicity. 1992 , 89, 8165-9	118
2054	Endometrial and ovarian malignancies: epidemiology, etiology and prognostic factors. 1992 , 71, 331-6	2
2053	Anti-oncogenic activity of signalling-defective epidermal growth factor receptor mutants. 1992 , 12, 491-8	120
2052	Amplification of c-erbB2 proto-oncogene and immunohistochemical expression of c-erbB2 gene product in parathyroid tumors.. 1992 , 25, 421-429	2
2051	High level Escherichia coli expression and production of a bivalent humanized antibody fragment. 1992 , 10, 163-7	202
2050	The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells. 1992 , 167, 1877-82	6
2049	Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro. 1992 , 28, 318-21	62
2048	Detection of the HER-2/neu proto-oncogene protein p185erbB2 by a novel monoclonal antibody (MAB-145ww) in breast cancer membranes from oestrogen and progesterone receptor assays. 1992 , 28, 322-6	5
2047	Hormonal therapy for stomach cancer. 1992 , 39, 137-9	12
2046	The type 1 (EGFR-related) family of growth factor receptors and their ligands. 1992 , 4, 1-24	296

2045	Identification of heregulin, a specific activator of p185erbB2. <i>Science</i> , 1992 , 256, 1205-10	33.3	890
2044	Clinical significance of erbB-2 (HER-2/neu) protein. 1992 , 10, 575-9		17
2043	Differential expression of the neu oncogene in mouse liver and pancreatic cell lines. 1992 , 186, 363-70		2
2042	Applications of image cytometry in the diagnostic laboratory. 1992 , 12, 41-48		
2041	NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. 1992 , 44, 245-53		62
2040	Prediction of response to adjuvant chemotherapy in premenopausal lymph node positive breast cancer patients with morphometry, DNA flow cytometry and HER-2/neu oncoprotein expression. Preliminary results. 1992 , 188, 344-9		12
2039	How are cancer associated genes activated or inactivated?. 1992 , 28, 248-51		9
2038	Association between chromosome 11q13 amplification and prognosis of patients with oesophageal carcinomas. 1992 , 28A, 755-7		24
2037	Hormonal regulation of c-erbB-2 oncogene expression in breast cancer cells. 1992 , 43, 21-5		25
2036	Expression of epidermal growth factor receptor and transforming growth factor alpha in human larynx carcinoma. 1992 , 65, 189-99		15
2035	Prognostic factors in human primary breast cancer: comparison of c-myc and HER2/neu amplification. 1992 , 43, 13-9		40
2034	Oral cancer progression and c-erbB-2/neu proto-oncogene expression. 1992 , 65, 215-20		63
2033	Expression of c-erbB2, TGF-beta 1 and pS2 genes in primary human breast cancers. 1992 , 28, 700-5		23
2032	The role of erbB-2 and its ligands in growth control of malignant breast epithelium. 1992 , 43, 229-36		21
2031	Evidence for the multistep theory of carcinogenesis in human breast cancer. 1992 , 1, 29-34		4
2030	Identification and interpretation of epidermal growth factor and c-erbB-2 overexpression. 1992 , 28, 263-7		34
2029	c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse. 1992 , 28A, 1600-4		40
2028	Rare occurrence of amplification of HER-2 (erbB-2/neu) oncogene in ovarian cancer patients. 1992 , 28A, 1300		3

2027	Signal transduction by the neu/erbB-2 receptor: a potential target for anti-tumor therapy. 1992 , 43, 95-103	20
2026	Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer. 1992 , 61, 95-103	73
2025	Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. 1992 , 23, 1141-50	51
2024	Retinoblastoma and p53 gene product expression in breast carcinoma: immunohistochemical analysis and clinicopathologic correlation. 1992 , 23, 1388-94	52
2023	Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. 1992 , 23, 974-9	335
2022	Current concepts in epithelial ovarian tumors: does benign to malignant transformation occur?. 1992 , 23, 846-7	61
2021	HER-2/neu expression: a major prognostic factor in endometrial cancer. 1992 , 47, 179-85	195
2020	C-erbB-2-oncogene expression in breast carcinoma: analysis by S1 nuclease protection assay and immunohistochemistry in relation to clinical parameters. 1992 , 47, 228-33	11
2019	Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. 1992 , 69, 205-16	490
2018	Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. 1992 , 69, 559-72	535
2017	Presence of expression products of c-erbB-1 and c-erbB-2/HER2 genes on mammalian sperm cell, and effects of their regulation on fertilization. 1992 , 21, 223-39	35
2016	p185 HER2/neu epitope mapping with murine monoclonal antibodies. 1992 , 11, 267-76	28
2015	Construction, bacterial expression and characterization of a bifunctional single-chain antibody-phosphatase fusion protein targeted to the human erbB-2 receptor. 1992 , 10, 1128-32	76
2014	Prognostic indicators in node-negative early stage breast cancer. 1992 , 92, 539-48	18
2013	Differential effects of cisplatin on the expression of chimeric marker genes in CV-1 cells. 1992 , 44, 107-19	11
2012	Tumor cell heterogeneity: an overview. 1992 , 206, 3-7	8
2011	Genes in the diagnosis of malignant disease. 1992 , 209, S15-26	1
2010	The role of positron emission tomography in oncology and other whole-body applications. 1992 , 22, 268-84	59

2009	Role of proto-oncogene activation in carcinogenesis. 1992 , 98, 13-24	78
2008	Different Assays for Her-2/neu Evaluation in Breast Cancer. 1992 , 78, 106-110	3
2007	Amplification of ERBB-2 (HER-2/NEU) oncogene in different neoplasms of patients from USSR. 1992 , 49, 162-5	11
2006	Correlations between c-erb beta-2 oncogene amplification and the expression of its mRNA and protein in human breast carcinomas. 1992 , 49, 9-14	5
2005	HER-2/Neu Gene in Primary and Local Metastatic Axillary Lymph Nodes in Human Breast Tumors. 1992 , 7, 107-113	4
2004	Preliminary evaluation of HER-2/neu oncogene and epidermal growth factor receptor expression in normal and neoplastic human ovaries. 1992 , 7, 114-118	8
2003	Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. 1992 , 10, 1044-8	264
2002	Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. 1992 , 10, 1436-43	102
2001	The HER-2/neu oncogene in breast cancer: so what is new?. 1992 , 10, 1034-6	15
2000	Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. 1992 , 6, 3275-82	273
1999	A subdomain in the transmembrane domain is necessary for p185neu* activation.. 1992 , 11, 923-932	54
1998	Prognostic Factors in Ovarian Cancer. 1992 , 6, 761-781	19
1997	Growth Regulation of Ovarian Cancer. 1992 , 6, 829-841	21
1996	Oncogenes in Ovarian Cancer. 1992 , 6, 813-827	16
1995	Enzyme-Linked Immunosorbent Assay of C-ErbB-2 Oncoprotein in Breast Cancer. 1992 , 38, 1471-1474	27
1994	Preliminary evaluation of HER-2/neu oncogene and epidermal growth factor receptor expression in normal and neoplastic human ovaries. 1992 , 7, 47-51	4
1993	Biologic and Immunologic Therapy of Ovarian Cancer. 1992 , 6, 941-965	9
1992	An immunohistological demonstration of c-erbB-2 oncoprotein expression in primary urothelial bladder cancer. 1992 , 20, 117-20	22

1991	Production and characterization of a polyclonal antibody to the c-erbB-3 protein: examination of c-erbB-3 protein expression in adenocarcinomas. 1992 , 168, 275-80	45
1990	Cancer staging: future directions for the TNM classification. 1992 , 8, 107-10	5
1989	Ovarian cancer, Part II: Treatment. 1992 , 16, 67-126	14
1988	Investigation of the c-neu proto-oncogene related protein, p185, in the serum of primary epithelial ovarian cancer patients. 1992 , 2, 134-140	2
1987	Amplification of HER-2/neu oncogene in human ovarian cancer. 1992 , 2, 291-4	15
1986	In vitro anti-tumor activity of anti-c-erbB-2 x anti-CD3 epsilon bifunctional monoclonal antibody. 1992 , 83, 563-7	6
1985	High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. 1992 , 83, 978-84	96
1984	Absence of activating mutations in the transmembrane domain of the c-erbB-2 protooncogene in human lung cancer. 1992 , 83, 1299-303	8
1983	p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. 1992 , 66, 583-8	88
1982	Chromosomal localisation of two putative 11p oncosuppressor genes involved in human ovarian tumours. 1992 , 66, 1030-6	46
1981	Study of the biological and prognostic significance of the antigen CaMBr8 on breast carcinoma. 1992 , 65, 466-70	5
1980	Hormonal aspects of breast cancer. Growth factors, drugs and stromal interactions. 1992 , 12, 1-23	117
1979	Ovarian cancer, Part I: Biology. 1992 , 16, 1-57	63
1978	Effects of beta-2 microglobulin anti-sense oligonucleotides on sensitivity of HER2/neu oncogene-expressing and nonexpressing target cells to lymphocyte-mediated lysis. 1992 , 141, 219-32	9
1977	Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments. 1992 , 31, 5434-41	97
1976	Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. 1992 , 118, 474-9	62
1975	Association of genetic alterations of c-myc, c-fos, and c-Ha-ras proto-oncogenes in colorectal tumors. Frequency and clinical significance. 1992 , 35, 444-51	15
1974	Human mammary epithelial cells in primary culture reflect c-myc and c-erbB-2 gene copy number in tissue. 1992 , 28A, 377-9	

1973	Differential immunoreactivity of her-2/neu oncoprotein in prostatic tissues. 1992 , 1, 151-5	12
1972	DNA sequences amplified in cancer cells: an interface between tumor biology and human genome analysis. 1992 , 276, 329-37	3
1971	Cerebrospinal fluid analysis Clinical neurochemistry. 1992 , 239, 85-91	
1970	Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary. 1992 , 421, 393-400	34
1969	Proliferating cell nuclear antigen in breast lesions: correlation of c-erbB-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer. 1992 , 421, 193-202	29
1968	Detection and temporal appearance of multiple copies of c-erb-B2 genes in advanced mammary carcinoma using fine needle biopsies and the polymerase chain reaction. 1992 , 23, 191-200	20
1967	Transfection of murine P19S18 embryonal carcinoma cells with the oncogene neu induces an epithelioid phenotype. 1992 , 51, 129-35	1
1966	Oncogenes as markers for early detection of cancer. 1992 , 16G, 131-6	13
1965	Indicators of increased breast cancer risk in humans. 1992 , 16G, 175-82	27
1964	Chromosome aberrations in 35 primary ovarian carcinomas. 1992 , 4, 58-68	113
1963	Amplification of the topoisomerase II alpha gene in a non-small cell lung cancer cell line and characterisation of polymorphisms at the human topoisomerase II alpha and beta loci in normal tissue. 1992 , 4, 169-75	20
1962	Detection of amplified DNA sequences in human tumor cell lines by fluorescence in situ hybridization. 1992 , 4, 314-20	23
1961	Effects of interferons on the expression of the proto-oncogene HER-2 in human ovarian carcinoma cells. 1992 , 50, 64-8	28
1960	Elevated activities of protein kinase C and tyrosine kinase correlate to leukemic cell aggressiveness. 1992 , 50, 136-41	11
1959	p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. 1992 , 50, 528-32	138
1958	Metastatic phenotype of murine tumor cells expressing different cooperating oncogenes. 1992 , 51, 798-804	2
1957	Expression of HER-2/neu in renal-cell carcinoma. Correlation with histologic subtypes and differentiation. 1992 , 52, 213-7	28
1956	Receptors for hormones and growth factors and (onco)-gene amplification in human ovarian cancer. 1992 , 52, 218-24	54

1955	Epidermal growth factor reduces HER-2 protein level in human ovarian carcinoma cells. 1992 , 52, 311-6	18
1954	Breast cancer is associated with loss of the c-kit oncogene product. 1992 , 52, 713-7	101
1953	Transforming growth factor beta 1 (TGF-beta 1) inhibits growth of a human ovarian carcinoma cell line (OVCCR1) and is expressed in human ovarian tumors. 1992 , 52, 766-70	24
1952	Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. 1992 , 5, 213-8	100
1951	Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines. 1992 , 5, 320-7	72
1950	Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-alpha genes on in vitro transformation of human mammary epithelial cells. 1992 , 6, 43-52	60
1949	T-cell recognition of oncogene products: a new strategy for immunotherapy. 1992 , 6, 77-82	16
1948	Biological monitoring of cancer chemoprevention. 1992 , 51, 195-202	6
1947	Somatic mutations and human breast cancer. A status report. 1992 , 69, 1582-8	92
1946	Selection of appropriate cellular and molecular biologic diagnostic tests in the evaluation of cancer. 1992 , 69, 1607-32	29
1945	Future directions for the American Joint Committee on Cancer. 1992 , 69, 1639-44	10
1944	Expression of transforming growth factor-alpha in gastric carcinoma and normal gastric mucosa cells. 1992 , 69, 2871-5	17
1943	C-erbB-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. 1992 , 69, 2953-60	57
1942	Cowden's disease. A case report with analyses at the molecular level. 1992 , 69, 2969-74	45
1941	Significance of c-erbB-2 amplification and DNA aneuploidy. Analysis in 78 patients with node-negative breast cancer. 1992 , 70, 770-6	26
1940	The integration of molecular genetics into cancer management. 1992 , 70, 1653-8	29
1939	Genetic markers as prognostic indicators in breast cancer. 1992 , 70, 1765-74	32
1938	The future of prognostic factors in outcome prediction for patients with cancer. 1992 , 70, 2367-77	135

1937	An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. 1992 , 70, 2493-8	131
1936	Expression of the HER-2/neu proto-oncogene in serous ovarian neoplasms. 1992 , 70, 2857-60	32
1935	Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. 1993 , 71, 3942-6	71
1934	An immunohistochemical study of the c-erbB-2 oncogene product in intraductal mucin-hypersecreting neoplasms and in ductal cell carcinomas of the pancreas. 1993 , 72, 51-6	59
1933	Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. 1993 , 72, 2433-40	140
1932	Expression of c-erbB-2 protein and epidermal growth receptor in endometrial carcinomas. Correlation with clinicopathologic and sex steroid receptor status. 1993 , 72, 2628-37	48
1931	Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. 1993 , 72, 3179-84	114
1930	Cellular oncogenes and suppressor genes as prognostic markers in cancer. 1993 , 26, 439-47	34
1929	Tyrosine kinase receptors in the control of epithelial growth and morphogenesis during development. 1993 , 15, 185-90	33
1928	Neu and its ligands: from an oncogene to neural factors. 1993 , 15, 815-24	255
1927	An immunohistochemical study of c-erbB-2 protein in gastric carcinomas and lymph-node metastases: is the c-erbB-2 protein really a prognostic indicator?. 1993 , 53, 75-9	37
1926	Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. 1993 , 53, 401-8	52
1925	Down-regulation of RI alpha subunit of cAMP-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-Ha-ras and c-erbB-2 proto-oncogenes. 1993 , 53, 438-43	41
1924	Cellular and in vivo characterization of the MCR rat mammary tumor model. 1993 , 53, 486-92	
1923	Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. 1993 , 54, 213-9	193
1922	Amplification of fgfr4 gene in human breast and gynecological cancers. 1993 , 54, 378-82	127
1921	c-erbB-2 oncoprotein in screen-detected breast carcinoma: an immunohistological study. 1993 , 55, 63-5	2
1920	Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy. 1993 , 53, 61-73	68

1919	Oncogenes, breast cancer, and chemoprevention. 1993 , 17G, 161-6	24
1918	Standardization and quality control of quantitative microscopy in pathology. 1993 , 17G, 199-204	12
1917	Expression of transforming growth factor alpha antisense mRNA inhibits the estrogen-induced production of TGF alpha and estrogen-induced proliferation of estrogen-responsive human breast cancer cells. 1993 , 156, 497-514	47
1916	Cell growth regulation in epithelial ovarian cancer. 1993 , 71, 1597-601	66
1915	Whole chromosome 17 loss in ovarian cancer. 1993 , 8, 195-8	30
1914	An animal model for in vivo evaluation of tumor glycolytic rates with positron emission tomography. 1993 , 53, 104-9	6
1913	Study of c-erbB-2 protein and epidermal growth factor receptor expression and DNA ploidy pattern in colorectal carcinoma. 1993 , 54, 246-51	13
1912	Quest for excellence: the ultimate goal of the radiation oncologist: ASTRO Gold Medal Address, 1992. 1993 , 26, 567-80	7
1911	Serum CA 125 as a tumor marker and the expression of c-erbB-2 oncogene in tubal malignancies. 1993 , 3, 116-121	5
1910	Expression of HER-2/neu oncoprotein, DNA-ploidy and S-phase fraction in advanced ovarian cancer. 1993 , 3, 271-278	14
1909	Four separate regions on chromosome 17 show loss of heterozygosity in familial breast carcinomas. 1993 , 91, 6-12	23
1908	Phenotypic identification of amplifications of the ADH4 and CUP1 genes of <i>Saccharomyces cerevisiae</i> . 1993 , 23, 392-6	10
1907	p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder. 1993 , 170, 67-72	79
1906	Expression of NEU/HER-2 oncoprotein (p185neu) in prostate tumors: an immunohistochemical study. 1993 , 23, 329-36	32
1905	Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. 1993 , 12, 287-301	103
1904	A new high frequency polymorphism in the HER-2/neu oncogene in normal tissue and breast tumors. 1993 , 28, 45-9	6
1903	William L. McGuire Memorial Symposium. The role of erbB2 signal transduction pathways in human breast cancer. 1993 , 27, 83-93	56
1902	Migration of fresh human malignant astrocytoma cells into hydrated gel wafers in vitro. 1994 , 18, 151-61	24

1901	Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. 1993 , 68, 1140-5	97
1900	C-erbB-2 oncoprotein immunostaining in serous effusions. 1993 , 4, 207-18	12
1899	Immunocytochemical staining for the c-erbB-2 gene product in breast aspirates: a preliminary report. 1993 , 4, 219-24	5
1898	Clinical and biological prediction of axillary and internal mammary lymph node metastases in breast cancer. 1993 , 2, 51-8	17
1897	Detection of c-erbB-2 amplification in breast cancer by in situ hybridization. 1993 , 2, 234-238	5
1896	Tamoxifen induces the expression of cytoplasmic c-erbB2 immunoreactivity in oestrogen-receptor positive breast carcinomas in-vivo. 1993 , 2, 93-99	8
1895	Overexpression of asparagine synthetase in albizziin-resistant murine diploid embryonic stem cells. 1993 , 19, 321-30	1
1894	erbB-2/Her-2 gene amplification and overexpression in parotid gland tumors. 1993 , 250, 150-3	1
1893	erbB-3, a third member of the erbB/epidermal growth factor receptor gene family: its expression in head and neck cancer cell lines. 1993 , 250, 392-5	14
1892	Immunohistochemical overexpression of C-erbB-2 in the prognosis of breast cancer. 1993 , 23, 885-90	4
1891	A retrospective study on the clinical and biological prediction of axillary lymph node metastasis in breast cancer. 1993 , 23, 573-9	7
1890	Resistance of HER2/neu-overexpressing tumor targets to lymphokine-activated-killer-cell-mediated lysis: evidence for deficiency of binding and post-binding events. 1993 , 36, 307-14	5
1889	Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. 1993 , 37, 255-63	414
1888	Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). 1993 , 16, 93-104	54
1887	Die prognostische Wertigkeit der Überexpression des p185erbB2 Onkoproteins bei T1 Mammakarzinomen. 1993 , 254, 842-845	
1886	c-erbB-2 Onkogenexpression in Ovarialkarzinomen und Borderline-Tumoren. 1993 , 254, 942-943	
1885	Die Bedeutung der c-erbB-2 und c-myc Onkogen-Expression für die Prognose beim Ovarialkarzinom. 1993 , 254, 946-948	
1884	Immunhistochemische Untersuchungen über das c-erbB-2 Protein am Ovarialkarzinom. 1993 , 254, 951-952	

1883 P185erbB-2 im Serum von Ovarialkarzinompatientinnen. **1993**, 254, 955-957

1882 Molecular aspects of mesenchymal-epithelial interactions. **1993**, 9, 511-40 193

1881 Comparative clinical evaluation of biochemical and genomic tumor markers. **1993**, 217, 39-55 4

1880 Genetic and molecular heterogeneity of breast cancer cells. **1993**, 217, 63-73 23

1879 Drug resistance associated with altered DNA topoisomerase II. **1993**, 33, 113-27 71

1878 Characterization of cytotoxic activity of saporin anti-gp185/HER-2 immunotoxins. **1993**, 55, 122-7 16

1877 Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer. **1993**, 29A, 749-53 57

1876 Amplified met gene linked to double minutes in human glioblastoma. **1993**, 29A, 1991-5 24

1875 Oncogene-Transformed NIH 3T3 Cells Display Radiation Resistance Levels Indicative of a Signal Transduction Pathway Leading to the Radiation-Resistant Phenotype. **1993**, 135, 234 38

1874 A multidisciplinary approach to the early detection of ovarian carcinoma: rationale, protocol design, and early results. **1993**, 169, 494-501 68

1873 Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. **1993**, 168, 162-9 108

1872 Non palpable breast carcinomas. Histological and immunohistochemical studies of 160 cases. **1993**, 189, 267-74 2

1871 Partial reversion of transformed phenotype of B104 cancer cells by antisense nucleic acids. **1993**, 69, 27-32 7

1870 An immunohistochemical and molecular biological study of c-erbB-2 amplification and prognostic relevance in gallbladder cancer. **1993**, 189, 283-92 35

1869 Prospects for gene-directed therapy with antisense oligodeoxynucleotides. **1993**, 19, 169-79 16

1868 HER-2 and INT-2 amplification estimated by quantitative PCR in paraffin-embedded ovarian cancer tissue samples. **1993**, 29A, 1593-7 30

1867 The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. **1993**, 168, 228-32 28

1866 Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsin D and histologic grades. **1993**, 75, 195-206 19

1865	Oncogenes and tumour suppressor genes in transgenic mouse models of neoplasia. 1993 , 29A, 638-45	32
1864	Micrometastatic tumour cells in bone marrow in colorectal cancer. 1993 , 341, 501	14
1863	Structural features of the 5' region of the human erbB-2 gene. 1993 , 136, 361-4	7
1862	What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease. 1993 , 189, 1233-52	20
1861	Paget's disease of the nipple without clinically and radiologically detectable breast tumor. Histochemical and immunohistochemical study of 44 cases. 1993 , 189, 150-5	18
1860	The prognostic value of nuclear roundness and neopterin in ovarian cancer. 1993 , 29A, 1863-8	23
1859	Detection of aneuploidy and possible deletion in paraffin-embedded rhabdomyosarcoma cells with FISH. 1993 , 68, 99-103	30
1858	Double minutes are frequently found in ovarian carcinomas. 1993 , 71, 125-31	14
1857	Evidence of gene amplification in the form of double minute chromosomes is frequently observed in lung cancer. 1993 , 65, 120-4	32
1856	Overexpression of HER2/neu oncogene in human pancreatic carcinoma. 1993 , 24, 1127-34	186
1855	p53 accumulation in ovarian carcinomas and its prognostic implications. 1993 , 24, 1175-9	94
1854	Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. 1993 , 24, 584-9	68
1853	c-erbB-2 amplification and overexpression in breast cancer: evaluation and comparison of Southern blot, slot blot, ELISA and immunohistochemistry. 1993 , 25, 124-32	19
1852	Critical steps in breast carcinogenesis. 1993 , 698, 1-20	45
1851	Growth factors. Clinical implications in breast cancer. 1993 , 698, 85-101	9
1850	An activated allele of the c-erbB-2 oncogene impairs kidney and lung function and causes early death of transgenic mice. 1993 , 122, 199-208	82
1849	Neural expression and chromosomal mapping of Neu differentiation factor to 8p12-p21. 1993 , 90, 1867-71	107
1848	Tumour markers. 1993 , 4, S71-S77	30

1847	Argyrophilic nucleolar organizer regions in breast-carcinoma - correlation with clinicopathological and biological variables and prognostic value. 1993 , 2, 203-7	2
1846	Prognostic-significance of p53 and C-erbB-2 expression in operable breast-cancer. 1993 , 2, 587-91	2
1845	The prognostic-significance of proliferating cell nuclear antigen in breast-cancer - correlation with DNA ploidy, C-erbB-2 expression, histopathology, lymph-node metastases and patient survival. 1993 , 2, 985-9	
1844	Biochemical and immunohistochemical detection of the epidermal growth-factor receptor (EGF-R) in breast-tumor specimens. 1993 , 3, 389-97	1
1843	Cancer of the ovary. 1993 , 329, 1550-9	313
1842	Expression of androgen and progesterone receptors in primary human meningiomas. 1993 , 78, 456-62	64
1841	c-erbB-2 DNA amplification and mRNA expression in human primary breast tumors and its relationship to other prognostic factors. 1993 , 8, 29-35	5
1840	Inherited Breast and Ovarian Cancer. 1993 , 269, 1975	122
1839	Human-specific c-neu proto-oncogene protein overexpression in human malignant astrocytomas before and after xenografting. 1993 , 78, 240-51	24
1838	Molecular and biological factors in the pathogenesis of ovarian cancer. 1993 , 4 Suppl 4, 3-16	9
1837	Internal mammary nodal status is a more reliable prognostic factor than DNA ploidy and c-erb B-2 expression in patients with breast cancer. 1993 , 128, 242-6	30
1836	The Clinical Applications of New DNA Diagnostic Technology on the Management of Cancer Patients. 1993 , 270, 2331	8
1835	Application of Confocal Laser Scanning Microscope on Fluorescence in situ Hybridization (FISH).. 1993 , 26, 415-421	3
1834	Reduced expression of TGF beta is associated with advanced disease in transitional cell carcinoma. 1993 , 67, 578-84	33
1833	Prognostic significance of Helix pomatia lectin and c-erbB-2 oncoprotein in human breast cancer. 1993 , 68, 621-6	23
1832	Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. 1993 , 150, 126-31	106
1831	Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. 1993 , 150, 1427-33	136
1830	Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis. 1993 , 32, 289-94	15

1829	Expression of the c-erbB2 proto-oncogene in male breast carcinoma: lack of prognostic significance. 1993 , 50, 408-11	24
1828	Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells. 1993 , 90, 2900-4	113
1827	Inverse regulation of human ERBB2 and epidermal growth factor receptors by tumor necrosis factor alpha. 1993 , 90, 8972-6	32
1826	Improved quantitation of HER-2/neu gene copy number in breast tumor-derived DNA samples. 1993 , 100, 444-50	6
1825	Aneuploidy fraction but not DNA index is important for the prognosis of patients with stage I and II breast cancer--10-year results. 1993 , 4, 643-50	7
1824	Heterologous epidermal growth factor receptor (EGF-R) expression in larynx cancer cell lines: evidence for the existence of structurally modified receptors. 1993 , 113, 789-92	2
1823	Overexpression of p185 is not related to erbB2 amplification in ovarian cancer. 1993 , 4, 775-9	6
1822	Molecular genetic changes in human breast cancer. 1993 , 61, 25-56	47
1821	[The erbB gene family: significance for tumor development, prognosis and new therapeutic modalities]. 1993 , 53, 742-53	1
1820	New prognostic factors in prostatic carcinoma. 1993 , 24, 438-49	23
1819	Patent Update: Inhibitors of Tyrosine Kinase Activity as Anticancer Therapeutics: Recent Developments. 1993 , 3, 3-9	2
1818	Mechanisms of multistep carcinogenesis and carcinogen risk assessment. 1993 , 100, 9-20	167
1817	Cell-type specific interaction of Neu differentiation factor (NDF/herregulin) with Neu/HER-2 suggests complex ligand-receptor relationships.. 1993 , 12, 961-971	162
1816	Localization of a bidirectional DNA replication origin in the native locus and in episomally amplified murine adenosine deaminase loci. 1993 , 13, 2971-81	52
1815	Genetic alterations in c-erbB-2 protooncogene as prognostic markers in human primary breast tumors. 1993 , 50, 412-7	15
1814	The neu-oncogene product in serum and tissue of patients with breast carcinoma. 1993 , 4, 585-90	23
1813	Expression of hormone receptors, cathepsin D, and HER-2/neu oncoprotein in normal colon and colonic disease. 1993 , 128, 637-42	23
1812	17 beta-estradiol mimics ligand activity of the c-erbB2 protooncogene product. 1993 , 90, 10803-7	81

1811	Predisposing Genes in Breast and Ovarian Cancer: An Overview. 1993 , 79, 291-296	5
1810	A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines.. 1993 , 12, 2369-2375	91
1809	Immunohistochemical Detection of c-erbB-2 Expression by Neoplastic Human Tissue using Monospecific and Bispecific Monoclonal Antibodies. 1993 , 8, 233-239	4
1808	Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60. 1993 , 11, 891-8	58
1807	Perspectives on the future of cancer markers. 1993 , 39, 2444-2451	27
1806	Genomic components of carcinogenesis. 1993 , 39, 2375-2385	12
1805	The Genetics of Breast Cancer. 1994 , 8, 15-27	4
1804	Overview of the Biologic Markers of Breast Cancer. 1994 , 8, 73-100	43
1803	Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. 1994 , 107, 590-595	37
1802	Immunohistochemical study on the expression of c-erbB-2 oncoprotein in breast cancer. 1994 , 51, 47-51	22
1801	The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer.. 1994 , 13, 1331-1340	185
1800	Combination of Grading and New Biological Factors (S-Phase Fraction and Epidermal Growth Factor Receptor) Can Predict Relapse and Survival in Patients with Node-Negative Primary Breast Cancer. 1994 , 17, 166-172	2
1799	c-erbB-2 oncogene expression in salivary gland tumours. 1994 , 56, 206-12	22
1798	Novel family of gynecologic cancer antigens detected by anti-HIV antibody. 1994 , 2, 171-8	7
1797	Molecular analysis of the topoisomerase II alpha gene and its expression in human ovarian cancer. 1994 , 5, 75-81	20
1796	Comparison of c-erbB-2 oncoprotein expression in tissue and serum of patients with stomach cancer. 1994 , 15, 294-303	15
1795	Measuring c-erbB-2 oncogene amplification in fresh and paraffin-embedded tumors by competitive polymerase chain reaction. 1994 , 40, 630-636	33
1794	Molecular analysis of gene amplification in tumors. 2001 , Chapter 10, Unit 10.5	1

1793	Positron emission tomography scanning in cancer. 1994 , 12, 74-87	23
1792	Tumor Suppressor and Immediate Early Transcription Factor Genes in Non-small Cell Lung Cancer. 1994 , 106, 372S-376S	3
1791	Mechanisms of deregulated her2/neu expression in breast-cancer cell-lines. 1994 , 4, 599-608	3
1790	SEQUENCE MOTIFS OF HUMAN HER-2 PROTOONCOGENE IMPORTANT FOR PEPTIDE BINDING TO HLA-A2. 1994 , 5, 51	
1789	C-erbb-2, ras p21, and C-myc expression in breast-carcinoma - prognostic value and correlation with clinicopathological and biologic variables. 1994 , 4, 255-60	
1788	Characterization of variants of a human breast-cancer cell-line isolated from metastases in different organs of nude-mice. 1994 , 5, 459-67	10
1787	HER-2/NEU AND FIBRINOLYTIC FACTORS IN HUMAN BREAST-CANCER. 1994 , 5, 473	
1786	Detection of epidermal growth-factor receptor and C-erbb-2 gene amplification in transitional-cell bladder-carcinoma using the differential PCR technique. 1994 , 4, 1191-7	
1785	Pathogenesis of ovarian cancers. 1994 , 1, 181-90	36
1784	Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. 1994 , 8, 23-32	152
1783	Permissivity for methotrexate-induced DHFR gene amplification correlates with the metastatic potential of rat adenocarcinoma cells. 1994 , 15, 695-700	15
1782	Prognostische Relevanz der Amplifikation der Onkogene c-erb B-2 und c-myc beim Mammakarzinom. 1994 , 18, 255-259	
1781	Anatomy and Histology of the Uterine Corpus. 1994 , 327-366	4
1780	Immunohistochemical demonstration of c-erbB-2 oncoprotein in gastric adenocarcinoma: comparison of cryostat and paraffin wax sections and effect of fixation. 1994 , 47, 117-21	14
1779	Distinct isoforms of neuregulin are expressed in mesenchymal and neuronal cells during mouse development. 1994 , 91, 1064-8	161
1778	SH2 and SH3 domains in signal transduction. 1994 , 64, 87-110	107
1777	Tumours in Urology. 1994 ,	
1776	Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. 1994 , 47, 914-9	57

1775	C-erbB-2 immunostaining: problems with interpretation. 1994 , 47, 816-22	75
1774	Is c-erb B-2 a predictor for recurrent disease in early stage breast cancer?. 1994 , 28, 395-403	16
1773	Immunotoxins to the HER-2 oncogene product: functional and ultrastructural analysis of their cytotoxic activity. 1994 , 39, 318-24	7
1772	Molecular biology of breast carcinoma. 1994 , 18, 12-20	20
1771	Molecular biologic investigations of proto-oncogenes and growth factors in human testicular tumors. 1994 , 12, 74-8	8
1770	Oncogene overexpression in non-small-cell lung cancer tissue: prevalence and clinicopathological significance. 1994 , 72, 156-63	21
1769	p53 and c-erbB-2 expression in schistosomal urinary bladder carcinomas and schistosomal cystitis with premalignant lesions. 1994 , 424, 349-55	17
1768	The expression of c-erbB-2 (HER-2/neu) oncogene in invasive ovarian malignancies. 1994 , 4, 194-199	10
1767	Hereditary ovarian carcinoma. 1994 , 10, 249-54	9
1766	Salivary duct carcinoma--a highly aggressive salivary gland tumour with overexpression of c-erbB-2. 1994 , 172, 35-44	84
1765	Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. 1994 , 173, 65-75	106
1764	p53 expression, mutation, and allelic deletion in ovarian cancer. 1994 , 174, 159-68	46
1763	Modulation of breast cancer progression and differentiation by the gp30/hereregulin [correction of neregulin]. 1994 , 31, 175-82	22
1762	The type I growth factor receptors in human breast cancer. 1994 , 29, 3-9	107
1761	A new perspective on the nature of the cancer problem: anti-cellular senescence. 1994 , 10, 125-33	5
1760	Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix. 1994 , 73, 148-53	79
1759	Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. 1994 , 73, 652-8	94
1758	Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. 1994 , 73, 1456-9	63

1757	Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage. 1994 , 73, 1460-6	51
1756	Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. 1994 , 73, 2359-65	182
1755	Identification of a distinctive P-glycoprotein-mediated resistance phenotype in human ovarian carcinoma cells after their in vitro exposure to fractionated X-irradiation. 1994 , 73, 2990-9	17
1754	Prognostic value of N-myc immunoreactivity in medullary thyroid carcinoma. 1994 , 74, 134-41	21
1753	Steroid hormones and risk of breast cancer. 1994 , 74, 1111-24	106
1752	Estrogen receptors (ER) in human breast cancer. The significance of a new prognostic factor based on both ER protein and ER mRNA contents. 1994 , 74, 864-71	27
1751	S-phase fraction and nuclear size in long term prognosis of patients with breast cancer. 1994 , 74, 2287-99	41
1750	Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. 1994 , 74, 2956-63	84
1749	Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry. 1994 , 16, 160-8	32
1748	Immunocytochemical staining of c-erb B-2 oncogene in fine-needle aspirates of breast carcinoma: a comparison with tissue sections and other breast cancer prognostic factors. 1994 , 11, 250-4	26
1747	Retrospective c-erbB-2 immunostaining in aspiration cytology of breast cancer. 1994 , 11, 262-5	10
1746	Genome scanning detects genetic alterations in human ovarian carcinoma. 1994 , 4, 141-9	5
1745	Expression of gp185HER-2 in human cutaneous melanoma: implications for experimental immunotherapeutics. 1994 , 56, 341-6	32
1744	Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer. 1994 , 57, 498-503	47
1743	Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. 1994 , 58, 393-9	108
1742	Overexpression of the Met/HGF receptor in ovarian cancer. 1994 , 58, 658-62	197
1741	Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type. 1994 , 58, 763-8	33
1740	The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin. 1994 , 59, 242-7	14

1739	Colocalization of the p185HER2 oncoprotein and integrin alpha 6 beta 4 in Calu-3 lung carcinoma cells. 1994 , 55, 409-18	15
1738	Antigenic and immunogenic mimicry of the HER2/neu oncoprotein by phage-displayed peptides. 1994 , 24, 2868-73	18
1737	Analysis on heterogeneity of squamous cell carcinoma antigen by two-dimensional electrophoresis. 1994 , 15, 988-91	17
1736	Image analysis in quantitative PCR. An application for the measurement of c-erbB-2 oncogene amplification in DNA from human tumours. 1994 , 9, 223-8	13
1735	Immunohistochemical characterization of undifferentiated carcinomas of the ovary. 1994 , 120, 672-7	25
1734	Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy. 1994 , 120, 378-81	33
1733	Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. 1994 , 1198, 11-26	395
1732	Somatic genetic changes in human breast cancer. 1994 , 1198, 113-30	58
1731	The biology of erbB-2/neu/HER-2 and its role in cancer. 1994 , 1198, 165-84	370
1730	Receptor blockade with monoclonal antibodies as anti-cancer therapy. 1994 , 64, 127-54	75
1729	Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts. 1994 , 16, 183-310	1
1728	Biological studies and potential therapeutic applications of monoclonal antibodies and small molecules reactive with the neu/c-erbB-2 protein. 1994 , 24-25, 209-18	8
1727	Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection. 1994 , 8, 155-61	124
1726	Critical determination of the frequency of c-erbB-2 amplification in breast cancer. 1994 , 70, 434-9	21
1725	Prognosis based on primary breast carcinoma instead of pathological nodal status. 1994 , 70, 709-12	47
1724	Significance of erbB-2 gene product as a target molecule for cancer therapy. 1994 , 39, 459-66	29
1723	Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. 1994 , 25, 455-61	41
1722	Establishment and characterization of mouse-human chimeric monoclonal antibody to erbB-2 product. 1994 , 85, 172-8	16

1721	Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary. 1994 , 85, 1247-56	49
1720	Gene amplification in non-Hodgkin's lymphoma. 1994 , 86, 792-7	16
1719	Modern chemotherapy for gynaecological cancer. Part 1: models, mechanisms and methods. 1994 , 4, 14-22	
1718	The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. 1994 , 733, 393-406	108
1717	Neu is not involved in N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide- induced bladder carcinoma or 2-amino-4-(5-nitro-2-furyl)thiazole transformation of rat bladder epithelial cells. 1994 , 84, 7-13	
1716	neu is not involved in N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced bladder carcinoma or 2-amino-4-(5-nitro-2-furyl)thiazole transformation of rat bladder epithelial cells. 1994 , 84, 125-31	2
1715	c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. 1994 , 330, 1260-6	825
1714	Molecular mechanisms involved in tumorigenesis and their surgical implications. 1994 , 167, 428-34	13
1713	Estradiol receptors in combination with neu or myc oncogene amplifications might define new subtypes of breast cancer. 1994 , 229, 107-22	10
1712	Independent control of transcription initiations from two sites by an initiator-like element and TATA box in the human c-erbB-2 promoter. 1994 , 348, 80-8	13
1711	Functional interaction between the epidermal growth factor receptor and c-Src kinase activity. 1994 , 352, 296-300	24
1710	Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. 1994 , 25, 1075-83	88
1709	The neu-oncogene: more than a prognostic indicator?. 1994 , 25, 1264-8	62
1708	Reply. 1994 , 25, 549-550	1
1707	In vitro and in vivo activity of a recombinant toxin, OLX-209, which targets the erbB-2 oncoprotein. 1994 , 34, 119-28	3
1706	The GRB family of SH2 domain proteins. 1994 , 62, 223-44	44
1705	[Adjuvant treatments of early breast cancer without lymph node involvement]. 1994 , 15, 210-5	
1704	Correlation of C-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer. 1994 , 171, 1193-8	34

1703	Expression of c-erb B-2 oncogene product in persistent gestational trophoblastic disease. 1994 , 170, 1616-1622	11
1702	Immunohistochemical stains for breast cancer. 1994 , 69, 57-8	1
1701	Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas. 1994 , 170, 1177-83	72
1700	Clinical therapy and HER-2 oncogene amplification in breast cancer: chemo- vs radiotherapy. 1994 , 49, 39-42	3
1699	European School of Oncology Task Force Report. New approaches in cancer pharmacology: drug design and development (Part 2). 1994 , 30A, 1148-60	1
1698	Role of DNA ploidy and ERB-B2 oncogene expression in the prognosis of endometrial carcinoma. 1994 , 190, 1039-43	4
1697	Serum c-erbB-2 in breast cancer patients. 1994 , 33, 901-4	16
1696	The role of mitotic recombination in carcinogenesis. 1994 , 24, 323-53	63
1695	Molecular biology of breast cancer. 1994 , 5 Suppl 4, 31-7	9
1694	DNA diagnosis in oncology. 1994 , 10, 644-54	
1693	A subgroup of patients with chronic pancreatitis overexpress the c-erb B-2 protooncogene. 1994 , 220, 183-92	32
1692	Regulation of the Ras signalling pathway by protein-tyrosine kinases. 1994 , 22, 455-60	8
1691	Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. 1994 , 91, 8132-6	570
1690	Immune response against tumors. 1994 , 57, 281-351	55
1689	The Family of c-erbB Genes: From Basic Research to Clinical Oncology. 1994 , 17, 346-357	3
1688	Activation of the Src family of tyrosine kinases in mammary tumorigenesis. 1994 , 64, 111-23	30
1687	Interaction of epidermal growth factor with its receptor. 1994 , 49, 353-83	19
1686	Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. 1994 , 70, 1191-7	58

1685	Proto-oncogenes and tumor suppressor genes in human urological malignancies. 1994 , 151, 1479-97	57
1684	Evaluation of c-erbB-2 amplification in breast carcinoma by differential polymerase chain reaction. 1994 , 101, 493-9	23
1683	Expression of c-erb B-2 oncogene product in persistent gestational trophoblastic disease. 1994 , 170, 1616-1622	8
1682	Assay of the c-erbB-2 oncogene encoded protein by ELISA and immunocytochemistry in human breast cancer. 1994 , 31 (Pt 2), 171-3	4
1681	Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. 1994 , 14, 735-43	195
1680	Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene. 1994 , 91, 7202-6	129
1679	Prognostic association of c-erbB-2 oncogene amplification and protein overexpression in human breast cancer using archival tissues. A comparative study. 1994 , 33, 493-8	4
1678	Analysis of cerbB2 expression using a panel of 6 commercially available antibodies. 1994 , 26, 261-7	42
1677	Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene. 1994 , 219, 596-601; discussion 602-4	38
1676	Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. 1994 , 219, 332-41	81
1675	Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. 1994 , 14, 7068-77	184
1674	Involvement of pp60c-src with two major signaling pathways in human breast cancer. 1994 , 91, 83-7	242
1673	Induction of differentiation in HL60 cells by the reduction of extrachromosomally amplified c-myc. 1994 , 91, 6674-8	78
1672	Ligand-directed retroviral targeting of human breast cancer cells. 1995 , 92, 9747-51	117
1671	Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay. 1995 , 92, 8338-42	55
1670	Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. 1995 , 108, 157-62	38
1669	Tumour markers. 1995 ,	
1668	The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer. 1995 , 6, 581-7	62

1667	Biological indices in the assessment of breast cancer. 1995 , 48, M221-38	11
1666	Prevalence and significance of HER-2/neu amplification in epithelial ovarian cancer. 1995 , 40, 209-12	26
1665	Prolonged survival of mice with human gastric cancer treated with an anti-c-ErbB-2 monoclonal antibody. 1995 , 71, 969-73	27
1664	Oncogenes in tumor progression. 1995 , 3, 17-53	
1663	Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. 1995 , 72, 56-64	50
1662	Expression and prognostic significance of Bcl-2 in ovarian tumours. 1995 , 72, 1324-9	101
1661	Cytogenetic report of a male breast cancer. 1995 , 81, 66-71	12
1660	In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour. 1995 , 4, 41-9	13
1659	Detection of c-erbB-2/neu and fibroblast growth factor-3/INT-2 but not epidermal growth factor receptor gene amplification in endometrial cancer by differential polymerase chain reaction. 1995 , 75, 2139-46	23
1658	Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. 1995 , 75, 2147-52	103
1657	c-erbB-2 and p53 expression in fallopian tube carcinoma. 1995 , 75, 2891-6	33
1656	Ethnic differences in risk and prognostic factors for breast cancer. 1995 , 76, 268-74	60
1655	The molecular basis of ovarian cancer. 1995 , 76, 1992-7	45
1654	Molecular basis of endometrial cancer. 1995 , 76, 2034-40	84
1653	Prognostic indicators for neuroblastoma: stage, grade, DNA ploidy, MIB-1-proliferation index, p53, HER-2/neu and EGFr--a survival study. 1995 , 59, 21-7	28
1652	Prognosis of breast cancer: evidence for interaction between c-erbB-2 overexpression and number of involved axillary lymph nodes. 1995 , 60, 106-11	17
1651	Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab') ₂ for efficient lysis of p185HER2 overexpressing tumor cells. 1995 , 62, 319-24	41
1650	c-erbB-2 anti-sense phosphorothioate oligodeoxynucleotides inhibit growth and serum-induced cell spreading of P185c-erbB-2-overexpressing ovarian carcinoma cells. 1995 , 63, 604-8	33

1649	c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis. 1995 , 64, 146-51	71
1648	c-erbB growth-factor-receptor proteins in ovarian tumours. 1995 , 64, 202-6	42
1647	Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. 1995 , 64, 280-5	704
1646	ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin-embedded breast carcinoma tissues. 1995 , 64, 291-7	27
1645	Comparative genomic hybridization analysis of human sarcomas: I. Occurrence of genomic imbalances and identification of a novel major amplicon at 1q21-q22 in soft tissue sarcomas. 1995 , 14, 8-14	122
1644	Assessing sequential oncogene amplification in human breast cancer. 1995 , 21, 18-22	15
1643	Comparison of immunoreactivity of neu oncoprotein in fine-needle aspirates and paraffin-embedded materials. 1995 , 12, 142-5	4
1642	Genetic probes in cytology: principles and applications. 1995 , 13, 429-35	9
1641	Alterations in levels of different protein kinase C isotypes and their influence on behavior of squamous cell carcinoma of the oral cavity: epsilon PKC, a novel prognostic factor for relapse and survival. 1995 , 17, 516-25	38
1640	Biomarkers in the endometrium. 1995 , 23, 174-8	14
1639	Biomakers in the ovary. 1995 , 59, 223-226	18
1638	Screening for ovarian cancer: what are the optimal surrogate endpoints for clinical trials?. 1995 , 23, 227-32	10
1637	Identification and characterization of c-erbB-2 proteins in serum, breast tumor tissue, and SK-BR-3 cell line. 1995 , 9, 141-50	11
1636	Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein. 1995 , 9, 151-65	23
1635	The relationship between flow-cytometric and immunohistochemically detected c-erbB-2 expression, grade and DNA ploidy in breast cancer. 1995 , 41, 137-45	8
1634	p53 expression measured by flow cytometry. A comparison of three monoclonal antibodies and the relationship with grade and DNA ploidy in breast cancer. 1995 , 41, 146-50	10
1633	MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. 1995 , 34, 97-117	130
1632	SH2 domain-containing signaling proteins in human breast cancer. 1995 , 34, 85-92	6

1631	Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer. 1995 , 34, 253-63	34
1630	Studying environmental influences and breast cancer risk: suggestions for an integrated population-based approach. 1995 , 35, 79-89	21
1629	Protein kinases in human breast cancer. 1995 , 35, 105-14	44
1628	Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. 1995 , 35, 115-32	323
1627	Aberrant function of the Ras signal transduction pathway in human breast cancer. 1995 , 35, 133-44	176
1626	Combination of new biologic parameters as a prognostic index in epithelial ovarian carcinoma. 1995 , 5, 49-55	12
1625	The neu-protein and breast cancer. 1995 , 426, 107-15	53
1624	Molecular biology of testicular germ cell tumors: current status. 1995 , 73, 355-67	7
1623	Theories on the metastatic process and possible therapeutic options. 1995 , 23, 11-9	3
1622	Correlation of numerical chromosome 11 and 17 imbalance with metastasis of primary breast cancer to lymph nodes. 1995 , 176, 353-9	17
1621	Immunity to oncogenic proteins. 1995 , 145, 33-59	153
1620	Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. 1995 , 1, 644-8	92
1619	Targeting gene transcription: a new strategy to down-regulate c-erbB-2 expression in mammary carcinoma. 1995 , 71, 753-7	23
1618	c-erbB-3 protein expression in ovarian tumours. 1995 , 71, 758-62	32
1617	Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: correlation with tumour progression and nm23 gene expression. 1995 , 72, 691-5	30
1616	Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. 1995 , 71, 473-7	84
1615	Tumor therapy by immune recruitment with bispecific antibodies. 1995 , 145, 179-209	41
1614	c-erbB-2 oncogene expression in Stage I epithelial ovarian cancer. 1995 , 102, 65-7	5

1613	Prognostic Biomarkers in Breast Cancer: Factors Affecting Immunohistochemical Evaluation. 1995 , 1, 243-250	21
1612	Epidermal growth factor-related peptides and their receptors in human malignancies. 1995 , 19, 183-232	2150
1611	Synthesis and beta-lactamase-mediated activation of a cephalosporin-taxol prodrug. 1995 , 2, 223-7	57
1610	Detection of neu differentiation factor with a biospecific affinity sensor during chromatography. 1995 , 705, 163-9	0
1609	Proliferative indices and oncoprotein expression in benign and malignant breast biopsies. 1995 , 2, 416-23	8
1608	Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component. 1995 , 2, 440-4	14
1607	Type 1 growth factor receptors: an overview of recent developments. 1995 , 4, 11-18	21
1606	SH2 and SH3 domains: potential targets for anti-cancer drug design. 1995 , 34, 125-32	67
1605	Prognostic value of proliferating cell nuclear antigen and c-erbB-2 compared with conventional histopathological factors in breast cancer. 1995 , 121, 115-22	10
1604	Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. 1995 , 17, 15-21	51
1603	Frequent expression of genes for receptor tyrosine kinases and their ligands in human pancreatic cancer cells. 1995 , 18, 15-23	20
1602	The expression of Cathepsin-D, C-erbB-2 and EGFR in breast cancer and its correlation to lymphatic metastasis. 1995 , 7, 97-102	1
1601	Expressions of estrogen occupied receptor(EoR) and progesterone occupied receptor(PoR) and C-erbB-2 oncoprotein in human nasopharyngeal carcinomas. 1995 , 7, 103-107	
1600	Gene amplification for c-erbB-2, c-myc, epidermal growth factor receptor, int-2, and N-myc measured by quantitative PCR with a multiple competitor template. 1995 , 41, 826-832	44
1599	Expression of neu Antigen in Normal Lactating and Prepartum Mammary Epithelial Cells. 1995 , 2, 51-56	4
1598	Gene Therapy: A New Approach for Treatment of Cancer. 1995 , 2, 107327489500200	1
1597	Breast Cancer Genetics: Relevance to Oncology Practice. 1995 , 2, 107327489500200	2
1596	Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.. 1995 , 14, 4267-4275	279

1595	Biosynthetic processing of neu differentiation factor. Glycosylation trafficking, and regulated cleavage from the cell surface. 1995 , 270, 19188-96	74
1594	Delayed mammary tumor progression in Muc-1 null mice. 1995 , 270, 30093-101	198
1593	Multiple genetic lesions in laryngeal squamous cell carcinomas. 1995 , 75, 1292-301	24
1592	Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis. 1995 , 75, 1320-6	94
1591	Genetics of Colorectal and Breast Cancer. 1995 , 15, 957-971	4
1590	Roles for a cytoplasmic tyrosine and tyrosine kinase activity in the interactions of Neu receptors with coated pits. 1995 , 270, 7061-7	65
1589	Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. 1995 , 92, 3353-7	132
1588	Binding of Neu differentiation factor with the extracellular domain of Her2 and Her3. 1995 , 270, 24604-8	59
1587	G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210). 1995 , 4, 415-21	27
1586	Dominant-negative mutants of Grb2 induced reversal of the transformed phenotypes caused by the point mutation-activated rat HER-2/Neu. 1995 , 270, 30717-24	36
1585	Development of anti-p185HER2 immunoliposomes for cancer therapy. 1995 , 92, 1327-31	232
1584	Analysis of EGFR, TGF-alpha, neu and c-myc in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced mammary tumors using RT-PCR. 1995 , 16, 3087-92	17
1583	c-Myb repression of c-erbB-2 transcription by direct binding to the c-erbB-2 promoter. 1995 , 270, 9384-9	44
1582	HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. 1995 , 121, 1265-70	68
1581	Mat-8, a novel phospholemman-like protein expressed in human breast tumors, induces a chloride conductance in Xenopus oocytes. 1995 , 270, 2176-82	113
1580	Differential expression of Neu messenger-RNA and protein in hamster-kidney and estrogen-induced kidney tumors. 1995 , 7, 535-8	
1579	Loss of wild-type p53 and C-erbB2 amplification correlates with high-grade breast carcinomas. 1995 , 6, 181-6	
1578	Rodent p53 suppresses the transforming activity of the activated Neu oncogene by modulating the Basal promoter activity of Neu. 1995 , 6, 1087-92	1

1577	C-MYC PROTEIN DISTRIBUTION - MAMMARY ADENOCARCINOMAS OF MTV/MYC TRANSGENIC MICE. 1995 , 7, 5		
1576	Coexpression of C-erbB2 and int-2 oncogenes in invasive breast-cancer. 1995 , 6, 977-84		
1575	Cancer cytogenetics and molecular-genetics - clinical implications (review). 1995 , 7, 1241-51		
1574	Factors controlling growth, motility, and morphogenesis of normal and malignant epithelial cells. 1995 , 160, 221-66		36
1573	Hormonal modulation of neu-induced mammary carcinogenesis: evidence against a single-step induction of mammary cancer by neu. 1995 , 16, 1455-9		5
1572	Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. 1995 , 87, 682-4		82
1571	Prognostic Factors in Cancer. 1995 ,		30
1570	Prognostic Factors for Carcinoma of the Male Breast. 1995 , 2, 199-206		16
1569	Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. 1995 , 92, 432-6		366
1568	Tyrosine kinase inhibition: an approach to drug development. <i>Science</i> , 1995 , 267, 1782-8	33.3	1523
1567	Relationships between proto-oncogene expression and apoptosis induced by anticancer drugs in human prostate tumor cells. 1995 , 1270, 12-8		28
1566	Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. 1995 , 31A, 1425-7		185
1565	c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. 1995 , 31A, 2185-90		102
1564	An evaluation of prognostic factors in advanced ovarian cancer. 1995 , 63, 115-24		7
1563	Overexpression of genes in health and sickness. A bird's eye view. 1995 , 112, 1-13		22
1562	HER-2/neu-targeting gene therapy--a review. 1995 , 159, 65-71		58
1561	Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. 1995 , 159, 11-8		152
1560	Prognostic relevance of aberrations in the erbB oncogenes from breast, ovarian, oral and lung cancers: double-differential polymerase chain reaction (ddPCR) for clinical diagnosis. 1995 , 159, 35-42		36

1559	Biotechnological and gene therapeutic strategies in cancer treatment. 1995 , 159, 73-80	26
1558	The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review. 1995 , 159, 19-27	217
1557	Localization of an epithelial-specific receptor kinase (EDDR1) to chromosome 6q16. 1995 , 25, 584-7	19
1556	Amplification of the E2F1 transcription factor gene in the HEL erythroleukemia cell line. 1995 , 25, 130-8	75
1555	HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. 1995 , 85, 729-34	75
1554	Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions. 1995 , 26, 210-6	80
1553	DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer. 1995 , 59, 321-6	34
1552	Lasp-1 (MLN 50) defines a new LIM protein subfamily characterized by the association of LIM and SH3 domains. 1995 , 373, 245-9	115
1551	Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression. 1995 , 173, 1829-34	17
1550	neu/HER-2 cDNA vaccination and pregnancy loss. 1995 , 772, 274-7	4
1549	EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value. 1995 , 21, 167-78	27
1548	SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens. 1995 , 55, 279-89	63
1547	Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. <i>Science</i> , 1995 , 270, 1491-4	333 1660
1546	Modellsysteme für die Untersuchung genetischer Faktoren in der Krebsentstehung. 1995 , 82, 209-218	2
1545	Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. 1995 , 34, 499-504	73
1544	The Immunology of Breast Cancer. 1995 , 4, 279-300	2
1543	Genetic changes in ovarian cancer. 1995 , 27, 73-8	54
1542	CSF-1 and its receptor in ovarian, endometrial and breast cancer. 1995 , 27, 79-85	130

1541	CD44 variant exon epitopes in primary breast cancer and length of survival. 1995 , 345, 615-9	321
1540	Prognostic classification of breast ductal carcinoma-in-situ. 1995 , 345, 1154-7	638
1539	Amplification of HER-2/neu gene in human gastric adenocarcinomas: correlation with primary site. 1995 , 21, 56-60	22
1538	Oncogenes in cancer of the pancreas. 1995 , 21, 251-3	19
1537	Molecular and immunohistochemical study of class I growth factor receptors in squamous cell lung carcinomas. 1995 , 191, 973-81	6
1536	Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Correlation with expression of p53, c-erbB-2, estrogen receptor and P-glycoprotein. 1995 , 191, 1122-32	11
1535	Biological prognostic factors in non-small cell lung cancer. 1995 , 12 Suppl 1, S13-25	7
1534	mRNA phenotyping of the major ligands and receptors of the EGF supergene family in human ovarian epithelial cells. 1995 , 89, 63-71	12
1533	C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. 1996 , 155, 321-6	90
1532	Detection of C-ERBB-2 Amplification in Transitional Cell Bladder Carcinoma Using Competitive PCR Technique. 1996 , 156, 2089-2093	29
1531	Hormonal control of growth factor receptor expression. 1996 , 784, 336-48	6
1530	Rate-determining steps for tyrosine phosphorylation by the kinase domain of v-fps. 1996 , 35, 1533-9	27
1529	Effects of sodium saccharin and linoleic acid on mRNA levels of Her2/neu and p53 in a human breast epithelial cell line. 1996 , 102, 91-9	4
1528	Amplification in tumors and benign tissue of breast cancer patients. 1996 , 107, 235-9	5
1527	The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer. 1996 , 32A, 63-8	56
1526	Anti-oestrogen stimulation of ERBB2 ectodomain shedding from BT-474 human breast cancer cells with ERBB2 gene amplification. 1996 , 32A, 134-40	8
1525	Anti-idiotypic response to antigrowth factor receptor monoclonal antibodies. 1996 , 32A, 498-505	4
1524	DNA amplification on chromosome 3q26.1-q26.3 in squamous cell carcinoma of the lung detected by reverse chromosome painting. 1996 , 32A, 1205-8	40

1523	Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. 1996 , 99, 185-9	52
1522	Poor correlation with loss of heterozygosity on chromosome 17p and p53 mutations in ovarian cancers. 1996 , 63, 173-9	11
1521	ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies. 1996 , 226, 59-69	26
1520	Identification of a specific DNA region required for enhanced transcription of HER2/neu in the MDA-MB453 breast cancer cell line. 1996 , 15, 749-57	11
1519	Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. 1996 , 27, 119-24	170
1518	Minimal residual epithelial cancer: diagnostic approaches and prognostic relevance. 1996 , 30, 1-60	19
1517	Amplification of ERBB oncogenes in squamous cell carcinomas of the head and neck. 1996 , 32A, 2004-10	34
1516	The biochemistry of metastasis. 1996 , 32, 135-66	34
1515	The effects of dihydrotestosterone on the expression of p185(erbB-2) and c-erbB-2 mRNA in the prostatic cell line LNCaP. 1996 , 59, 441-7	13
1514	Inhibition of erbB-2-positive breast cancer cell growth by erbB-2 antisense oligonucleotides. 1996 , 6, 9-16	22
1513	Status of Bispecific Monoclonal Antibodies for Cancer Therapy. 1996 , 5, 30-39	1
1512	Risk Assessment and Presymptomatic Molecular Diagnosis in Hereditary Breast Cancer. 1996 , 16, 139-167	1
1511	H-RYK, an Unusual Receptor Kinase: Isolation and Analysis of Expression in Ovarian Cancer. 1996 , 2, 189-203	26
1510	. 1996 ,	49
1509	Biomarker expression in prostatic intraepithelial neoplasia. 1996 , 30, 153-66	45
1508	ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.. 1996 , 15, 254-264	441
1507	Detection of heterozygosity loss in microdissected fine needle aspiration specimens of breast carcinoma. 1996 , 40, 642-8	15
1506	c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. 1996 , 14, 2702-8	332

1505	Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. 1996 , 16, 5726-36	125
1504	bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. 1996 , 105, 341-9	121
1503	Estudio de la expresi3n del ant3geno nuclear de proliferaci3n celular y pl85 en el carcinoma no microc3nico de pulm3n. 1996 , 32, 165-169	1
1502	Variations in c-erbB-2 proto-oncogene status in breast cancer tumors as detected by two different cDNA probes. 1996 , 5, 181-6	3
1501	Stem Cell Factor und sein Rezeptor c-Kit: Bedeutung f3r die Keimzellmaturation und die Pathogenese testikul3rer Keimzelltumoren. 1996 , 27, 61-66	
1500	Relationship of Haptoglobin-Related Protein (OA-519) to Newer Prognostic Markers in Breast Cancer. An Immunohistochemical Study on Routine Paraffin Sections. 1996 , 19, 13-22	
1499	Hereditary onset of multiple seborrheic keratoses: a variant of Leser Tr3lat sign?. 1996 , 23, 191-5	3
1498	A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. 1996 , 16, 5276-87	829
1497	Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. 1996 , 14, 737-44	1125
1496	Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. 1996 , 74, 1749-56	154
1495	The Role of the HER-2/neu Oncogene in Gynecologic Cancers. 1996 , 3, 99-105	2
1494	Receptor protein tyrosine kinases. 265-284	1
1493	Allele loss from large regions of chromosome 17 is common only in certain histological subtypes of ovarian carcinomas. 1996 , 74, 1592-7	24
1492	Laminin activates the p185HER2 oncoprotein and mediates growth inhibition of breast carcinoma cells. 1996 , 74, 1427-33	16
1491	Expression of the double-stranded RNA-dependent protein kinase (p68) in human breast tissues. 1996 , 17, 5-12	39
1490	Absence of constitutive EGF receptor activation in ovarian cancer cell lines. 1996 , 74, 446-52	16
1489	c-erbB3 protein expression in ovarian cancer. 1996 , 49, M199-202	26
1488	Use of a polyclonal antibody for the determination of the prognostic value of c-erbB-2 protein over-expression in human breast cancer. 1996 , 35, 23-30	5

1487	Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization. 1996 , 88, 8-16	64
1486	Instability of chromosomes 1, 3, 16, and 17 in primary breast carcinomas inferred by fluorescence in situ hybridization. 1996 , 88, 1-7	17
1485	Improved in vitro growth inhibitory effect of N-(phosphonacetyl)-L-maspartic acid in immunoliposomes. 1996 , 40, 101-109	1
1484	Enhanced cellular uptake of oligonucleotides by EGF receptor-mediated endocytosis in A549 cells. 1996 , 13, 57-61	19
1483	Effectiveness of an adriamycin immunoconjugate that recognizes the C-erbB-2 product on breast cancer cell lines. 1996 , 26, 501-7	13
1482	The neu oncogene product in serum and tissue of patients with metastatic gastrointestinal carcinomas. 1996 , 122, 118-21	6
1481	Expression of stem-cell factor and its receptor c-kit protein in normal testicular tissue and malignant germ-cell tumours. 1996 , 122, 301-6	90
1480	The performance of e23(Fv)PEs, recombinant toxins targeting the erbB-2 protein. 1996 , 7, 79-86	14
1479	Preclinical testing of an anti-erbB-2 recombinant toxin. 1996 , 38, 19-25	15
1478	The significance of heregulin in breast cancer tumor progression and drug resistance. 1996 , 38, 57-66	100
1477	Transgenic mouse models of breast cancer. 1996 , 39, 119-35	43
1476	FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. 1996 , 39, 203-12	48
1475	INT2 and ERBB2 amplification and ERBB2 expression in breast tumors from patients with different outcomes. 1996 , 37, 65-76	14
1474	Human papilloma virus DNA: a factor in the pathogenesis of mammary Paget's disease?. 1996 , 41, 51-7	28
1473	ErbB2 activation and signal transduction in normal and malignant mammary cells. 1996 , 1, 199-206	15
1472	HER-2/neu gene amplification in cervical cancer in Chinese women of Hong Kong and China. 1996 , 22, 171-5	6
1471	Adenocarcinoma of duodenum and ampulla of Vater: clinicopathology study and expression of p53, c-neu, TGF-alpha, CEA, and EMA. 1996 , 61, 100-5	33
1470	ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. 1996 , 77, 71-8	174

1469	New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2 expression. 1996 , 77, 1419-26	97
1468	Expression of cell regulatory proteins in ovarian borderline tumors. 1996 , 77, 2092-8	20
1467	Serial serum c-erbB-2 levels in patients with breast carcinoma. 1996 , 78, 267-72	37
1466	Validation of a differential PCR and an ELISA procedure in studying HER-2/neu status in breast cancer. 1996 , 65, 129-33	17
1465	Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer. 1996 , 68, 34-8	29
1464	c-erbB-2 expression in FNAB smears and matched surgical specimens of breast cancer. 1996 , 14, 135-9	12
1463	NDF induces expression of a novel 46 kD protein in estrogen receptor positive breast cancer cells. 1996 , 62, 102-112	7
1462	ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization. 1996 , 16, 130-7	18
1461	Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2. 1996 , 15, 227-38	23
1460	The metastatic phenotype--prognostic implications. 1996 , 24, 71-96	11
1459	Early ovarian cancer: A review of its genetic and biologic factors, detection, and treatment. 1996 , 20, 86-137	1
1458	Genetic and molecular events in the pathogenesis of lung cancer. 1996 , 20, 247-265	
1457	c-erb B-2 and p53 expression in breast cancer fine needle aspirates. 1996 , 7, 178-86	4
1456	Oncogene amplification in archival ovarian carcinoma detected by fluorescent differential polymerase chain reaction - a routine analytical approach. 1996 , 6, 291-297	6
1455	The molecular genetics of sporadic and familial epithelial ovarian cancer. 1996 , 6, 337-355	13
1454	Detection of the metastatic potential of blood-borne and immunomagnetically enriched epithelial cells by quantitative erbB-2 RT-PCR. 1996 , 14, 399-408	7
1453	Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas. 1996 , 27, 117-26	24
1452	Coexpression of p53 and c-erbB-2 proteins is associated with histological type, tumour stage, and cell proliferation in malignant salivary gland tumours. 1996 , 428, 75-83	37

1451	Breast Cancer Cytogenetics: Clues to Genetic Complexity of the Disease. 1996 , 2, 27-30	1
1450	Breast Cancer Cytogenetics: Clues to Genetic Complexity of the Disease. 1996 , 2, 124-140	
1449	c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. 1996 , 73, 620-3	24
1448	In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. 1996 , 73, 1362-5	64
1447	Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. 1996 , 74, 874-80	154
1446	Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3. 1996 , 74, 1126-31	58
1445	DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours. 1996 , 74, 1984-9	61
1444	Quantitative radioimmunohistochemical measurements of p185(erbB-2) in frozen tissue sections. 1996 , 44, 1251-9	15
1443	Dietary Fats, Lipids, Hormones, and Tumorigenesis. 1996 ,	0
1442	Use of a fluorescent-PCR reaction to detect genomic sequence copy number and transcriptional abundance. 1996 , 6, 1013-26	45
1441	Epidermal growth factor. 1996 , 1, 85-121	
1440	Human cancer cells exhibit protein kinase C-dependent c-erbB-2 transmodulation that correlates with phosphatase sensitivity and kinase activity. 1996 , 271, 21786-92	19
1439	A Heterodimeric Nuclear Protein Complex Binds Two Palindromic Sequences in the Proximal Enhancer of the Human erbB-2 Gene. 1996 , 271, 5183-5188	10
1438	Selective cleavage of the heregulin receptor ErbB-4 by protein kinase C activation. 1996 , 271, 18989-95	131
1437	Activated neu induces rapid tumor progression. 1996 , 271, 7673-8	103
1436	Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides. 1996 , 24, 4558-64	26
1435	The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. 1996 , 271, 30897-903	96
1434	¹⁸⁶ Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with ¹²⁵ I and ¹³¹ I-labeled counterparts. 1996 , 11, 133-44	14

1433	Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation. 1996 , 271, 7992-8	102
1432	Transforming Growth Factor-alpha and c-erbB-2 Oncogene Products in Ovarian Epithelial Tumors. 1996 , 4, 129-135	
1431	Identification of differentially expressed genes in breast cancer. 1996 , 8, 395-400	3
1430	Growth inhibition of gastric cancer cell lines by the tyrphostin RG13022 and its effects on intracellular signalling. 1996 , 8, 589-96	
1429	HER-2/neu in bladder carcinoma. 1996 , 8, 957-61	1
1428	Aberrant FGF-2, FGF-3, FGF-4 and C-erb-B2 gene copy number in human ovarian, breast and endometrial tumours. 1996 , 13, 19-35	13
1427	erbB-2 knockout employing an intracellular single-chain antibody (sFv) accomplishes specific toxicity in erbB-2-expressing lung cancer cells. 1996 , 15, 348-54	21
1426	Translation initiation factor eIF-4gamma is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma. 1997 , 6, 33-9	107
1425	Targeting of Liposomes to Solid Tumors: The Case of Sterically Stabilized Anti-Her2 Immunoliposomes. 1997 , 7, 391-417	25
1424	Bispecific antibodies for the treatment of tumours and infectious diseases. 1997 , 6, 1169-78	1
1423	Growth factors in lung cancer. 1997 , 355-380	
1422	Secondary dimerization between members of the epidermal growth factor receptor family. 1997 , 272, 12052-6	83
1421	Cross-talk between phorbol ester-mediated signaling and tyrosine kinase proto-oncogenes. I. Activation of protein kinase C stimulates tyrosine phosphorylation and activation of ErbB2 and ErbB3. 1997 , 272, 31172-81	27
1420	Low frequency of ErbB-2 proto-oncogene overexpression in human leukocyte antigen-A2-positive breast cancer patients. 1997 , 89, 319-21	12
1419	Regulation of the ERBB-2 promoter by RBPJkappa and NOTCH. 1997 , 272, 14110-4	85
1418	1.6 Genetic Engineering of Antibodies and Derivatives from Mammalian Cells.	
1417	Human DNA topoisomerase II-alpha. 1997 , 10, 1229-34	1
1416	Proto-oncogene products as target antigens for cancer vaccines. 1997 , 11, 863-8	1

1415	Liposome Targeting Following Intravenous Administration: Defining Expectations and a Need for Improved Methodology. 1997 , 7, 331-361	6
1414	Immunoliposomes for cancer treatment. 1997 , 40, 399-435	78
1413	The receptor-like protein-tyrosine phosphatase DEP-1 is constitutively associated with a 64-kDa protein serine/threonine kinase. 1997 , 272, 12158-63	20
1412	HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targeting. 1997 , 272, 29482-6	51
1411	Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1). 1997 , 89, 1524-9	35
1410	A c-erbB-2 promoter-specific nuclear matrix protein from human breast tumor tissues mediates NF-kappaB DNA binding activity. 1997 , 272, 15715-20	20
1409	Association of csk-homologous kinase (CHK) (formerly MATK) with HER-2/ErbB-2 in breast cancer cells. 1997 , 272, 1856-63	47
1408	HER2-targeted gene transfer. 1997 , 8, 719-27	31
1407	Competitive-differential polymerase chain reaction for gene dosage estimation of erbB-1 (egfr), erbB-2, and erbB-3 oncogenes. 1997 , 16, 443-8	18
1406	Biomarkers--the new frontier in the pathology of invasive and preinvasive neoplasias. 1997 , 72, 59-61	1
1405	Oncogene Expression and Amplification in Barrett Adenocarcinoma. 1997 , 4, 203-211	2
1404	Anti-P-glycoprotein antibody C219 cross-reactivity with c-erbB2 protein: diagnostic and clinical implications. 1997 , 89, 1473-6	12
1403	Inhibition of proliferation and modulation of estradiol metabolism: novel mechanisms for breast cancer prevention by the phytochemical indole-3-carbinol. 1997 , 216, 246-52	54
1402	Control of differentiation, transformation, and apoptosis in granulosa cells by oncogenes, oncoviruses, and tumor suppressor genes. 1997 , 18, 435-61	100
1401	Mammalian Cell Biotechnology in Protein Production. 1997 ,	14
1400	Overexpression of the Epidermal Growth Factor Receptor Family in Gastric Cancer Suggests a Role in Tumor Pathogenesis. 1997 , 14, 252-259	5
1399	Loss of expression of a 55 kDa nuclear protein (nmt55) in estrogen receptor-negative human breast cancer. 1997 , 6, 209-21	22
1398	Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation. 1997 , 17, 5410-25	124

1397	HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival. 1997 , 14, 229-36	59
1396	neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice. 1997 , 17, 3155-63	89
1395	[Detection of an "autocrine loop" between EGF receptor and TGF-alpha in head-neck carcinomas]. 1997 , 76, 415-20	0
1394	HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. 1997 , 71, 343-71	119
1393	Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. 1997 , 18, 188-96	56
1392	Targeted tumor cytotoxicity mediated by intracellular single-chain anti-oncogene antibodies. 1997 , 40, 51-84	3
1391	c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival. 1997 , 75, 1667-73	29
1390	Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3-13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: evidence for two new tumour-suppressor genes. 1997 , 75, 1256-62	44
1389	The use of biomarker expression to characterize neoplastic processes. 1997 , 72, 96-104	10
1388	The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. 1997 , 75, 315-325	56
1387	Identification of p185neu sequences required for monoclonal antibody- or ligand-mediated receptor signal attenuation. 1997 , 16, 1395-405	6
1386	Retrospective evaluation of c-erbB-2 oncogene amplification using competitive PCR in collecting duct carcinoma of the kidney. 1997 , 158, 245-7	42
1385	Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases. 1997 , 40, 1130-5	95
1384	p53 and HER-2 alterations in renal cell carcinoma. 1997 , 50, 636-42	22
1383	Human ovarian cancer of the surface epithelium. 1997 , 54, 541-4	73
1382	Molecular cloning of human GRB-7 co-amplified with CAB1 and c-ERBB-2 in primary gastric cancer. 1997 , 232, 5-9	40
1381	Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. 1997 , 236, 76-85	187
1380	Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy. 1997 , 64, 378-85	57

1379	Overexpression of cyclin D1 in epithelial ovarian cancers. 1997 , 64, 189-95	89
1378	p53 and HER-2/neu overexpression in ovarian borderline tumors. 1997 , 65, 218-24	31
1377	Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. 1997 , 12, 117-23	48
1376	Tracking the MEN1 gene. 1997 , 174, 266-70	3
1375	Radioiodinated antibody targeting of the HER-2/neu oncoprotein. 1997 , 24, 451-459	14
1374	Applications of genetic technologies to cancer screening, prevention, diagnosis, prognosis, and treatment. 1997 , 13, 74-81	5
1373	Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. 1997 , 28, 321-31	101
1372	Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. 1997 , 28, 1180-8	113
1371	Estrogens and glucocorticoids induce the expression of c-erbB2/NEU receptor in Ishikawa human endometrial cells. 1997 , 61, 1083-95	14
1370	Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. 1997 , 36, 66-75	374
1369	Clinical applications of tumor suppressor genes and oncogenes in cancer. 1997 , 257, 157-80	8
1368	The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. 1997 , 112, 1103-13	172
1367	Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor. 1997 , 71, 173-9	92
1366	Inducible antisense inhibition of erbB-2 expression reduces anchorage independent growth of ovarian carcinoma cells. 1997 , 117, 73-9	7
1365	Translational research studies of erbB oncogenes: selection strategies for breast cancer treatment. 1997 , 118, 143-51	3
1364	Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. 1997 , 121, 169-75	109
1363	Growth factors in human ovarian cancer. 1997 , 23, 113-31	35
1362	Unconjugated antibodies for cancer therapy: lessons from the clinic. 1997 , 23, 305-19	4

1361	Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy. 1997 , 15, 2262-8	34
1360	Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. 1997 , 15, 2518-25	196
1359	HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. 1997 , 15, 2894-904	662
1358	Quantification of c-erbB-2 gene expression in breast cancer by competitive RT-PCR. 1997 , 43, 2114-2120	19
1357	Gynecologic Cancer in the Elderly. 1997 , 13, 363-379	5
1356	Role of c-Src tyrosine kinase in EGF-induced mitogenesis. 1997 , 2, d501-18	97
1355	Sequence of Events in Lung Carcinogenesis. 1997 , 86-102	
1354	Intrabodies: turning the humoral immune system outside in for intracellular immunization. 1997 , 4, 11-5	92
1353	Activation of erbB2 and c-src in phorbol ester-treated mouse epidermis: possible role in mouse skin tumor promotion. 1997 , 14, 1435-44	55
1352	A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. 1997 , 14, 2099-109	151
1351	Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu. 1997 , 14, 1965-71	25
1350	Localization of a growth suppressor activity in MCF7 breast cancer cells to chromosome 17q24-q25. 1997 , 14, 2339-45	28
1349	BRK tyrosine kinase expression in a high proportion of human breast carcinomas. 1997 , 15, 799-805	131
1348	Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. 1997 , 15, 953-60	82
1347	Potent antitumour activity of a new class of tumour-specific killer cells. 1997 , 385, 78-80	94
1346	Soluble ectodomain of c-erbB-2 oncoprotein in relation to tumour stage and grade in human renal cell carcinoma. 1997 , 75, 1674-7	6
1345	Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas. 1997 , 75, 1782-7	58
1344	Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. 1997 , 76, 917-22	58

1343	Protein tyrosine kinases and cancer. 1997 , 1333, F217-48	89
1342	Heparin-binding EGF-like growth factor. 1997 , 1333, F179-99	156
1341	Overexpression of c-erbB-2 protein and locoregional recurrence in node-positive breast cancer. 1997 , 6, 354-360	4
1340	Molecular genetic events in the development and progression of ovarian cancer in humans. 1997 , 3, 207-13	4
1339	Molecular profile of advanced-stage transitional cell carcinoma of the ovary. 1997 , 177, 120-5	9
1338	The differential expression of the HER-2/neu oncogene among high-risk human papillomavirus-infected glandular lesions of the uterine cervix. 1997 , 177, 133-8	7
1337	Cytogenetic and fluorescence in situ hybridization analyses of a microcystic adnexal carcinoma with del(6)(q23q25). 1997 , 98, 106-10	12
1336	Bivalence of EGF-like ligands drives the ErbB signaling network. 1997 , 16, 4938-50	173
1335	Transcriptional regulation of type I receptor tyrosine kinases in the mammary gland. 1997 , 2, 153-63	19
1334	Hormonal regulation of type I receptor tyrosine kinase expression in the mammary gland. 1997 , 2, 175-85	13
1333	ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling. 1997 , 2, 97-107	88
1332	Mutational analysis of the BRCA1 tumor suppressor gene in endometrial carcinoma. 1997 , 66, 449-53	10
1331	Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. 1997 , 43, 87-95	59
1330	Guidelines for systemic therapy of early stage breast cancer. 1997 , 43, 259-76	10
1329	Low-density lipoprotein receptor mRNA in human breast cancer cells: influence by PKC modulators. 1997 , 42, 195-205	32
1328	Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. 1997 , 42, 1-5	81
1327	Possibilities of a viral etiology for human breast cancer. A review. 1997 , 56, 131-42	51
1326	Immunohistochemically detected HER-2/neu-expression and prognosis in endometrial carcinoma. 1997 , 259, 189-95	21

1325	The oncoproteins c-erb-B2, c-fos and the tumour suppressor protein p53 in human embryos and fetuses. 1997 , 195, 345-52	9
1324	Identification of an amplified gene cluster in glioma including two novel amplified genes isolated by exon trapping. 1997 , 101, 190-7	18
1323	[Tyrosine kinase inhibitors. An approach to pathogenesis-oriented tumor therapy]. 1997 , 38, 1074-82	
1322	Specific cytotoxic T lymphocytes in gene therapy. 1997 , 75, 259-66	32
1321	Cytogenetic, morphologic and oncogene analysis of a cell line derived from a heterologous mixed mullerian tumor of the ovary. 1997 , 33, 325-31	19
1320	HER-2/neu signal transduction in human breast and ovarian cancer. 1997 , 15, 1-8	156
1319	Estrogen action in human ovarian cancer. 1997 , 25, 1-9	67
1318	Prognostic factors in advanced ovarian cancer. 1997 , 7, 4-8	9
1317	The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. 1997 , 27, 1115-23	70
1316	Fast isolation of RNA to detect expression of tumor markers. 1997 , 11, 340-2	2
1315	c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. 1997 , 30, 195-201	44
1314	Binding-induced activation of overexpressed p185HER2 is essential in triggering neuronal differentiation of PC12 cells. 1997 , 67, 316-326	2
1313	Distinct characteristics of heregulin signals mediated by HER3 or HER4. 1997 , 173, 187-95	34
1312	Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas. 1997 , 20, 234-242	39
1311	Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. 1997 , 20, 320-328	147
1310	Four regions of allelic imbalance on 17q12-qter associated with high-grade breast tumors. 1997 , 20, 354-362	36
1309	Alterations of the p16INK4A gene in human ovarian cancers. 1997 , 18, 134-41	14
1308	Gene expression changes associated with chemically induced rat mammary carcinogenesis. 1997 , 20, 204-15	75

1307	A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma. 1997 , 79, 1587-1594	44
1306	Immunohistochemically detected p53 and HER-2/neu expression and nuclear DNA content in familial epithelial ovarian carcinomas. 1997 , 79, 2147-53	12
1305	Mechanisms of escape from CD8+ T-cell clones specific for the HER-2/neu proto-oncogene expressed in ovarian carcinomas: related and unrelated to decreased MHC class 1 expression. 1997 , 70, 112-9	25
1304	Quantitative analysis of p185(HER-2/neu) protein in breast cancer and its association with other prognostic factors. 1997 , 74, 175-9	9
1303	Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells. 1997 , 73, 143-50	22
1302	Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. 1997 , 73, 875-9	48
1301	Common patterns of genetic evolution in human solid tumors. 1997 , 29, 1-27	100
1300	c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. 1998 , 51, 109-19	89
1299	The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A. 1998 , 17, 195-202	25
1298	Cyclin D1 in breast cancer. 1998 , 52, 1-15	206
1297	HER-2/neu as a predictive marker of response to breast cancer therapy. 1998 , 52, 65-77	210
1296	The relationship between prognostic and predictive factors in the management of breast cancer. 1998 , 52, 261-88	126
1295	c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. 1998 , 52, 55-64	44
1294	Prognostic significance of micrometastatic bone marrow involvement. 1998 , 52, 201-16	52
1293	Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. 1998 , 17, 3385-97	286
1292	Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. 1998 , 17, 5948-63	102
1291	Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines. 1998 , 70, 49-55	4
1290	Analysis of allelic imbalance on chromosome 17p13 in stage I and stage II epithelial ovarian cancers. 1998 , 71, 77-82	12

1289	Borderline tumors of the ovary: a clinico-pathologic and immunohistochemical study of 54 cases. 1998 , 24, 437-45	7
1288	Tumor-specific activation of mitogen-activated protein kinase in human colorectal and gastric carcinoma tissues. 1998 , 89, 903-9	20
1287	Human tumor growth suppression by apoptosis induced with anti-ErbB-2 chimeric monoclonal antibody. 1998 , 89, 562-70	8
1286	Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model. 1998 , 5, 1538-44	39
1285	Analysis of EGF receptor amplicons reveals amplification of multiple expressed sequences. 1998 , 16, 191-5	24
1284	Role of morphogenetic factors in metastasis of mammary carcinoma cells. 1998 , 16, 9-20	106
1283	Transformation of NIH3T3 fibroblasts by the c-Kit receptor tyrosine kinase: effect of receptor density and ligand-requirement. 1998 , 16, 179-90	24
1282	The N-terminal 178-amino-acid domain only of the SV40 large T antigen acts as a transforming suppressor of the HER-2/neu oncogene. 1998 , 16, 547-54	18
1281	The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase. 1998 , 16, 301-10	64
1280	The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin. 1998 , 16, 1249-58	90
1279	Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells. 1998 , 16, 2803-13	63
1278	Determinants for transformation induced by the Axl receptor tyrosine kinase. 1998 , 16, 3177-87	45
1277	Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation. 1998 , 17, 425-32	42
1276	Active signaling by Neu in transgenic mice. 1998 , 17, 1877-84	47
1275	The her-2/neu oncogene stimulates the transcription of N-acetylglucosaminyltransferase V and expression of its cell surface oligosaccharide products. 1998 , 17, 2087-93	77
1274	Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. 1998 , 17, 2235-49	301
1273	Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice. 1998 , 17, 2403-11	35
1272	Cancer vaccines. 1998 , 4, 525-31	441

1271	Tissue microarrays for high-throughput molecular profiling of tumor specimens. 1998 , 4, 844-7	3329
1270	Immunohistochemical expression of c-erbB-2 oncoprotein and EGF-R in pre- and postmenopausal breast cancer. 1998 , 106, 1075-80	3
1269	Nonsyntenic amplification of MYC with CDK4 and MDM2 in a malignant mixed tumor of salivary gland. 1998 , 105, 160-3	26
1268	The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. 1998 , 1377, M25-37	72
1267	Utilization of polymerase chain reaction technology in the detection of solid tumors. 1998 , 82, 1419-42	131
1266	Gynecologic cancers. 1998 , 83, 1751-1756	2
1265	The uncoupling of race and cancer genetics. 1998 , 83, 1765-1769	10
1264	90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells. 1998 , 79, 23-6	25
1263	Interferon-alpha and -gamma inhibit the growth and neoplastic potential of v-src-transformed human epithelial cells by reducing Src tyrosine kinase activity. 1998 , 76, 423-9	5
1262	Cooperativity between the polyamine pathway and HER-2neu in transformation of human mammary epithelial cells in culture: role of the MAPK pathway. 1998 , 76, 563-70	18
1261	Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients. 1998 , 76, 824-8	62
1260	Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. 1998 , 78, 202-8	64
1259	Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. 1998 , 78, 661-6	185
1258	Prognostic significance of c-erbB-2 oncoprotein expression in intestinal-type adenocarcinoma of the sinonasal tract. 1998 , 20, 224-31	25
1257	Isolation of the intact molecule and ectodomain of C-erbB-2 oncoprotein from SK-BR-3 cells and development of immunoassays on microplate. 1998 , 12, 298-303	2
1256	Amplification of oncogenes in human cancer cells. 1998 , 20, 473-9	135
1255	Regulation of heregulin beta1-induced differentiation in a human breast carcinoma cell line by the extracellular-regulated kinase (ERK) pathway. 1998 , 70, 587-95	22
1254	Severe follicular hyperplasia and spontaneous papilloma formation in transgenic mice expressing the neu oncogene under the control of the bovine keratin 5 promoter. 1998 , 21, 2-12	39

1253	Involvement of tyrosine phosphorylation of p185c-erbB2/neu in tumorigenicity induced by x-rays and the neu oncogene in human breast epithelial cells. 1998 , 21, 225-233	34
1252	Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells. 1998 , 21, 261-72	129
1251	A novel splice variant of HER2 with increased transformation activity. 1998 , 23, 62-8	111
1250	Molecular pathology of ovarian carcinomas. 1998 , 433, 103-11	37
1249	Identification, localization and characterization of the human gamma-synuclein gene. 1998 , 103, 106-12	148
1248	Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides. 1998 , 5, 743-50	36
1247	Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity. 1998 , 5, 64-76	26
1246	Detection of eIF4E gene amplification in breast cancer by competitive PCR. 1998 , 5, 232-7	45
1245	Adrenocorticotropin-Producing Pituitary Carcinoma with Expression of c-erbB-2 and High PCNA Index: A Comparative Study with Pituitary Adenomas and Normal Pituitary Tissues. 1998 , 9, 53-62	32
1244	Immunologic approaches to inhibiting cell-surface-residing oncoproteins in human tumors. 1998 , 17, 179-89	8
1243	Oligoclonal T cells in human cancer. 1998 , 15, 203-11	19
1242	Expression of c-erbB-2 and PCNA in cervical adenocarcinoma and its signification. 1998 , 10, 68-70	
1241	[Molecular genetics of epithelial ovarian neoplasms: correlations with phenotype and biological behavior]. 1998 , 19, 95-103	4
1240	The level of erbB2 expression predicts sensitivity to the cytotoxic effects of an intracellular anti-erbB2 sFv. 1998 , 76, 451-8	12
1239	Genetic initiation, progression and prognostic markers in transitional cell carcinoma of the bladder: a summary of the structural and transcriptional changes, and the role of developmental genes. 1998 , 82, 503-12	16
1238	Genetic alterations in endometrial carcinomas. 1998 , 8, 415-422	3
1237	Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. 1998 , 32, 69-80	110
1236	No evidence for c-erbB-2 overexpression in gastric carcinogenesis. 1998 , 32, 335-9	5

1235	Type 1 protein tyrosine kinases in benign and malignant breast lesions. 1998 , 33, 514-21	20
1234	Radiosensitization mediated by a transfected anti-erbB-2 single-chain antibody in vitro and in vivo. 1998 , 42, 817-22	20
1233	Changes in heregulin beta1 (HRGbeta1) signaling after inhibition of ErbB-2 expression in a human breast cancer cell line. 1998 , 138, 163-71	6
1232	c-erbB-2 oncoprotein assay in ovarian carcinoma and its clinical correlation with prognostic factors. 1998 , 132, 91-7	15
1231	The promise of cancer genetics. 1998 , 351 Suppl 2, S11-8	47
1230	The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. 1998 , 59, 1-14	180
1229	High-dose chemotherapy: how resistant is breast cancer?. 1998 , 1, 62-72	14
1228	Quantitative determination of c-erbB-2 in human breast tumours: potential prognostic significance of low values. 1998 , 34, 476-81	20
1227	Expression of abnormal transcripts of the FHIT (fragile histidine triad) gene in ovarian carcinoma. 1998 , 34, 745-9	9
1226	ERBB2 oncogene in human breast cancer and its clinical significance. 1998 , 34, 791-808	346
1225	Cellular and molecular determinants of cisplatin resistance. 1998 , 34, 1535-42	310
1224	Histopathology and molecular biology of ovarian epithelial tumors. 1998 , 2, 195-207	17
1223	Immunohistochemical analysis of the oncoprotein c-erbB-2 expression in oral benign and malignant lesions. 1998 , 27, 209-12	20
1222	Possible retroviral etiology of human breast cancer. 1998 , 52, 6-12	6
1221	Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology. 1998 , 29, 34-40	69
1220	Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. 1998 , 29, 771-7	105
1219	Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. 1998 , 425, 145-50	110
1218	From amplification to gene in thyroid cancer: a high-resolution mapped bacterial-artificial-chromosome resource for cancer chromosome aberrations guides gene discovery after comparative genome hybridization. 1998 , 63, 625-37	55

1217	PROGNOSTIC MARKERS IN BLADDER CANCER: A CONTEMPORARY REVIEW OF THE LITERATURE. 1998 , 160, 645-659	219
1216	erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. 1998 , 90, 1361-70	549
1215	Hematopoietic progenitor cell transplantation in breast cancer: current status and future directions. 1998 , 16, 102-26	22
1214	c-erbB-2 as a target for immunotherapy. 1998 , 7, 1879-96	4
1213	Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1. 1998 , 37, 3220-8	22
1212	Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. 1998 , 273, 28238-46	227
1211	erbB genes in the mouse uterus: cell-specific signaling by epidermal growth factor (EGF) family of growth factors during implantation. 1998 , 204, 97-110	46
1210	Adjacent carboxyterminal tyrosine phosphorylation events identify functionally distinct ErbB2 receptor subsets: implications for molecular diagnostics. 1998 , 241, 467-75	10
1209	A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2. 1998 , 281, 475-83	33
1208	Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu. 1998 , 77, 85-90	19
1207	Multivariate analyses of DNA index, p62c-myc, and clinicopathological status of patients with ovarian cancer. 1998 , 51, 455-61	2
1206	Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals a novel target selectivity for erbB3. 1998 , 273, 7717-24	77
1205	Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. 1998 , 90, 1262-9	92
1204	Cloning and characterization of Krct, a member of a novel subfamily of serine/threonine kinases. 1998 , 7, 2157-66	19
1203	erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. 1998 , 90, 1346-60	510
1202	A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer. 1998 , 9, 1775-98	40
1201	Expression of metastasis-associated genes h-mts1 (S100A4) and nm23 in carcinoma of breast is related to disease progression. 1998 , 17, 335-42	42
1200	Disease genes and chromosomes: disease maps of the human genome. Chromosome 17. 1998 , 2, 357-81	2

1199	Tyrosine phosphorylation of c-ErbB-2 is regulated by the cellular form of prostatic acid phosphatase in human prostate cancer cells. 1998 , 273, 22096-104	70
1198	Csk homologous kinase, a novel signaling molecule, directly associates with the activated ErbB-2 receptor in breast cancer cells and inhibits their proliferation. 1998 , 273, 4065-72	30
1197	Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. 1998 , 17, 313-21	27
1196	Effects of protein tyrosine phosphatase inhibitors on EGF- and insulin-dependent mammary epithelial cell growth. 1998 , 217, 180-7	9
1195	Marker Panel Predictive of Lymph Node Metastasis in Young Patients with Breast Carcinoma. 1998 , 6, 55-60	3
1194	Biologic Markers in Breast Cancer: An Update. 1998 , 21, 317-325	2
1193	p185 overexpression in 220 samples of breast cancer undergoing primary surgery: comparison with c-erbB-2 gene amplification. 1998 , 1, 855-61	4
1192	c-erbB-2 status is an independent predictor of survival after first recurrence. 1998 , 12, 123-8	1
1191	Gene Analysis in Solid Tumors: In Situ Hybridization. 1998 , 21, 327-333	1
1190	Targeting of Drugs to Solid Tumors Using Anti-Her2 Immunoliposomes. 1998 , 8, 425-442	18
1189	ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. 1998 , 95, 6809-14	91
1188	Gene amplification in a p53-deficient cell line requires cell cycle progression under conditions that generate DNA breakage. 1998 , 18, 3089-100	78
1187	Gene therapy: ovarian carcinoma as the paradigm. 1998 , 109, 444-67	13
1186	Role of estrogen and estrogen-related growth factor in the mechanism of hormone dependency of endometrial carcinoma cells. 1998 , 55 Suppl 1, 35-44	18
1185	Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc. 1998 , 18, 5178-88	136
1184	Histological features and prognosis of patients with mucoepidermoid carcinoma of the parotid gland. 1998 , 112, 944-7	22
1183	Antiproliferative and apoptotic activities of ketonucleosides and keto-C-glycosides against non-small-cell lung cancer cells with intrinsic drug resistance. 1998 , 42, 779-84	10
1182	Expression of Grb7 growth factor receptor signaling protein in kidney development and in adult kidney. 1998 , 275, F770-6	6

1181	Adaptor PCR for the specific amplification of unknown DNA fragments. 1998 , 24, 26, 28	10
1180	Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. 1998 , 16, 2409-16	58
1179	Immune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation. 1998 , 92, 1471-1490	264
1178	Chromosomal and Gene Amplification in Diffuse Large B-Cell Lymphoma. 1998 , 92, 234-240	284
1177	Expression of the ErbB Family of Receptors in Ovarian Cancer. 1998 , 5, 161-165	10
1176	Aberrant Splicing of the TSG101 Tumor Suppressor Gene in Human Breast and Ovarian Cancers. 1998 , 5, 281-285	1
1175	Comparative PCR: an improved method to detect gene amplification. 1998 , 24, 22-4, 26	16
1174	C-erbB-2 Expression in Primary Breast Cancer. 1999 , 14, 16-26	19
1173	Clinical use of serum c-erbB-2 in patients with ovarian masses. 1999 , 48, 133-7	13
1172	Transforming growth factor-alpha levels in the serum and ascites of patients with advanced epithelial ovarian cancer. 1999 , 47, 200-4	13
1171	Quantitation of c-erbB-2 gene amplification in breast cancer tissue by competitive PCR. 1999 , 20, 153-61	6
1170	Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different?. 1999 , 17, 3653-63	82
1169	Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. 1999 , 17, 1974-82	254
1168	Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. 1999 , 17, 2180-9	127
1167	The epidemiology of Her-2/neu and P53 in breast cancer. 1999 , 41 Suppl 2, S114-23	3
1166	Therapiestrategien bei der Behandlung des metastasierten Mammakarzinoms. 1999 , 22, 16-17	
1165	New non-cytotoxic approaches to ovarian cancer. 1999 , 10, S65-S68	
1164	The 3rd Annual NIH Symposium on Therapeutic Oligonucleotides. Bethesda, Maryland, USA. December 4, 1998. Abstracts. 1999 , 9, 359-431	6

1163	Bone marrow-derived dendritic cells incorporate and process hydrophobized polysaccharide/oncoprotein complex as antigen presenting cells. 1999 , 14, 695-701	3
1162	Prognostic value of plasma HER-2/neu in African American and Hispanic women with breast cancer. 1999 , 14, 1021-37	7
1161	Mutation analysis of the Smad3 gene in human ovarian cancers. 1999 , 15, 949-53	9
1160	Induction of apoptosis and inhibition of c-erbB-2 in MDA-MB-435 cells by genistein. 1999 , 15, 525-33	30
1159	Overview of immunocytochemical approaches to the differential diagnosis of tumors. 1999 , 115, 415-37	
1158	Strong Epidermal Growth Factor Receptor Expression But Not HER2/neu Expression Correlates with Cell Proliferation in Anal Canal Carcinomas. 1999 , 7, 193-203	2
1157	Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. 1999 , 10, 1621-36	156
1156	Domain-specific interactions between the p185(neu) and epidermal growth factor receptor kinases determine differential signaling outcomes. 1999 , 274, 574-83	27
1155	Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer. 1999 , 96, 10848-53	152
1154	An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling. 1999 , 274, 5263-6	150
1153	c-Src, receptor tyrosine kinases, and human cancer. 1999 , 76, 61-119	185
1152	The c-erbB-2 oncogene amplification by competitive PCR in aneuploid cell clones flow sorted from breast cancer samples. 1999 , 37, 649-54	6
1151	Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells. 1999 , 27, 4008-17	74
1150	ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. 1999 , 274, 8865-74	245
1149	Concepts of immortalization in human mammary epithelial cells. 2000 , 24, 155-72	1
1148	The p185(neu)-containing glycoprotein complex of a microfilament-associated signal transduction particle. Purification, reconstitution, and molecular associations with p58(gag) and actin. 1999 , 274, 25651-8	12
1147	Take your partners, please--signal diversification by the erbB family of receptor tyrosine kinases. 1999 , 16, 255-63	59
1146	Perceptions of Herceptin: a monoclonal antibody for the treatment of breast cancer. 1999 , 14, 5-10	38

1145	Growth factor signal transduction and hormone independence in breast cancer. 1999 , 2, 11-80	
1144	HER-2/neu oncogene amplification in cervical cancer studied by fluorescent in situ hybridization. 1999 , 3, 237-42	11
1143	The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. 1999 , 96, 10869-74	101
1142	Gene expression in human breast epithelial cells exposed to 60 Hz magnetic fields. 1999 , 20, 1633-6	19
1141	Translational control by an upstream open reading frame in the HER-2/neu transcript. 1999 , 274, 24335-41	85
1140	A model-based approach for assessing in vivo combination therapy interactions. 1999 , 96, 13023-8	18
1139	Analysis of heregulin symmetry by weighted evolutionary tracing. 1999 , 12, 943-51	56
1138	Molecular biology of prostate carcinogenesis. 1999 , 32, 197-208	18
1137	Expression of the membrane protein tyrosine phosphatase CD148 in human tissues. 1999 , 54, 485-98	38
1136	Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. 1999 , 45, 73-83	54
1135	Chronic and acute stress as predictors of relapse in primary breast cancer patients. 1999 , 37, 265-72	19
1134	T cell receptor usage in malignant diseases. 1999 , 21, 19-35	
1133	Expression of c-erbB-2 oncoprotein in human thyroid tumours. 1999 , 34, 60-5	21
1132	Marked Intratumoral Heterogeneity of the Proto-Oncogene Her-2/neu Determined by Three Different Detection Systems. 1999 , 5, 369-374	52
1131	Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2. 1999 , 42, 209-18	53
1130	Oncogenic activating mutations in the neu/erbB-2 oncogene are involved in the induction of mammary tumors. 1999 , 889, 45-51	22
1129	A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. 1999 , 5, 280-5	799
1128	Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors. 1999 , 6, 209-19	27

1127	Neuregulin receptor-mediated gene transfer by human epidermal growth factor receptor 2-targeted antibodies and neuregulin-1. 1999 , 6, 537-45	1
1126	Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530. 1999 , 18, 1227-37	96
1125	Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. 1999 , 18, 731-8	116
1124	Immune responses to all ErbB family receptors detectable in serum of cancer patients. 1999 , 18, 1267-75	53
1123	Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. 1999 , 18, 2241-51	569
1122	Collagen-homology domain 1 deletion mutant of Shc suppresses transformation mediated by neu through a MAPK-independent pathway. 1999 , 18, 2617-26	4
1121	NDF/hereregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways. 1999 , 18, 3440-51	84
1120	Cooperative activity between HER oncogenes and the tumor suppressor IRF-1 results in apoptosis. 1999 , 18, 3725-36	38
1119	MYC oncogenes and human neoplastic disease. 1999 , 18, 3004-16	958
1118	Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. 1999 , 18, 6050-62	123
1117	Serine phosphorylation of paxillin by heregulin-beta1: role of p38 mitogen activated protein kinase. 1999 , 18, 7253-64	57
1116	Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. 1999 , 79, 1220-6	168
1115	Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. 1999 , 81, 1419-25	91
1114	Differential regulation of MAP kinase cascade in human colorectal tumorigenesis. 1999 , 81, 1116-21	10
1113	Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer. 1999 , 66, 170-8	49
1112	HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma. 1999 , 66, 163-9	36
1111	Fluorescence in situ hybridization analysis of HER-2/neu, c-myc, and p53 in endometrial cancer. 1999 , 67, 135-43	31
1110	An alternative HER-2/neu transcript of 8 kb has an extended 3'UTR and displays increased stability in SKOV-3 ovarian carcinoma cells. 1999 , 74, 408-15	13

1109	Oncogene amplification in solid tumors. 1999 , 9, 319-25	157
1108	Comparison of alterations of chromosome 17 in carcinoma of the ovary and of the breast. 1999 , 434, 517-22	7
1107	Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210. 1999 , 53, 199-207	51
1106	Biological characteristics of micrometastatic cancer cells in bone marrow. 1999 , 18, 75-90	29
1105	Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family. 1999 , 58, 41-56	40
1104	Toward checkmate: biology and breast cancer therapy for the new millennium. 1999 , 17, 417-27	9
1103	Control of EGF receptor signalling: lessons from fruitflies. 1999 , 18, 181-201	50
1102	Target antigens for prostate cancer immunotherapy. 1999 , 18, 437-49	25
1101	Immunohistochemical expression of internal and external ErbB-2 domains in invasive breast cancer. 1999 , 58, 107-14	8
1100	Analysis of protooncogene c-erbB-2 in benign and malignant human prostate. 1999 , 31, 61-73	11
1099	The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing. 1999 , 18, 3348-58	77
1098	Herceptin in the treatment of metastatic breast cancer. 1999 , 32, 624-631	
1097	Therapy of metastatic breast cancer with humanized antibodies against the HER2 receptor protein. 1999 , 125, 520-4	17
1096	Cancer vaccines: novel approaches and new promise. 1999 , 81, 121-39	20
1095	Adjuvant systemic management of early stage carcinoma of the breast. 1999 , 8, 93-101	1
1094	Leukocyte common antigen-related tyrosine phosphatase receptor: Increased expression and neuronal-type splicing in breast cancer cells and tissue. 1999 , 25, 139-149	25
1093	Inhibition of focal contact formation in cells transformed by p185neu. 1999 , 25, 150-154	8
1092	The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. 1999 , 85, 1894-902	377

1091	Genetic cancer risk assessment. 1999 , 86, 2483-2492	44
1090	American Joint Committee on Cancer prognostic factors consensus conference. 1999 , 86, 2436-46	113
1089	Expression of the SART-1 tumor rejection antigen in breast cancer. 1999 , 80, 64-7	18
1088	Amplification and over-expression of OZF, a gene encoding a zinc finger protein, in human pancreatic carcinomas. 1999 , 80, 369-72	15
1087	Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease. 1999 , 84, 1-5	88
1086	v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells. 1999 , 80, 731-7	44
1085	Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. 1999 , 82, 525-31	21
1084	DNA amplification on chromosome 6p12 in non small cell lung cancer detected by arbitrarily primed polymerase chain reaction. 1999 , 84, 344-9	11
1083	Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastatic prostate cancer. 1999 , 84, 421-5	56
1082	Alteration of jun proto-oncogene status by plasmid transfection affects growth of human ovarian cancer cells. 1999 , 82, 687-93	13
1081	Genetic alterations in early-onset invasive breast carcinomas: correlation of c-erbB-2 amplification detected by fluorescence in situ hybridization with p53 accumulation and tumor phenotype. 1999 , 84, 511-5	7
1080	ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells. 1999 , 83, 564-70	98
1079	Host immunosurveillance contributes to the control of erbB-2 overexpression in HLA-A2-breast-cancer patients. 1999 , 84, 598-603	11
1078	Immunohistochemical screening for oncogenic tyrosine kinase activation. 1999 , 187, 588-93	12
1077	Asymmetrische Synthese der Nakijichinone – selektive Inhibitoren des Her-2/Neu-Protoonkogens. 1999 , 111, 3935-3938	5
1076	Immunocytochemical Methods and Protocols. 1999 ,	19
1075	Molecular chemotherapy for breast cancer. 1999 , 14, 75-90	21
1074	Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors. 1999 , 25-79	367

1073	Trastuzumab: a viewpoint by Mark Pegram. 1999 , 12, 136-8	0
1072	Trastuzumab. 1999 , 12, 129-35	9
1071	Monoclonal antibodies. 1999 , 4, 355-365	
1070	C-erbB-2 immunostaining in laryngeal cancer. 1999 , 119, 392-5	7
1069	Expression analysis of genes at 3q26-q27 involved in frequent amplification in squamous cell lung carcinoma. 1999 , 35, 641-6	61
1068	Discovering novel chemotherapeutic drugs for the third millennium. 1999 , 35, 2010-30	117
1067	Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. 1999 , 26, 781-90	31
1066	Cell type-dependent and -independent control of HER-2/neu translation. 1999 , 31, 201-13	15
1065	Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer. 1999 , 83, 201-6	16
1064	Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. 1999 , 21, 309-18	344
1063	Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents. 1999 , 126, 413-421	19
1062	Hormone refractory prostate cancer. 1999 , 54, 1-7	63
1061	RECOMBINANT ONCOTOXIN AR209 (ANTI-P185erbB-2) DIMINISHES HUMAN PROSTATE CARCINOMA XENOGRAFTS. 1999 , 161, 984-989	13
1060	The role of chemotherapy for metastatic breast cancer. 1999 , 13, 415-34	44
1059	Molecular aspects of ovarian cancer. Is gene therapy the solution?. 1999 , 13, 109-33, viii	7
1058	Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. 1999 , 18, 2149-64	333
1057	The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. 1999 , 96, 4995-5000	351
1056	Solution structure of a DNA.RNA hybrid containing an alpha-anomeric thymidine and polarity reversals: d(ATGG-3'-3'-alphaT-5'-5'-GCTC). r(gagcaccu). 1999 , 38, 15448-58	14

1055	Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGFalpha transgenic rats. 1999 , 155, 303-14	33
1054	Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. 1999 , 154, 1777-83	124
1053	Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle. 1999 , 155, 1543-7	20
1052	The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. 1999 , 253, 78-87	153
1051	Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor. 1999 , 85, 37-42	45
1050	Toward selection of internalizing antibodies from phage libraries. 1999 , 255, 386-93	143
1049	Complete sequence of the human mucin MUC4: a putative cell membrane-associated mucin. 1999 , 338, 325-333	218
1048	Complete sequence of the human mucin MUC4: a putative cell membrane-associated mucin. 1999 , 338, 325	61
1047	Demystified ... oncogenes. 1999 , 52, 55-63	7
1046	Sensitive fluorescent in situ hybridisation method for the characterisation of breast cancer cells in bone marrow aspirates. 1999 , 52, 68-74	15
1045	Biology of high risk benign breast lesions. 1999 , 2, 81-116	
1044	Chapter 8 Molecular progression of prostate cancer. 1999 , 3, 155-187	
1043	Biotechnology Update: First MAb Approved for Treatment of Metastatic Breast Cancer. 1999 , 39, 236-238	22
1042	Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer. 1999 , 112, 459-69	26
1041	Accelerated mammary tumor development in mutant polyomavirus middle T transgenic mice expressing elevated levels of either the Shc or Grb2 adapter protein. 1999 , 19, 8169-79	36
1040	Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. 1999 , 17, 2639-48	2310
1039	New molecular targets for cancer chemotherapy. 1999 , 38, 186-90	
1038	Molecular Analysis and Therapeutic Application. Molecular Targeting for Breast Cancer Treatment.. 2000 , 33, 185-188	1

1037	Biochemistry of HER2 oncogenesis in breast cancer. 2000 , 11, 31-48	12
1036	HER2 testing: laboratory, technical and clinical considerations. 2000 , 11, 77-87	3
1035	HER2 as a predictor of therapeutic response in breast cancer. 2000 , 11, 91-102	20
1034	Emerging antibody-based HER2 (ErbB-2/neu) therapeutics. 2000 , 11, 113-24	18
1033	Suppressing HER2/neu-mediated cell transformation by transcriptional repressors. 2000 , 11, 133-44	6
1032	Expression of erbB receptors and their ligands in breast cancer: implications to biological behavior and therapeutic response. 2000 , 11, 63-75	20
1031	HER2/neu: a target for breast cancer therapy. 2000 , 11, 7-18	7
1030	Development of herceptin. 2000 , 11, 103-11	23
1029	c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. 2000 , 18, 2201-9	225
1028	Regular review: tumour markers in malignancies. 2000 , 320, 424-7	52
1027	Serum level of HER-2/neu in patients with gastric cancer: correlation with HER-2/neu overexpression in gastric carcinoma tissue. 2000 , 21, 139-44	19
1026	[Milestones in Gynecological Oncology over the Last 20 Years]. 2000 , 23, 615-618	
1025	Prognostic Value of Immunohistochemical Expression of Topoisomerase Alpha II, MIB-1, p53, E-Cadherin, Retinoblastoma Gene Protein Product, and HER-2/neu in Adrenal and Extra-adrenal Pheochromocytomas. 2000 , 8, 267-274	22
1024	Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: evolution of a model beyond TNM staging. 2000 , 12, 229-39	41
1023	Prognostic Value of Immunohistochemical Expression of Topoisomerase Alpha II, MIB-1, p53, E-Cadherin, Retinoblastoma Gene Protein Product, and HER-2/neu in Adrenal and Extra-adrenal Pheochromocytomas. 2000 , 8, 267-274	2
1022	Mammary gland neoplasia: insights from transgenic mouse models. 2000 , 22, 554-63	33
1021	The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. 2000 , 88, 804-13	87
1020	ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation. 2000 , 86, 644-51	25

1019	c-erbB2 oncoprotein expression, gene amplification, and chromosome 17 aneusomy in apocrine adenosis of the breast. 2000 , 191, 138-42	19
1018	Ectopic expression of the ErbB-3 binding protein ebp1 inhibits growth and induces differentiation of human breast cancer cell lines. 2000 , 183, 321-9	79
1017	Angiogenesis, p53, and c-erbB-2 immunoreactivity and clinicopathological features in male breast cancer. 2000 , 75, 252-7	27
1016	Increased expression of c-erbB-3 protein and proliferating cell nuclear antigen during development of verrucous carcinoma of the oral mucosa. 2000 , 89, 2597-605	21
1015	p185neu protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. 2000 , 87, 186-194	70
1014	Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. 2000 , 89, 329-36	41
1013	HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. 2000 , 87, 349-359	50
1012	Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. 2000 , 87, 487-498	112
1011	A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes. 2000 , 87, 553-8	35
1010	Salivary carcinoma in HER-2/neu transgenic male mice: An angiogenic switch is not required for tumor onset and progression. 2000 , 88, 329-335	13
1009	Up-regulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression. 2000 , 88, 363-368	64
1008	Linking chromatin architecture to cellular phenotype: BUR-binding proteins in cancer. 2000 , 79, 36-45	9
1007	Retinoids and ovarian cancer. 2000 , 185, 1-20	73
1006	Applying phage antibodies to proteomics: selecting single chain Fv antibodies to antigens blotted on nitrocellulose. 2000 , 286, 119-28	47
1005	Role of erbB2 in breast cancer chemosensitivity. 2000 , 22, 673-80	97
1004	A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals. 2000 , 30, 3338-46	41
1003	Prognostic significance of cell cycle proteins and genomic instability in borderline, early and advanced stage ovarian carcinomas. 2000 , 10, 477-487	38
1002	Molecular approaches to management of epithelial ovarian cancer. 2000 , 10, 2-7	10

1001	New cytotoxics and non-cytotoxics in epithelial ovarian cancer. 2000 , 10, 38-43	6
1000	Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. 2000 , 37, 411-9	49
999	Applied genomics: integration of the technology within pharmaceutical research and development. 2000 , 11, 602-9	34
998	Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol. 2000 , 144, 221-8	27
997	The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. 2000 , 6, 189-95	146
996	Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells. 2000 , 7, 241-8	55
995	DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice. 2000 , 7, 703-6	64
994	Signal transduction in mammary tumorigenesis: a transgenic perspective. 2000 , 19, 1038-44	79
993	RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer cell invasion. 2000 , 19, 1318-28	88
992	Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers. 2000 , 19, 1466-72	22
991	Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. 2000 , 19, 2664-77	60
990	The N-terminal common domain of simian virus 40 large T and small t antigens acts as a transformation suppressor of the HER-2/neu oncogene. 2000 , 19, 2704-13	13
989	A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRK. 2000 , 19, 4273-82	66
988	Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development. 2000 , 19, 4243-54	75
987	Ductal growth is impeded in mammary glands of C-neu transgenic mice. 2000 , 19, 5982-7	18
986	Transgenic mouse models of human breast cancer. 2000 , 19, 6130-7	116
985	Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. 2000 , 19, 6115-21	312
984	Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells. 2000 , 19, 6271-6	30

983	The EGF receptor family as targets for cancer therapy. 2000 , 19, 6550-65	1132
982	Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells. 2000 , 91, 213-22	23
981	Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. 2000 , 28, 1413-22	79
980	Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries. 2000 , 3, 282-291	36
979	The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. 2000 , 88, 229-79	77
978	Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma. 2000 , 63, 163-9	10
977	Ethanol enhances erbB-mediated migration of human breast cancer cells in culture. 2000 , 63, 61-9	36
976	Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study. 2000 , 63, 181-92	47
975	Ras activation in human breast cancer. 2000 , 62, 51-62	142
974	Immunohistochemical versus molecular detection of RAK antigens in breast cancer. 2000 , 69, 27-36	3
973	Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma. 2000 , 77, 1-7	28
972	Molecular characteristics of cancers: the way of the future?. 2000 , 77, 8-10	1
971	Loss of DCC gene expression during ovarian tumorigenesis: relation to tumour differentiation and progression. 2000 , 82, 571-8	22
970	Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by heregulin. 2000 , 82, 683-90	105
969	Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. 2000 , 82, 1446-52	62
968	The ErbB signaling network: receptor heterodimerization in development and cancer. 2000 , 19, 3159-67	1806
967	Antisense Downregulation of the Apoptosis-related Bcl-2 and Bcl-xL Proteins: A New Approach to Cancer Therapy. 2000 , 34, 875-887	2
966	Conformational dynamics in mixed alpha/beta-oligonucleotides containing polarity reversals: a molecular dynamics study using time-averaged restraints. 2000 , 18, 287-302	14

965	Sensitivity of c-erbB positive cells to a ligand toxin and its utility in purging breast cancer cells from peripheral blood stem cell (PBSC) collections. 2000 , 18, 422-7	10
964	Histological grading in ductal carcinoma in situ of the breast. 2000 , 12, 212-215	1
963	Prognostic significance of c-erb B-2 protein status using an enzyme immunoassay in breast cancer. 2000 , 5, 12-7	
962	Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. 2000 , 126, 205-11	43
961	Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. 2000 , 96, 3102-3108	452
960	Comparative study of clinical, pathological and biological characteristics of symptomatic versus asymptomatic breast cancers. 2000 , 11, 581-6	17
959	Tumors of the breast and female genital organs. 2000 , 236-303	
958	Detection of Breast Cancer Cells in the Bone Marrow or Peripheral Blood: Methods and Prognostic Significance. 2000 , 86, 183-190	10
957	Pharmacology and therapeutic use of trastuzumab in breast cancer. 2000 , 57, 2063-2076	28
956	HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. 2000 , 18, 267-74	84
955	Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. 2000 , 18, 632-5	63
954	Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. 2000 , 18, 3651-64	553
953	Automated Assay for HER-2/neu in Serum. 2000 , 46, 175-182	68
952	Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. 2000 , 2000, 394-408	6
951	A Mouse Model for Breast Cancer Induced by Amplification and Overexpression of the neu Promoter and Transgene. 2000 , 6, 4-16	23
950	Ovarian Cancer. 2000 ,	3
949	Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. 2000 , 275, 24735-9	99
948	ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases. 2000 , 148, 385-97	152

947	Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity. 2000 , 165, 5112-21	69
946	Characterization of a repressor element and a juxtaposed tissue-restricted activator element located on the distal neu gene promoter. 2000 , 275, 6600-7	5
945	Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. 2000 , 97, 1230-5	198
944	Molecular assembly of mitogen-activated protein kinase module in ras-transformed NIH3T3 cell line. 2000 , 32, 120-6	2
943	Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. 2000 , 92, 412-7	126
942	Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours. 2000 , 82, 142-50	102
941	Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. 2000 , 97, 3444-3449	176
940	HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. 2000 , 113, 251-8	81
939	HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. 2000 , 113, 852-9	166
938	Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma. 2000 , 113, 669-74	27
937	Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer. 2000 , 17, 103-6	9
936	C-Cbl protein in human cancer tissues is frequently tyrosine phosphorylated in a tumor-specific manner. 2000 , 17, 335-9	3
935	Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines. 2000 , 17, 629-41	25
934	Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). 2000 , 16, 567-76	63
933	Gene amplification at chromosome 1pter-p33 including the genes PAX7 and ENO1 in squamous cell lung carcinoma. 2000 , 17, 67-73	8
932	p185HER2 overexpression in human breast cancer using molecular and immunohistochemical methods. 2000 , 18, 336-42	18
931	Her-2-neu expression and progression toward androgen independence in human prostate cancer. 2000 , 92, 1918-25	288
930	Eradication of c-erbB-2-Positive Ovarian Cancer Cells Mediated by Intracellular Expression of Anti-c-erbB-2 Antibody. 2001 , 39, 757-68	

- 929 Intratumoral gene transfer of the Cytosine deaminase gene for the treatment of breast cancer. **2000**, 35, 523-34
- 928 Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. **2000**, 13, 1238-43 93
- 927 ELISA-Based Quantification of p105 (c-erbB-2, HER2/neu) in Serum of Ovarian Carcinoma. **2001**, 39, 125-33 1
- 926 HER-2/neu als prädiktiver Faktor beim Mammakarzinom. **2000**, 60, 609-619 1
- 925 The quality of Her-2/Neu predictive immunohistochemistry: something FISHy?. **2000**, 13, 1-3 19
- 924 c-erbB-2 Immunohistochemistry in Paraffin Tumors. **2001**, 39, 529-33
- 923 c-erbB-2 Antisense Oligonucleotides Inhibit Serum-Induced Cell Spreading of Ovarian Cancer Cells. **2001**, 39, 769-74 1
- 922 E1A-Mediated Gene Therapy. **2001**, 39, 775-82 1
- 921 Signal transduction : a technical overview. **2001**, 39, 555-65
- 920 Alterations in oncogenes, tumor suppressor genes, and growth factors associated with epithelial ovarian cancers. **2001**, 39, 37-48 3
- 919 Double- and competitive-differential PCR for gene dosage quantitation. **2001**, 39, 347-56 1
- 918 Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. **2000**, 13, 37-45 172
- 917 Vitamin D receptor gene BsmI polymorphism correlates with erbB-2/HER-2 expression in human rectal cancer. **2000**, 58, 242-7 21
- 916 Endocrine Oncology. **2000**,
- 915 Utility of c-erbB-2 expression in tissue and sera of ovarian cancer patients. **2000**, 18, 110-4 17
- 914 Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation. **2000**, 275, 26625-31 64
- 913 Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. **2000**, 53, 374-81 128
- 912 ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. **2000**, 20, 3210-23 247

911	Gene Therapy of Cancer. 2000 ,	1
910	Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?. 2000 , 1, 187-206	49
909	Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. 2000 , 275, 41439-46	239
908	The association of HER-2/neu amplification with breast cancer recurrence. 2000 , 135, 1469-74	37
907	Relevance of the viral RAK alpha gene in diagnosis of malignant versus nonmalignant tumors of the ovary and uterus. 2000 , 7, 360-5	1
906	Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta1-mediated angiogenesis. 2000 , 275, 39451-7	88
905	Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer. 2000 , 275, 33937-44	65
904	The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. 2000 , 103, 57-75	157
903	Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice. 2000 , 97, 9609-14	108
902	Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. 2000 , 277, 757-63	118
901	Protein kinase expression during murine mammary development. 2000 , 219, 259-76	44
900	Cloning, characterization, and chromosomal localization of Pnck, a Ca(2+)/calmodulin-dependent protein kinase. 2000 , 63, 279-88	29
899	Analysis of serum ErbB-2 protein and HLA-DRB1 in Japanese patients with lung cancer. 2000 , 152, 87-95	8
898	Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective. 2000 , 26, 29-52	72
897	Herceptin (trastuzumab) in advanced breast cancer. 2000 , 26, 287-90	100
896	Issues in the treatment of metastatic breast cancer. 2000 , 16, 197-205	3
895	Genetic alterations in breast cancer. 2000 , 6, 271-281	4
894	Herceptin: increasing survival in metastatic breast cancer. 2000 , 4, 24-9	18

893	What is HER2?. 2000 , 4, 2-9	8
892	Herceptin: implications for breast cancer management. 2000 , 4, 37-41	2
891	Immunoelectron microscopical identification of the c-erbB-2 oncoprotein in patients with laryngeal squamous cell carcinoma. 2000 , 102, 403-11	7
890	Assessment of HER2 status in breast cancer: why, when and how?. 2000 , 36, 170-6	89
889	HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. 2000 , 31, 35-9	127
888	C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer. 2000 , 55, 679-83	62
887	[Pathology and molecular biology of lung cancer]. 2000 , 21, 404-23	3
886	Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. 2000 , 19, 1647-56	130
885	Metastases: the glycan connection. 2000 , 2, 321-3	69
884	Tyrosine kinase signalling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer. 2000 , 2, 211-6	41
883	Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. 2000 , 2, 203-10	243
882	Biological Therapy of Breast Cancer. 2000 , 14, 221-246	7
881	Tumor progression and metastasis. 2000 , 21, 497-503	276
880	Current and potential chemotherapeutic agents used for induction chemotherapy in the treatment of breast cancer. 2000 , 6, 327-43	11
879	Expression and function of EGF-related peptides and their receptors in gynecological cancer--from basic science to therapy. 2000 , 20, 1-46	15
878	Liposome targeting to tumors using vitamin and growth factor receptors. 2000 , 60, 285-332	41
877	Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5. 2000 , 11, 327-34	31
876	Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4. 2000 , 275, 10379-87	244

875	Breast cancer genetics. Implications of clinical practice. 2000 , 14, 705-25	5
874	Concomitant oncoprotein detection with fluorescence in situ hybridization (CODFISH): a fluorescence-based assay enabling simultaneous visualization of gene amplification and encoded protein expression. 2000 , 2, 78-83	19
873	A practical guide to HER2 testing. 2000 , 4, 18-23	9
872	Anti-HER2 therapy: how to use Herceptin in clinical practice. 2000 , 4, 30-6	1
871	Prognostic and predictive implications of HER2 status for breast cancer patients. 2000 , 4, 10-7	16
870	Characterization of four novel epithelial ovarian cancer cell lines. 2000 , 36, 357-61	129
869	Risks and benefits of taxanes in breast and ovarian cancer. 2000 , 23, 401-28	84
868	Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. 2000 , 59, 753-67	127
867	Insights into the HER-2 receptor tyrosine kinase mechanism and substrate specificity using a transient kinetic analysis. 2000 , 39, 9786-803	30
866	3D QSAR analyses of novel tyrosine kinase inhibitors based on pharmacophore alignment. 2001 , 41, 1032-40	29
865	HER2/neu as a predictive factor in breast cancer. 2001 , 2, 129-35; discussion 136-7	53
864	Molecular determinants of occult metastatic tumor cells in bone marrow. 2001 , 2, 222-8	14
863	Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations. 2001 , 2 Suppl 1, S15-9	6
862	Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. 2001 , 344, 783-92	8714
861	New horizons in treating metastatic disease. 2001 , 1, 276-87	15
860	New agents for prostate cancer. 2001 , 15, 547-57	0
859	Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3). 2001 , 21, 709-20	19
858	Rapid Cycle Real-Time PCR. 2001 ,	19

857	Biology of HER2 and its importance in breast cancer. 2001 , 61 Suppl 2, 1-13	442
856	Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. 2001 , 17, 615-75	933
855	Tob-mediated cross-talk between MARCKS phosphorylation and ErbB-2 activation. 2001 , 283, 273-7	23
854	Cloning and characterization of hMAP126, a new member of mitotic spindle-associated proteins. 2001 , 287, 116-21	45
853	Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation. 2001 , 271, 315-28	51
852	Targeted gene transduction of mammalian cells expressing the HER2/neu receptor by filamentous phage. 2001 , 313, 965-76	46
851	Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. 2001 , 159, 1645-50	144
850	Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. 2001 , 158, 419-29	431
849	Effects of in vivo heregulin beta1 treatment in wild-type and ErbB gene-targeted mice depend on receptor levels and pregnancy. 2001 , 158, 1871-80	6
848	Status of HER-2 in male and female breast carcinoma. 2001 , 182, 389-92	98
847	Abstracts of the 7th Lung Cancer Biology Workshop: Molecular Biology and Pharmacogenetic Research in the Treatment of Lung Cancer, Barcelona, Spain, April 30â€”May 3, 2001. 2001 , 34, S1-S26	2
846	Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. 2001 , 98, 10869-74	8341
845	Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. 2001 , 15, 50-65	648
844	Evaluation of oncogene amplification in intact and truncated cell nuclei of gastro-esophageal cancer cell lines by DNA in situ hybridisation. 2001 , 103, 127-38	6
843	Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor. 2001 , 19, 2598-606	45
842	Molecular cloning of pituitary tumor transforming gene 1 from ovarian tumors and its expression in tumors. 2001 , 163, 131-9	70
841	Amplification of oncogenes revisited: from expression profiling to clinical application. 2001 , 167, 115-23	100
840	Targeting HER-2/neu-overexpressing breast cancer cells by an antisense iron responsive element-directed gene expression. 2001 , 174, 151-8	3

839	c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. 2001 , 37, 347-54	47
838	The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker. 2001 , 37, 3-10	40
837	Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). 2001 , 37, 11-17	40
836	Introduction. 2001 , 37, 1-2	10
835	What the clinician needs from the pathologist: evidence-based reporting in breast cancer. 2001 , 37 Suppl 7, S5-17	5
834	Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. 2001 , 490, 142-52	256
833	Dynamic chromatin remodeling on the HER2 promoter in human breast cancer cells. 2001 , 507, 88-94	30
832	C�ncer de mama. Clasificaci�n y concepto. 2001 , 8, 3041-3049	
831	Chromosome 7 Aneusomy. A Marker for Metastatic Melanoma?. 2001 , 3, 245-254	54
830	Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. 2001 , 166, 1514-9	101
829	DECREASED EXPRESSION OF CELLULAR PROSTATIC ACID PHOSPHATASE INCREASES TUMORIGENICITY OF HUMAN PROSTATE CANCER CELLS. 2001 , 166, 1943-1950	59
828	Pharmacogenomics: a clinician's primer on emerging technologies for improved patient care. 2001 , 76, 299-309	62
827	The role of distinct p185neu extracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling. 2001 , 98, 5526-31	24
826	Molecular genetics of prostate cancer. 2001 , 33, 130-41	75
825	Structural, dynamic, and enzymatic properties of mixed alpha/beta-oligonucleotides containing polarity reversals. 2001 , 20, 493-9	2
824	Mechanism of action of anti-HER2 monoclonal antibodies. 2001 , 12 Suppl 1, S35-41	139
823	Cdc25B functions as a novel coactivator for the steroid receptors. 2001 , 21, 8056-67	51
822	Ovarian surface epithelium: biology, endocrinology, and pathology. 2001 , 22, 255-88	778

821	A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. 2001 , 10, 43-49	32
820	Quantification of HER2/neu Gene Amplification by Competitive PCR Using Fluorescent Melting Curve Analysis. 2001 , 47, 844-851	49
819	Her2 and trastuzumab in breast cancer. 2001 , 8, 103-10	14
818	Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. 2001 , 19, 1698-706	79
817	The Receptor Tyrosine Kinases. 2001 , 10, 271-288	34
816	Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. 2001 , 19, 2587-95	474
815	Effectiveness of Trastuzumab (Herceptin) in a patient with locally recurrent breast cancer after cardiac failure caused by severe cytotoxic pretreatment. 2001 , 61, 271-4	1
814	Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. 1992 , 61, 193-211	23
813	Tyrosine kinase receptor--nuclear protooncogene interactions in breast cancer. 1992 , 61, 249-73	19
812	Casein gene expression: from transfection to transgenics. 1992 , 61, 379-97	2
811	Mechanisms involving an expanding erbB/EGF receptor family of tyrosine kinases in human neoplasia. 1992 , 61, 139-60	8
810	c-erb B2 amplification and overexpression in human tumors. 1991 , 161-179	23
809	Clinical significance of erbB2 protein overexpression. 1992 , 61, 181-91	10
808	New mechanisms of gene amplification in drug resistance (the episome model). 1991 , 57, 1-11	9
807	Immunoblot detection of P-glycoprotein in human tumors and cell lines. 1991 , 57, 121-49	8
806	Oncogenes as clinical prognostic indicators. 1991 , 53, 3-22	7
805	The insulin-like growth factors, their receptors, and their binding proteins in human breast cancer. 1991 , 53, 93-106	43
804	Steroid modulation of the expression of growth factors and oncogenes in breast cancer. 1991 , 53, 197-220	1

803	Molecular Pathogenesis of Tumors of Thyroid Follicular Cells. 1998 , 59-83	2
802	Immunization of metastatic breast cancer patients with CD80-modified breast cancer cells and GM-CSF. 1998 , 451, 511-8	15
801	Prognostic factors in ovarian cancer. 1998 , 95, 287-352	15
800	Tyrosine Phosphorylation in Oxidative Stress. 1997 , 181-199	5
799	New strategies in locally advanced breast cancer. 1997 , 90, 253-71	4
798	Spontaneous transformation of the ovarian surface epithelium and the biology of ovarian cancer. 1995 , 145-156	2
797	Molecular and biological factors in the pathogenesis of ovarian cancer. 1995 , 77-87	2
796	Cancer. 1996 , 129-161	1
795	The scientific basis of early detection of epithelial ovarian cancer: the National Ovarian Cancer Early Detection Program (NOCEDP). 2002 , 107, 3-28	35
794	Generation of in vitro autologous human cytotoxic T-cell response to E7 and HER-2/neu oncogene products using ex-vivo peptide loaded dendritic cells. 1997 , 417, 583-9	6
793	T-Cell and NK-Mediated Surveillance of Cancer. 1998 , 249-271	1
792	Deciphering Molecular Circuitry Using High-Density DNA Arrays. 1998 , 85-108	1
791	Retroviruses and Their Role in Cancer. 1994 , 313-362	20
790	Characterization of HER2 status by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). 2014 , 1180, 181-207	3
789	The Molecular Basis of Breast Carcinogenesis. 2002 , 347-363	2
788	Novel Molecular Targets for Cancer Drug Discovery. 2002 , 521-540	2
787	Epidermal Growth Factor-Related Peptides in Endocrine Neoplasias. 2000 , 137-191	1
786	Fluorescence In Situ Hybridization. 1999 , 443-471	2

785	Oncogene Activation and Breast Cancer Progression. 1999 , 133-153	1
784	Cisplatin Resistance. 2006 , 283-307	7
783	Tissue microarrays from frozen tissues-OCT technique. 2010 , 664, 73-80	7
782	Amplification testing in breast cancer by multiplex ligation-dependent probe amplification of microdissected tissue. 2011 , 755, 107-18	3
781	Use of formalin-fixed and paraffin-embedded tissues for diagnosis and therapy in routine clinical settings. 2011 , 785, 109-22	27
780	Polyclonal and monoclonal antibodies in clinic. 2014 , 1060, 79-110	21
779	Therapeutic Options for Metastatic Breast Cancer. 2019 , 1152, 131-172	14
778	The Multifaceted Role of HSF1 in Tumorigenesis. 2020 , 1243, 69-85	6
777	The role of E-cadherin and scatter factor in tumor invasion and cell motility. 1991 , 59, 109-26	39
776	Mammary tumor fibroblasts are phenotypically distinct from non-tumor fibroblasts. 1995 , 74, 249-71	6
775	Tumor-stromal cytokine interactions in ovarian neoplasms. 1995 , 74, 181-90	5
774	HER-2 involvement in osteosarcoma. 2014 , 804, 161-77	11
773	Passive vs. Active Targeting: An Update of the EPR Role in Drug Delivery to Tumors. 2014 , 3-45	3
772	IgE immunotherapy against cancer. 2015 , 388, 109-49	12
771	The Future of Biobanking: A Conceptual Look at How Biobanks Can Respond to the Growing Human Biospecimen Needs of Researchers. 2015 , 864, 11-27	25
770	Clinical Aspects of Estrogen and Progesterone Receptors and ERBB2 Testing. 2016 , 161-185	1
769	Breast Cancer Gene Therapy. 2006 , 705-740	0
768	Molecular Profiling in Breast Cancer. 2006 , 977-1006	1

767	Tyrosine kinase inhibitors and cancer therapy. 2007 , 172, 25-44	4
766	Molecular Therapies for Malignant Gliomas. 2009 , 57-84	1
765	HER2-positive DTCs/CTCs in breast cancer. 2012 , 195, 203-15	17
764	Challenges in drug and biomarker co-development. 2012 , 195, 229-39	2
763	Special Ancillary Techniques: Immunohistochemistry. 2013 , 159-168	2
762	Ductal carcinoma in situ of the breast: histological classification and genetic alterations. 1998 , 152, 123-34	7
761	Mamma. 1997 , 133-368	6
760	Quantitative Measurement of the mRNA Expression of the Tumor-Associated Antigen PRAME by Real-Time RT-PCR Using LightCycler and SYBR Green I Technology. 2002 , 177-186	2
759	Genetic alterations in human tumors. 1997 , 221, 149-76	7
758	Biological characteristics of micrometastatic carcinoma cells in bone marrow. 1996 , 213 (Pt 1), 163-77	13
757	Epithelial differentiation and the control of metastasis in carcinomas. 1996 , 213 (Pt 2), 117-35	35
756	Growth factor receptors. 1991 , 83, 159-86	1
755	Discovery and Design of Inhibitors of Oncogenic Tyrosine Kinases. 1994 , 55-70	2
754	Ovarian Cancer. 1995 , 207-215	1
753	Tumorinvasion â€” Die Rolle der Rezeptoren. 1995 , 17-27	1
752	Genetic Alterations in Colorectal Cancers in Correlation to Clinical Parameters. 1990 , 509-516	2
751	Possible Mechanisms of EB PUFA Anti-tumour Action. 2010 , 3-38	5
750	Antibody-Based Therapies for Solid Tumors. 2011 , 245-256	1

749	Taxanes and Epothilones in Cancer Treatment. 2011 , 39-60	1
748	FcR-directed immunotherapies. 1998 , 291-305	1
747	HER-2/neu Assessment in Breast Cancer by Immunohistochemistry and Fluorescence In Situ Hybridization: Comparison of Results and Correlation With Survival. 2000 , 5, 199-207	9
746	Design, synthesis and cytotoxic evaluation of a novel series of benzo[d]thiazole-2-carboxamide derivatives as potential EGFR inhibitors. 2017 , 26, 2180-2189	6
745	Immunohistochemically detected HER-2/neu-expression and prognosis in endometrial carcinoma. 1997 , 259, 189	3
744	HER2-targeted therapy influences CTC status in metastatic breast cancer. 2020 , 182, 127-136	12
743	Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer. 2021 , 185, 183-194	4
742	The Epidermal Growth Factor Receptor Family. 2010 , 435-441	2
741	HER-2/neu Oncogene Amplification and Expression in Human Mammary Carcinoma. 1991 , 75-97	6
740	Female reproductive system. 2011 , 1399-1657	1
739	Molecular Biology and Molecular Genetics of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. 2004 , 385-398	1
738	EGF Family Receptors and Their Ligands in Human Cancer. 1998 , 113-165	8
737	Targeting HER-2/neu-Overexpressing Cancer Cells with Transcriptional Repressor Genes Delivered by Cationic Liposome. 1999 , 357-377	3
736	Cancer Immunotherapy with Rationally Designed Synthetic Peptides. 2006 , 491-498	2
735	E1A Cancer Gene Therapy. 2002 , 465-477	4
734	Targeting of sterically stabilized liposomes to cancers overexpressing HER2/neu proto-oncogene. 1998 , 325-345	2
733	Congenital and Acquired Disturbances of Breast Development and Growth. 2009 , 189-207	1
732	Molecular Oncology of Breast Cancer. 2009 , 501-531	1

731	Trastuzumab and Hypofractionated Whole Breast Radiotherapy: A Victorious Combination?. 2018 , 18, e363-e371	9
730	Canady cold plasma conversion system treatment: An effective inhibitor of cell viability in breast cancer molecular subtypes. 2020 , 19-20, 100109	4
729	Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product.. 1994 , 269, 24747-24755	149
728	ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/hereregulin isoforms.. 1994 , 269, 25226-25233	197
727	Binding of an ETS-related protein within the DNase I hypersensitive site of the HER2/neu promoter in human breast cancer cells.. 1994 , 269, 19848-19858	64
726	c-erbB-2 promoter-specific DNA-binding protein isolated from human breast cancer tissues displays mitogenic activity.. 1994 , 269, 12285-12289	7
725	The erbB3 gene product is a receptor for heregulin.. 1994 , 269, 14303-14306	248
724	Characterization of a breast cancer cell differentiation factor that specifically activates the HER4/p180erbB4 receptor.. 1993 , 268, 18407-18410	49
723	Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists.. 1992 , 267, 15160-15167	82
722	Tyrosine phosphatase inhibition permits analysis of signal transduction complexes in p185HER2/neu-overexpressing human tumor cells.. 1992 , 267, 4357-4363	39
721	The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. 1991 , 266, 1716-1720	141
720	p185HER2 signal transduction in breast cancer cells. 1991 , 266, 14300-14305	72
719	Structure and inducible regulation of the human MET promoter.. 1994 , 269, 12852-12857	36
718	Structure and inducible regulation of the human c-erb B2/neu promoter.. 1990 , 265, 4389-4393	37
717	Isolation and characterization of a novel receptor-type protein tyrosine kinase (hek) from a human pre-B cell line.. 1992 , 267, 3262-3267	64
716	Intracellular expression of single chain antibodies reverts ErbB-2 transformation.. 1994 , 269, 23931-23936	112
715	Monoclonal antibody therapy for breast cancer: herceptin. 2003 , 21, 223-33	31
714	Hereditary Ovarian Cancer. 1994 , 3, 523-543	1

713	Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.	1
712	HER2: biology, detection, and clinical implications. 2011 , 135, 55-62	173
711	Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. 2000 , 97, 3444-9	112
710	Serum HER-2/neu Extracellular Domain Levels in Men Presenting with Suspected Prostate Cancer. 2002 , 2, 99-102	1
709	Her2/neu genetic cancer vaccine in non human primates: relevance of single nucleotide polymorphisms. 2008 , 081208041813023	1
708	c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. 1999 , 13, 1939-49	76
707	Oncogenes, malignant transformation, and modern medicine. 1990 , 300, 59-69	8
706	Molecular advances in gynecologic oncology. 1999 , 11, 394-400	3
705	Recent advances in breast cancer biology. 1999 , 11, 429-34	16
704	Clinical applications of genetic technologies to cancer care. 1997 , 20, 359-77	4
703	Detection of C-ERBB-2 Amplification in Transitional Cell Bladder Carcinoma Using Competitive PCR Technique. 1996 , 2089-2093	2
702	PROGNOSTIC MARKERS IN BLADDER CANCER. 1998 , 645-659	11
701	HER-2/NEU EXPRESSION IN PROSTATE CANCER:. 2001 , 1514-1519	5
700	Oncogenes in gynecologic oncology. 1996 , 51, 710-7	2
699	The genetics of ovarian cancer: molecular biology and clinical application. 1998 , 53, 248-56	5
698	Primary peritoneal carcinoma: a review of the literature. 1999 , 54, 323-35	42
697	Her-2/neu and breast cancer. 2001 , 10, 139-52	154
696	Adjuvant Trastuzumab Emtansine (T-DM1) and Concurrent Radiotherapy for Residual Invasive HER2-positive Breast Cancer: Single-center Preliminary Results. 2020 , 43, 895-901	7

695	Her-2/neu expression in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridization study. 2008 , 16, 54-8	45
694	Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity. 2021 , 40, 263-271	5
693	MUMdex: MUM-based structural variation detection.	3
692	High-resolution ROMA CGH and FISH analysis of aneuploid and diploid breast tumors. 2005 , 70, 51-63	11
691	Signal-transduction therapy. A novel approach to disease management. 1994 , 226, 1-13	140
690	Human immunodeficiency virus type 1-like DNA sequences and immunoreactive viral particles with unique association with breast cancer. 1998 , 5, 645-53	12
689	The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity. 1990 , 10, 2749-2756 ³⁶	
688	Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. 1991 , 11, 979-986	35
687	Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene. 1991 , 11, 1745-1750	19
686	Anti-oncogenic activity of signalling-defective epidermal growth factor receptor mutants. 1992 , 12, 491-498	34
685	Localization of a bidirectional DNA replication origin in the native locus and in episomally amplified murine adenosine deaminase loci. 1993 , 13, 2971-2981	24
684	Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. 1994 , 14, 735-743	84
683	Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. 1994 , 14, 7068-7077	100
682	Delivery of Barnase to Cells in Liposomes Functionalized by Her2-Specific DARPIn Module. 2020 , 46, 1156-11618	
681	Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. 1990 , 86, 131-40	149
680	Elevated insulin receptor content in human breast cancer. 1990 , 86, 1503-10	246
679	Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. 1992 , 89, 1517-22	269
678	Triplex formation inhibits HER-2/neu transcription in vitro. 1993 , 92, 2433-9	64

677	Targeted tumor killing via an intracellular antibody against erbB-2. 1995 , 96, 2980-9	76
676	Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. 2006 , 116, 2695-706	372
675	Shock the heat shock network. 2009 , 119, 445-8	4
674	Hunk is required for HER2/neu-induced mammary tumorigenesis. 2011 , 121, 866-79	23
673	ErbB-2 signals through Plexin-B1 to promote breast cancer metastasis. 2012 , 122, 1296-305	69
672	Reovirus as a novel oncolytic agent. 2000 , 105, 1035-8	79
671	Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. 2000 , 2000, 394-408	1
670	Immune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation. 1998 , 92, 1471-1490	5
669	Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. 2000 , 96, 3102-3108	23
668	Turmeric as Cure-Cumin. 2008 ,	4
667	The Development of the HercepTest. 2010 , 43-60	7
666	ElTocotrienol. 2012 , 117-134	1
665	The molecular basis of children's cancers. 2004 , 25-51	1
664	ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. 1997 , 124, 4999-5011	315
663	Developmental role of the SNF1-related kinase Hunk in pregnancy-induced changes in the mammary gland. 2000 , 127, 4493-4509	23
662	The effects of the neuN and neuT genes on differentiation and transformation of mammary epithelial cells. 1994 , 107, 2919-2929	1
661	The peroxisome proliferator-activated receptor β is an inhibitor of ErbBs activity in human breast cancer cells. 2001 , 114, 4117-4126	34
660	Risk Profiling of Cancer Treatment-Related Cardiovascular Disorders in Breast Cancer Patients Who Received Adjuvant Chemotherapy With Trastuzumab. 2020 , 2, 235-242	1

659	Lgl2 executes its function as a tumor suppressor by regulating ErbB signaling in the zebrafish epidermis. 2009 , 5, e1000720	62
658	The human splice variant Δ 6HER2 induces rapid tumor onset in a reporter transgenic mouse. 2011 , 6, e18727	55
657	Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. 2011 , 6, e21030	132
656	ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers. 2012 , 7, e30447	21
655	Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. 2012 , 7, e30996	28
654	Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells. 2012 , 7, e31422	89
653	ErbB2 receptor over-expression improves post-traumatic peripheral nerve regeneration in adult mice. 2013 , 8, e56282	19
652	Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice. 2013 , 8, e60455	11
651	Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. 2013 , 8, e74950	29
650	Theranostic protein targeting ErbB2 for bioluminescence imaging and therapy for cancer. 2013 , 8, e75288	8
649	Serum soluble CD14 is a potential prognostic indicator of recurrence of human breast invasive ductal carcinoma with Her2-enriched subtype. 2013 , 8, e75366	10
648	Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody. 2013 , 8, e75589	9
647	Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-Ig α) proteins with unique activities. 2014 , 9, e97292	12
646	A universal approach to prepare reagents for DNA-assisted protein analysis. 2014 , 9, e108061	4
645	Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs. 2015 , 10, e0131241	37
644	Embryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene. 2015 , 10, e0136817	11
643	The Practicability of a Novel Prognostic Index (PI) Model and Comparison with Nottingham Prognostic Index (NPI) in Stage I-III Breast Cancer Patients Undergoing Surgical Treatment. 2015 , 10, e0143537	8
642	The Efficacy of Trastuzumab in Animal Models of Breast Cancer: A Systematic Review and Meta-Analysis. 2016 , 11, e0158240	6

641	Synthesis and biochemical characterization of EGF receptor in a water-soluble membrane model system. 2017 , 12, e0177761	3
640	Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants. 2018 , 13, e0190942	4
639	Cardiotoxicity of the adjuvant trastuzumab in a Saudi population: clinical experience of a single institution. 2016 , 7, 1-6	2
638	Molecular Targeting of Her-2/neu Protein Is Not Recommended as an Adjuvant Therapy in Oral Squamous Cell Carcinoma and Oral Lichen Planus. 2015 , 5, 649-52	6
637	ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy. 2016 , 23, T243-T257	30
636	ErbB2+ metastatic breast cancer treatment after progression on trastuzumab: a cost-effectiveness analysis for a developing country. 2014 , 16, 270-80	5
635	Marcadores tumorais no c�ncer de pulm�o: um caminho para a terapia biol�gica. 2002 , 28, 143-149	1
634	Immunotherapeutic approaches for glioma. 2009 , 29, 1-42	118
633	Segment-specific c-ErbB2 expression in human autosomal recessive polycystic kidney disease. 2001 , 12, 379-384	25
632	Correlation of the HER-2 protein expression and other clinicopathological features of ductal infiltrative breast cancer. 2005 , 5, 3-7	1
631	Non-small cell lung carcinoma: cyclin D1, bcl-2, p53, Ki-67 and HER-2 proteins expression in resected tumors. 2007 , 7, 205-11	8
630	[Modern approach to breast cancer diagnostics]. 2014 , 60, 141-60	5
629	HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer. 2015 , 2, 207-24	19
628	HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285. 2014 , 1, 196-204	18
627	Conserved E2F mediated metastasis in mouse models of breast cancer and HER2 positive patients. 2015 , 2, 867-71	11
626	CD147 knockdown improves the antitumor efficacy of trastuzumab in HER2-positive breast cancer cells. 2016 , 7, 57737-57751	12
625	Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1-dependent ACTA2 induction. 2017 , 8, 50570-50581	17
624	Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. 2013 , 4, 1592-605	108

623	ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas. 2016 , 7, 73337-73346	24
622	A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy. 2016 , 7, 87016-87030	18
621	Tumor suppressor role of miR-3622b-5p in ERBB2-positive cancer. 2017 , 8, 23008-23019	12
620	Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation. 2017 , 8, 19039-19048	18
619	Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody. 2017 , 8, 42742-42751	5
618	Cooperative but distinct early co-signaling events originate from ERBB2 and ERBB1 receptors upon trastuzumab treatment in breast cancer cells. 2017 , 8, 60109-60122	5
617	Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth. 2017 , 8, 73947-73963	19
616	Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells. 2017 , 8, 58847-58864	10
615	A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib. 2017 , 8, 85120-85135	11
614	BET inhibitors as novel therapeutic agents in breast cancer. 2017 , 8, 71285-71291	27
613	Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems. 2017 , 8, 80804-80819	17
612	The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2. 2017 , 8, 112245-112257	1
611	Prognostic implications of HER2 heterogeneity in gastric cancer. 2018 , 9, 9262-9272	12
610	Esophageal cancer cells resistant to T-DM1 display alterations in cell adhesion and the prostaglandin pathway. 2018 , 9, 21141-21155	12
609	Oncodriver inhibition and CD4 Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies. 2018 , 9, 23058-23077	15
608	Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells. 2018 , 9, 26527-26542	6
607	Advances in targeted therapies and new promising targets in esophageal cancer. 2015 , 6, 1348-58	31
606	Hypoxia/HIF1 β induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2. 2015 , 6, 1967-80	36

605	The potential utility of acetyltanshinone IIA in the treatment of HER2-overexpressed breast cancer: Induction of cancer cell death by targeting apoptotic and metabolic signaling pathways. 2015 , 6, 21865-77	22
604	Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. 2015 , 6, 30306-16	11
603	A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells. 2016 , 7, 18851-64	8
602	Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer. 2016 , 7, 22650-64	26
601	Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study. 2016 , 7, 50643-50657	7
600	Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem.. 2020 , 3, 179-198	3
599	A paradigm shift in biomarker guided oncology drug development. 2019 , 7, 148	18
598	Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer. 2016 , 28, 330-8	13
597	Influence of chelator and near-infrared dye labeling on biocharacteristics of dual-labeled trastuzumab-based imaging agents. 2016 , 28, 362-9	1
596	Studies on the Safety and Efficacy of Pyrotinib in the Treatment of HER2- Positive Advanced Solid Tumors Excluding Breast Cancer. 2020 , 12, 13479-13487	6
595	Epigenomics in cancer management. 2010 , 2, 255-65	20
594	Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies. 2011 , 3, 25-38	39
593	Immunonanoshells for targeted photothermal ablation of tumor cells. 2006 , 1, 149-54	219
592	MEK inhibition increases lapatinib sensitivity via modulation of FOXM1. 2013 , 20, 2486-99	20
591	Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer. 2020 , 27, 7003-7031	4
590	Genetic and Epigenetic Modulation of Drug Resistance in Cancer: Challenges and Opportunities. 2019 , 20, 1114-1131	14
589	Antibody-based imaging of HER-2: moving into the clinic. 2013 , 13, 1523-37	13
588	The Biochemical and Clinical Perspectives of Lactate Dehydrogenase: An Enzyme of Active Metabolism. 2020 , 20, 855-868	15

587	PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients. 2017 , 18, 57-64	6
586	Genetic modification of natural killer cells for adoptive cellular immunotherapy. 2009 , 1, 623-30	14
585	[Alterations of c-Myc and c-erbB-2 genes in ovarian tumours]. 2009 , 137, 47-51	2
584	Impact of 2013 ASCO/CAP guidelines on various HER2 reporting categories in breast cancer by fluorescentin-situhybridization and Immunohistochemistry: A meta-analysis with systematic review. 2019 , 5, 14-26	1
583	In silico Evaluation of PLAC1-fluC As a Chimeric Vaccine against Breast Cancer. 2020 , 24, 173-82	6
582	An immunohistological study of epidermal growth factor receptor and neu receptor and neu receptor expression in proliferative glomerulonephritis. 1993 , 25, 327-32	11
581	Chemotherapy and metastatic breast cancer. 2006 , 41-68	1
580	Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. 2008 , 15, 24-35	112
579	Overexpression of S100A4 is closely associated with progression of colorectal cancer. 2005 , 11, 4852-6	44
578	Death decoy receptor overexpression and increased malignancy risk in colorectal cancer. 2014 , 20, 4440-5	16
577	Identification of new cancer stem cell markers and signaling pathways in HER-2-positive breast cancer by transcriptome sequencing. 2019 , 55, 1003-1018	7
576	Autologous tumor-derived microvesicles influence gene expression profiles and enhance protumorigenic chemotactic potential, signal transduction and cellular respiration in gastric cancer cells. 2020 , 56, 359-367	2
575	miR-204-5p promotes apoptosis and inhibits migration of gastric cancer cells by targeting HER-2. 2020 , 22, 2645-2654	4
574	Serum follicle-stimulating hormone level is associated with human epidermal growth factor receptor type 2 and Ki67 expression in post-menopausal females with breast cancer. 2013 , 6, 1128-1132	8
573	Pyrotinib enhances the radiosensitivity of HER2-overexpressing gastric and breast cancer cells. 2020 , 44, 2634-2644	9
572	Effect of Different Levels of Zinc and Phosphorus on Growth and Chlorophyll Content of Wheat. 2002 , 1, 364-366	6
571	Androgen receptor and prostate cancer. 2016 , 3, 280-299	11
570	Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. 2014 , 2, 122	27

569	Treatment Challenges and Survival Analysis of Human Epidermal Growth Factor Receptor 2-positive Breast Cancer in Real World. 2017 , 38, 22-27	15
568	Salivary duct carcinoma in the mandibular anterior region: The role of immunohistochemical markers in its definitive diagnosis. 2016 , 20, 505-509	4
567	Continuous requirement of ErbB2 kinase activity for loss of cell polarity and lumen formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast cancer. 2011 , 10, 29	7
566	Retrospective study of efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive locally advanced and oligometastatic breast cancer: An Indian experience. 2017 , 54, 343-346	6
565	Importance of MACC1 expression in breast cancer and its relationship with pathological prognostic markers. 2020 , 63, 19-24	4
564	Association between Overexpression of Her-2 and Other Clinicopathologic Prognostic Factors in Breast Cancer in Morocco. 2012 , 03, 787-792	5
563	Dietary Conjugated Linoleic Acids Arrest Cell Cycle Progression and Prevent Ovarian Cancer Xenografts Growth Suggesting a Trans-10 Cis-12 Isoform Specific Activity. 2013 , 04, 33-42	3
562	Role of the Rb-mediated cell cycle regulatory pathway in human ovarian cancer cell lines. 1997 , 6, 51-57	1
561	Diagnostic Value of Diffusion-weighted Imaging and Apparent Diffusion Coefficient Values in the Differentiation of Breast Lesions, Histopathologic Subgroups and Correlation with Prognostic Factors using 3.0 Tesla MR. 2016 , 12, 123-132	14
560	Effects of psoralens as anti-tumoral agents in breast cancer cells. 2014 , 5, 348-58	30
559	Tissue Microarray: A powerful and rapidly evolving tool for high-throughput analysis of clinical specimens. 2010 , 01, 1	8
558	Development and characterization of a fully functional small anti-HER2 antibody. 2009 , 42, 636-41	5
557	MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN. 2014 , 47, 268-73	60
556	Pharmacophore approaches in protein kinase inhibitors design. 2014 , 3, 162	5
555	New vistas in the histopathological assessment of cancer. 1992 , 157, 699-701	7
554	Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. 2011 , 30, 327-35	28
553	Next generation of antibody therapy for cancer. 2011 , 30, 293-302	8
552	p53, c-erbB2, and PCNA status in benign, proliferative and malignant ovarian surface epithelial neoplasms: a study of 75 cases. 1999 , 123, 310-6	18

551	Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. 2000 , 124, 966-78	786
550	HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists. 2006 , 130, 325-31	33
549	American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. 2007 , 131, 18-43	1105
548	Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. 2008 , 132, 1008-15	44
547	HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab. 2008 , 132, 61-5	23
546	HER2: Biology, Detection, and Clinical Implications. 2011 , 135, 55-62	293
545	Extracellular HSP90 in Cancer Invasion and Metastasis: From Translational Research to Clinical Prospects. 2015 , 4, 178-190	1
544	Prognostic significance of HER-2/neu and survival of breast cancer patients attending a specialized breast clinic in Kolkata, Eastern India. 2012 , 13, 3851-5	12
543	Determination of HER2 gene amplification in breast cancer using dual-color silver enhanced in situ hybridization (dc- SISH) and comparison with fluorescence ISH (FISH). 2013 , 14, 6131-4	8
542	HER2 expression in ovarian mucinous carcinomas in Tunisia. 2014 , 15, 8121-5	4
541	Effect of hormone therapy on long-term outcomes of patients with human epidermal growth factor receptor 2- and hormone receptor-positive metastatic breast cancer: real world experience in China. 2015 , 16, 903-7	2
540	Understanding EGFR Signaling in Breast Cancer and Breast Cancer Stem Cells: Overexpression and Therapeutic Implications. 2016 , 17, 445-53	20
539	Ovarian Cancer: Potential biomarkers and nanotechnology based diagnostic tools. 2021 , 12, 033001	
538	Identification of a risk prediction model for clinical prognosis in HER2 positive breast cancer patients. 2021 , 113, 4088-4097	1
537	A careful reassessment of anthracycline use in curable breast cancer. 2021 , 7, 134	6
536	The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. 2021 , 1	9
535	Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer. 2021 , 40, 313	2
534	Survival Is Related to Estrogen Signal Transduction Pathway Activity in Postmenopausal Women Diagnosed with High-Grade Serous Ovarian Carcinoma. 2021 , 13,	1

- 533 MicroRNA Expression Profiles and Breast Cancer Chemotherapy. **2021**, 22, 4
- 532 Effects of Tumor-Derived Exosome Programmed Death Ligand 1 on Tumor Immunity and Clinical Applications. **2021**, 9, 760211 0
- 531 Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for Mutation Positive Non-Small Cell Lung Cancer. **2021**, 12, 103-114 0
- 530 Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets. **2021**, 48, 8075-8095 6
- 529 Adjuvant trastuzumab with or without chemotherapy in stage 1 pT1N0 HER2+ breast cancer: a National Cancer Database analysis. **2021**, 191, 169 0
- 528 Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development. **2021**, 340, 1-34 1
- 527 Molecular Genetics and Markers of Progression. **2000**, 47-70
- 526 HER2/neu Gene Amplification Quantified by PCR and Melting Peak Analysis Using a Single Base Alteration Competitor as an Internal Standard. **2001**, 207-217
- 525 Corpuscarcinom. **2001**, 113-133
- 524 DECREASED EXPRESSION OF CELLULAR PROSTATIC ACID PHOSPHATASE INCREASES TUMORIGENICITY OF HUMAN PROSTATE CANCER CELLS. **2001**, 1943-1950
- 523 Reovirus Therapy of Ras-Associated Cancers. **2002**, 31-43
- 522 Prognostische und prädiktive Faktoren bei Patientinnen mit Mammakarzinom. **2002**, 143-159
- 521 Molekulare Pathologie bösartiger pulmonaler und pleuraler Tumoren. **2002**, 27-86
- 520 Signal Transduction Abnormalities as Therapeutic Targets. **2002**, 287-323
- 519 Molekulare Diagnostik. **2002**, 309-387
- 518 Molekulare Grundlagen des sporadischen Mammakarzinoms. **2002**, 87-123
- 517 Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing. **2002**, 126, 803-8 67
- 516 Cell Cycle Regulatory Mechanisms in Head and Neck Squamous Cell Carcinoma. **2003**, 101-116

515 Future Strategies in Immunotherapy. **2003**, 223-246

514 The Genetic Etiology of Sporadic Ovarian Cancer. **2003**, 139-155

513 The Long-Term Management of Ovarian Cancer. **2003**, 467-476

512 Detection of HER-2/neu CEP 17 mutations at invasive bladder cancer. **2003**, 539, 87-97

511 Radionuclide Therapy. **2003**, 1613-1645

510 Effect of Carotenoids on the Growth of HT-29 Human Colon Cancer Cells. **2003**, 32, 428-436

509 Investigational Approaches to the Treatment of Gynecologic Cancers. **2004**, 820-831

508 Particulate Drug Carriers as a Field of Nano-Technology (2) : Therapeutic Application. **2004**, 4, 367-372,360

507 Adjuvant Treatment for Early-Stage Epithelial Ovarian Cancer. **2004**, 411-428

506 Biologic Therapy for Gynecologic Malignancies. **2004**, 953-968

505 In Vitro Models for Human Breast Cancer. **2004**, 227-280

2

504 Signal transduction and apoptosis pathways as therapeutic targets. **2004**, 36, 307-23

503 HER2 and Topoisomerase II β in Breast Carcinoma. **2004**, 261-283

502 Applications of Optical Biosensors to Structure-Function Studies on the EGF/EGF Receptor System. **2004**, 133-164

501 HER-2/neu Gene Amplification in Prostate Cancer from Egyptian Patients by Fluorescence in situ Hybridization. **2004**, 1, 5-9

1

500 Breast Cancer: An Overview. **2004**, 1, 71-80

2

499 Gold- and Silver-Facilitated Metallographic In Situ Hybridization Procedures for Detection of HER2 Gene Amplification. **2004**, 123-128

498 Systemic adjuvant therapies for breast cancer. **2005**, 440-454

497 Biology of Breast Cancer. **2006**, 39-70

496 DCIS: Pathology and Molecular Markers. **2006**, 97-123

495 Use of Molecular Biology Methods on Tissues. **2006**, 403-407

494 Overview of molecular target-based drugs. **2006**, 21, 18-23

2

493 Guidelines and recommendations for clinical use of tumor markers. **2006**, 25, 103-118

492 Identification of Treatment Response Genes. **2006**, 1-19

491 Molecular and Genetic Events in Neoplastic Transformation. **2006**, 47-64

490 Expanding the Role of EGFR Inhibitors in Prostate Cancer. **2006**, 209-221

489 Neoplastic Diseases of the Ovary. **2007**, 839-881

0

488 Immunology and Molecular Oncology in Gynecologic Cancer. **2007**, 731-741

487 HER 1/2 inhibitors in breast cancer: Uses in adjuvant and metastatic therapy. **2007**, 6, 47-54

486 Anti-Epidermal Growth Factor Receptor Strategies for Advanced Breast Cancer. **2007**, 213-234

485 Genes and Cancer. **2007**, 637-667

484 Overview of Existing Therapies. **2007**, 13-30

483 Metabolism of Cell Growth and Proliferation. **2008**, 189-203

1

482 Invasive Breast Cancer: Overexpression of HER-2 Determined by Immunohistochemistry and Multiplex Ligation-Dependent Probe Amplification. **2008**, 291-304

481 HER Family of Receptors as Treatment Targets in Pancreatic Cancer. **2008**, 609-634

480 Negative regulation of signaling by the EGFR family. **2008**, 161-178

479 Novel Targeting and Activation Strategies for Photodynamic Therapy. **2008**, 127-146

478 Biomarkers in neoadjuvant trials. **2009**, 147, 1-36

477 Management of Central Nervous System Metastases in Breast Cancer. **2009**, 1297-1319

476 Molecular Pathology of Breast Cancer. **2009**, 360-378

475 Modeling Human Breast Cancer. **2009**, 103-121

474 Timing of adjuvant therapy. **2009**, 151, 255-79

473 Targeted Approaches to Drug Development. **2009**, 57-98

0

472 Clinicopathologic Characteristics and Prognosis of Early Stage Triple Negative Breast Cancer: Comparison with Non-triple Negative Group. **2009**, 77, 37

2

471 Pharmacogenomics and Personalized Medicine in the Treatment of Human Diseases. **2009**, 613-622

470 HER2 Overexpression Attenuates the Antiproliferative Effect of Aromatase Inhibitor in MCF-7 Breast Cancer Cells Stably Expressing Aromatase. **2009**, 3-28

469 Chemokines and Chemokine Receptors in Cancer Progression. **2009**, 1-30

468 Vaccine Therapy for Lung Cancer. **2010**, 279-303

1

467 HER2-Targeted Therapy. **2010**, 373-389

466 Prognostische und prädiktive Faktoren (unter Berücksichtigung von Genexpressionsanalysen). **2010**, 98-108

465 Cancer Cell Proteomics using Molecular Aptamers. 1

464 Principles of Systemic Cancer Therapy. **2010**, 428-437

463 Epithelial-to-Mesenchymal Transition and Cellular Membrane Receptors in Ovarian Cancer: Moving Forward in the Era of Molecularly Targeted Therapy. **2011**, 165-187

462 Imaging Efficacy in Tumor Models. **2011**, 215-241

461 References. **2011**, 249-347

460 Malignant disease of the breast. **2011**, 707-749

459 The genetics and molecular biology of gynaecological cancer. **2011**, 522-538

458 Oncoproteins and Early Tumor Detection. **2011**, 1400-1414

457 Targeting HER2+and trastuzumab-resistant metastatic breast cancer. **2011**, 035-049

456 Oncology.

455 Preclinical Considerations for Development of Antibody-Based Therapeutics in Oncology. **2012**, 183-240

454 Surexpression de HER2 : un dictat?. **2012**, 168-173

453 Apoptotic Regulators and Its Clinical Implications in Mammary Carcinoma. **2012**, 227-245

452 ASSOCIATION BETWEEN GROWTH FACTOR HEREGULIN -1^α AND RECEPTORS IN GROWTH OF OVARIAN CANCER CELL LINE WITH HIGH POTENTIALITY OF PERITONEAL DISSEMINATION. **2012**, 58, 22-32

451 Presurgical Therapy for Renal Cell Carcinoma and Implications for Window-of-Opportunity Trials. **2012**, 271-282

450 Computational Models as Novel Tools for Cancer Vaccines. **2012**, 227-248

449 Tumor Markers. **2012**, 617-667

1

448 Prerequisite Genetic Traits for Metastasis. **2013**, 403-444

447 Delphinidin inhibits cell proliferation and induces apoptosis in MDA-MB-231 human breast cancer cell lines. **2013**, 46, 503

3

446 Heterogeneity of Cancers and Its Implication for Targeted Drug Delivery. **2013**, 337-362

445 Molecular Oncology in Gynecologic Cancer. **2013**, 623-633

1

444 Neoplastic Diseases of the Ovary. **2013**, 731-771

1

443 TYPES OF DNA DAMAGE. **2013**, 115-118

442 Pharmacogenomics of Gynecological Disorders. **2013**, 707-741

441 Systemic Therapy. **2014**, 381-420

440 Chemotherapy as a Treatment for Breast Cancer. 149-172

439 An Overview of the Breast and Breast Cancer. 1-18

o

438 miRNAs as Cancer Biomarkers. **2014**, 97-124

437 The role of adjuvant systemic therapy in patients with operable breast cancer. **2014**, 199-218

436 Pathology, Biomarkers, and Molecular Diagnostics. **2014**, 226-252.e6

435 Topical dual-stain fluorescence imaging for intra-operative margin detection enhances tumor-to-normal tissue contrast in excised fresh specimens. **2014**,

434 Molecular Testing in Breast Cancer. **2014**, 169-188

433 Predictive Modeling of Signaling Transduction Mediated by Tyrosine-Kinase Receptors. **2014**, 1-6

432 Current Status of Immunotherapy in Gastroesophageal Cancer. **2014**, 179-191

431 Prognostic Factors in Breast Cancer. **1990**, 17-30

3

430 Prognostic Factors in Node-Negative Breast Cancer Patients. **1990**, 31-41

429 Transformation of NIH 3T3 cells by overexpression of the normal coding sequence of the rat neu gene. **1990**, 10, 3247-3252

29

428 cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. **1990**, 10, 6316-6324

90

427 Multiple cis- and trans-acting elements involved in regulation of the neu gene. **1990**, 10, 6306-6315

17

426 Molecular Biology of Oncogenes. **1991**, 137-154

- 425 Overexpression des NEU-Onkogens in Primärtumoren und Rezidiven von Mammakarzinomen. **1991**, 215-216
- 424 A chimeric EGFR/neu receptor in studies of neu function. **1992**, 61, 213-28
- 423 Expression and Prognostic Significance of the HER-2/neu Oncogene During the Evolutionary Progression of Human Breast Cancer. **1991**, 69-82 1
- 422 Growth Factors as Local Regulators of Normal and Malignant Human Mammary Epithelium. **1991**, 129-148 1
- 421 Transformation of Human Tracheal Gland Epithelial Cells in vitro. **1991**, 333-341
- 420 C-erb-B2-Onkogenexpression bei Ovarialkarzinomen. **1991**, 183-184
- 419 Molecular Action of Steroids and Growth Factors in Human Breast Tumor Cells. **1991**, 256-287
- 418 Identification and characterization of a novel enhancer for the rat neu promoter. **1991**, 11, 1875-1882 6
- 417 Monoclonal 3C6F9 distribution in human breast carcinomas: image cytometry of immunocytochemical assays. **1991**, 8, 243-51 2
- 416 Role of Ras Oncogene in Human Breast Cancer: An Experimental Approach. **1992**, 105-117
- 415 Cancer. **1992**, 121-156
- 414 Concepts of Preneoplasia for the Goal of Cancer Prevention. **1992**, 3-13
- 413 Expression of the MET Oncogene in Human Tumors. **1992**, 11-21
- 412 Human Neuroblastoma: Paradigm for a Tumor with Oncogene Amplification and Loss of a Putative Tumor Suppressor Gene. **1992**, 241-250
- 411 Das Mammakarzinom aus pathohistologischer Sicht. **1992**, 24-35
- 410 Cerebrospinal fluid analysis Clinical neurochemistry. **1992**, 85-91
- 409 Unanswered questions in the adjuvant therapy of breast cancer. **1992**, 60, 257-78
- 408 Negative autoregulation of the neu gene is mediated by a novel enhancer. **1992**, 12, 2739-2748 6

- 407 Isolation and structural analysis of a 1.2-megabase N-myc amplicon from a human neuroblastoma. **1992**, 12, 5563-5570 16
- 406 Ovarian Carcinoma: Tumor- and Molecular Biology. **1993**, 7-19 2
- 405 c-erbB-2 Onkogenexpression in Ovarialkarzinomen und Borderline-Tumoren. **1993**, 942-943
- 404 Establishing a Clinical Molecular Biology Laboratory. **1993**, 1-38
- 403 P185erbB-2 im Serum von Ovarialkarzinompatientinnen. **1993**, 955-957
- 402 HER-2/Neu/c-ERB-B2 Amplification: Clinical Relevance in Mammary Carcinoma. **1993**, 169-174
- 401 Die Bedeutung des Onkogens HER 2 beim Ovarialkarzinom. **1993**, 28-36 1
- 400 Immunhistochemische Untersuchungen über das c-erbB-2 Protein am Ovarialkarzinom. **1993**, 951-952
- 399 Die prognostische Wertigkeit der Überexpression des p185erbB2 Onkoproteins bei T1 Mammakarzinomen. **1993**, 842-845
- 398 Die Bedeutung der c-erbB-2 und c-myc Onkogen-Expression für die Prognose beim Ovarialkarzinom. **1993**, 946-948
- 397 Applications of Recombinant DNA Technology to the Diagnosis of Genetic Disease: Molecular Methods for Detecting the Genetic Basis of Diseases. **1993**, 155-192
- 396 On the Mechanism and Consequences of Radiation-Induced Gene Amplification in Mammalian Cells. **1993**, 143-154 1
- 395 Gene amplification and herbicide resistance in plants. **1993**, 9, 3-16 1
- 394 Molecular Biology and Bladder Cancer. **1994**, 19-45
- 393 Applications for Escherichia coli-Derived Humanized Fab-Fragments: Efficient Construction of Bispecific Antibodies. **1994**, 135-145
- 392 Signal-transduction therapy. **1994**, 195-207
- 391 Immunohistochemistry. **1994**, 1131-1159 2
- 390 Hereditary and familial ovarian cancer. **1994**, 136, 133-45

- 389 Migration of fresh human malignant astrocytoma cells into hydrated gel wafers in vitro. **1994**, 63-73 0
- 388 Molecular Biology. **1994**, 1173-1198
- 387 The epidermal growth factor family in the mammary gland and other target organs for ovarian steroids. **1994**, 71, 131-60 2
- 386 MOLECULAR BIOLOGY AND GENETICS OF EPITHELIAL OVARIAN CANCER. **1994**, 21, 25-40 5
- 385 Oncogenes and Tumor-Suppressor Genes in Gynecological Malignancies. **1995**, 111-138 1
- 384 ErbB2. **1995**, 126-128
- 383 C-myc as a Tumor Marker for Primary Human Cancers. **1995**, 53-76
- 382 Cell growth regulation in ovarian cancer: tyrosine kinases, tyrosine phosphatases and tumour necrosis factor- α . **1995**, 109-113
- 381 Antibody targeting of ovarian cancer: recombinant single-chain fragments and the role of internalization. **1995**, 347-356
- 380 Antiestrogen Regulation of erbB2 Expression in Human Breast Cancer Cells. **1996**, 343-358
- 379 Estrogen and Anti-Estrogen Regulation of Amplified erbB2 Gene Expression in Human Breast Cancer Cells. **1996**, 418-423
- 378 Gene Expression in Familial Breast Cancer: A Genetic-Epidemiologic Study of Premenopausal Bilateral Breast Cancer. **1996**, 107-112
- 377 C-ERBB-2 in Bladder Cancer. **1996**, 321-326 0
- 376 Breast Susceptibility to Carcinogenesis. **1996**, 120-131 1
- 375 In vitro priming to tumor-associated proteins. **1997**, 417, 503-9
- 374 Malignancies of the Ovaries. **1997**, 297-396
- 373 References. **1997**, 215-326
- 372 Growth Factors and Growth Factor Inhibitors. **1997**, 337-370 1

- 371 Breast Tumor Cytogenetic Markers. **1997**, 111-149 1
- 370 The Use of HLA Transgenic Mice in Identifying and Targeting Human Tumor Cell Antigens. **1997**, 41-48
- 369 Intracellular Antibody-Mediated Knockout of the ErbB-2 Oncoprotein as a Cancer Gene Therapy Approach. **1998**, 97-128
- 368 HER-2/neu as a predictive marker of response to breast cancer therapy. **1998**, 155-167
- 367 Cyclin D1 in breast cancer. **1998**, 91-105
- 366 The relationship between prognostic and predictive factors in the management of breast cancer. **1998**, 351-378 O
- 365 Prognostic significance of micrometastatic bone marrow involvement. **1998**, 291-306
- 364 c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. **1998**, 145-154
- 363 Pharmacologic advantages of anthracyclines encapsulated in poly-ethylene-glycol coated Stealth liposomes: Potential for tumor targeting. **1998**, 259-274 1
- 362 HER-2/neu in Breast Cancer: A Possible Means of Therapy?. **1998**, 121-136
- 361 Antisense strategy for cancer therapy. **1998**, 151-162
- 360 Prognostic Factors in Bladder Cancer: Emphasis on Immunohistochemical Analysis. **1998**, 23-35
- 359 Biological therapy for gynecologic malignancies. **1998**, 95, 115-47
- 358 Drug Resistance in Breast Cancer. **1999**, 481-517
- 357 Molecular Alterations in Breast Cancer. **1999**, 143-170
- 356 Cancer Immunotherapy. **1999**, 170-204
- 355 The Role of Fibroblast Growth Factors in Breast Cancer Pathogenesis and Progression. **1999**, 59-93
- 354 Factors Influencing Tumor-Selective Localization of Antibody Conjugates. **1999**, 39-96

353 Breast Cancer Therapy Using Monoclonal Antibodies Against Epidermal Growth Factor Receptor and HER-2. **1999**, 419-436

352 Expression of C-Erb B-2/Her-2 in Patients with Metastatic Breast Cancer Undergoing High-Dose Chemotherapy and Autologous Blood Stem Cell Support. **1999**, 91-102

351 Translational Research in Breast Cancer. **1999**, 345-356

350 RECOMBINANT ONCOTOXIN AR209 (ANTI-P185erbB-2) DIMINISHES HUMAN PROSTATE CARCINOMA XENOGRAFTS. **1999**, 984-989

349 Development of a Mass Spectrometric Method for Pharmacokinetic Study of Trastuzumab. **2014**, 35, 1845-1847

348 Molecular Medicine and Personalized Therapy for Breast Cancer Patients. **2015**, 321-334

347 Adjuvant Biologic Agents for Breast Cancer. **2015**, 363-375

346 Insight into the Intermolecular Recognition Mechanism between HLA-A*24:02 and Antitumor Peptides against Breast Cancer. **2015**, 15, 1-4

345 The EGFR/ERBB Receptor Family. **2015**, 107-164

o

344 Molecular Pathology of HER Family of Oncogenes in Breast Cancer: HER-2 Evaluation and Role in Targeted Therapy. **2015**, 119-136

343 Molekulare Grundlagen der malignen Transformation. **2015**, 1-16

342 Targeted Therapies for Gastric Cancer. **2015**, 103-126

341 Tumors of the breast. 426-446

340 HER2-Targeted Therapy. **2016**, 391-410

339 Molecular Targeted Anticancer Drugs. **2016**, 175-238

338 Overview. **2016**, 1284-1302.e3

1

337 Systemic Therapy. **2016**, 335-390

336 Breast Cancer. **2016**, 433-446

335 Thérapie ciblée anti-HER2 : principes, validation, indication. **2016**, 89-94

334 Facteurs tumoraux pronostiques. **2016**, 53-56

333 Modeling and Analysis of Hormone and Mitogenic Signal Integration in Prostate Cancer.

332 Targeting FGFR for the Treatment of Breast Cancer. **2017**, 117-137

1

331 Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R. **2017**, 1-31

330 Risikoadaptierte Diagnostik und Therapie. **2017**, 43-53

329 CORRELATION OF HER2/NEU EXPRESSION AND HISTOPATHOLOGICAL GRADING AND STAGING OF COLORECTAL CARCINOMAS. **2017**, 6, 4407-4411

1

328 Immunothérapie par anticorps monoclonaux : ingénierie, indications et perspectives. **2017**, 201, 1023-1035

327 Breast Cancer and Immunosenescence. **2018**, 1-31

326 Phosphorylated S6 Kinase-1 as Predictive Marker of Lapatinib Efficacy in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. **2017**, 5, 57-63

325 Trastuzumab Emtansine: Antibody-drug Conjugate in Treatment of Human Epidermal Growth Factor Receptor-2-Positive Metastatic Breast Cancer. **2018**, 39, 79-87

324 Incidence and Risk Factors of the Infusion-Related Reactions in Breast Cancer Patients Receiving Trastuzumab. **2018**, 35, 177-183

323 Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study. **2018**, 14, 160-165

2

322 COMPARISON OF CLINICO-PATHOLOGICAL FEATURES AND PROGNOSIS OF TRIPLE-NEGATIVE AND NON-TRIPLE-NEGATIVE FEMALE BREAST CANCER PATIENTS. **2018**, 7, 3412-3418

321 Automated detection of the HER2 gene amplification status in Fluorescence in situ hybridization images for the diagnostics of cancer tissues.

320 STATISTICAL ANALYSIS OF 100 BREAST CANCER CASES WITH EVALUATION OF HER2/NEU STATUS IMMUNOHISTOCHEMISTRY CORRELATION WITH GENE AMPLIFICATION BY FLUORESCENCE IN SITU HYBRIDIZATION ASSAY. **2018**, 7, 5298-5303

319 The synergistic antitumor effect of combined Anti-Human Epidermal Growth Factor Receptor 2 (HER2) antibody and Gamma Interferon therapy to Ab resistant breast cancer cells.

318 Nanotechnology: The Future for Cancer Treatment. **2019**, 389-418

- 317 Breast Cancer and Immunosenescence. **2019**, 2115-2145
- 316 Clinical Aspects of Estrogen and Progesterone Receptors and ERBB2 Testing. **2019**, 143-161
- 315 Personalized Medicine: Cutting Edge Developments. **2019**, 33-42 1
- 314 Modelling the role of dual specificity phosphatases in Herceptin resistant breast cancer cell lines.
- 313 Molecular Pathway and Fluorescence In Situ Hybridization Testing of ERBB2 (HER2) Gene Amplification in Invasive Ductal Carcinoma of Breast. **2019**, 237-268
- 312 Gene expression profiles and pathway enrichment analysis to identification of differentially expressed gene and signaling pathways in epithelial ovarian cancer based on high-throughput RNA-seq data.
- 311 Metastatik meme kanseri tedavisinde lapatinib kapesitabin kombinasyonun etkinliđinin retrospektif deđlendirilmesi..
- 310 Droplet digital polymerase chain reaction offers an improvisation over conventional immunohistochemistry and fluorescent hybridization for ascertaining Her2 status of breast cancer. **2019**, 8, 203-210
- 309 The Effect of Prognostic Factors on Long-Term Protection in Breast Cancer. **2020**, 12, e8878 1
- 308 Features, Outcomes, and Management Strategies of Male Breast Cancer: A Single Institution Comparison to Well-Matched Female Controls. **2020**, 16, 201-207 1
- 307 Recombinant Bispecific Antibodies to the Human ErbB2 Receptor and Interferon-Beta. **2020**, 12, 95-104 1
- 306 Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics. **2021**, 1 1
- 305 Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis. **2021**, 11, 731148 1
- 304 Direct targeting of amplified gene loci for proapoptotic anticancer therapy. **2021**, 2
- 303 Updated Bayesian Network Meta-Analysis of Adjuvant Targeted Treatment Regimens for Early Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer. **2020**, 23, 410-429
- 302 Drug Targets for Biologics. **2020**, 71-88
- 301 Development of Gold Nanorods Conjugated with Radiolabeled Anti-human Epidermal Growth Factor Receptor 2 (HER2) Monoclonal Antibody as Single-Photon Emission Computed Tomography/Photoacoustic Dual-Imaging Probes Targeting HER2-Positive Tumors. **2020**, 43, 1859-1866 0
- 300 Synergistic Effects of Metformin-Lapatinib Combination on the Expression of Bax in SK-BR3 Cells. **2020**, 11,

- 299 Amyloid fibril-based hydrogels for high-throughput tumor spheroid modeling. 0
- 298 Quantitative real-time PCR assay with immunohistochemical evaluation of HER2/neu oncogene in breast cancer patients and its correlation with clinicopathological findings. **2020**, 63, S123-S128 1
- 297 Opportunities and Challenges Provided by Boolean Modelling of Cancer Signalling Pathways. **2020**, 199-216
- 296 Key genes and drug delivery systems to improve the efficiency of chemotherapy. **2021**, 4, 163-191 1
- 295 Epidemiology and Socioeconomic Impact of CNS Metastases. **2020**, 3-18 1
- 294 Application of Pharmacogenomics in Drug Discovery and Development. **2020**, 257-276
- 293 Epigenetic downregulation of HER2 during EMT leads to tumor resistance to HER2-targeted therapies in breast cancer. 1
- 292 RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer. **2021**, 12, 6427 1
- 291 Advances with antibody-drug conjugates in breast cancer treatment. **2021**, 169, 241-255 1
- 290 Clinical studies with letrozole. **2008**, 69-100
- 289 Significance of Oncogene Amplifications in Breast Cancer in Atomic Bomb Survivors: Associations with Radiation Exposure and Histological Grade. **2009**, 285-293
- 288 Detection and Characterisation of Occult Metastatic Cells in Bone Marrow of Breast Cancer Patients: Implications for Adjuvant Therapy. **2003**, 47-56
- 287 Immunophenotypic Characterization of Infiltrating Poly- and Mononuclear Cells in Childhood Brain Tumors. **2005**, 13-161
- 286 Breast cancer with HER 2 overexpressed. From laboratory to clinical practice. **2006**, 205-220
- 285 Les nouvelles cibles thérapeutiques. Les nouvelles thérapeutiques ciblées. **2006**, 233-266
- 284 Tumor models for preclinical development of targeted agents. **2005**, 63, 43-66
- 283 Clinical studies with letrozole. **2006**, 65-93
- 282 Detection and Characterisation of Occult Metastatic Cells in Bone Marrow of Breast Cancer Patients: Implications for Adjuvant Therapy. **2003**, 47-65

- 281 The Impact of ErbB2 on Cancer Progression and Metastasis through Modulation of Tumor and Tumor Microenvironment. **2008**, 43-56
- 280 Lymph Node-Negative Breast Carcinoma: Assessment of HER-2/neu Gene Status as Prognostic Value. **2008**, 569-581
- 279 Breast Cancer and Immunosenescence. **2009**, 1139-1163
- 278 Reovirus as an Oncolytic Agent. **2005**, 249-260
- 277 Antimetastasis. **2005**, 287-298
- 276 Chemosensitization. **2005**, 335-348
- 275 Principles of Medical Management. **2006**, 93-100
- 274 Role of TGF- β in Tumor Progression and Metastasis. **2006**, 469-489
- 273 Molecular Profiling in Breast Cancer. **2006**, 559-576
- 272 Development of Therapeutic Genes for Breast Cancer Treatment. **2007**, 435-446
- 271 Patient Selection for Rational Development of Novel Anticancer Agents. **2008**, 641-648
- 270 Combining Targeted Therapies. **2008**, 361-381
- 269 La d termination du statut HER2: quels garde-fous?. **2007**, 415-424
- 268 Autres traitements cibl s (trastuzumab exclu). **2007**, 453-498
- 267 Prognostische und pr diktive Faktoren bei Patientinnen mit Mammakarzinom. **2006**, 183-198
- 266 A clinically motivated 2-fold framework for quantifying and classifying immunohistochemically stained specimens. **2007**, 10, 287-94 4
- 265 Chemotherapy in brain metastases of lung and breast cancer. **2004**, 1, 101-110
- 264 Monoclonal Antibodies for Cancer Immunotherapy. **2021**, 273-312 1

- 263 Análisis del comportamiento clínico-patológico del cáncer de mama mucinoso: primer estudio multicéntrico en México. Revisión a 10 años. **2020**, 34, 133-133
- 262 Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. **2001**, 3, 245-54 13
- 261 Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. **1995**, 14, 4267-75 138
- 260 The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. **1994**, 13, 1331-40 80
- 259 Cell-type specific interaction of Neu differentiation factor (NDF/hereregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. **1993**, 12, 961-71 65
- 258 A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. **1993**, 12, 2369-75 31
- 257 ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. **1996**, 15, 254-64 179
- 256 Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. **1991**, 10, 2077-86 31
- 255 A subdomain in the transmembrane domain is necessary for p185neu* activation. **1992**, 11, 923-32 29
- 254 Autocrine growth factors and solid tumor malignancy. **1991**, 155, 152-63 11
- 253 Complete sequence of the human mucin MUC4: a putative cell membrane-associated mucin. **1999**, 338 (Pt 2), 325-33 71
- 252 Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. **1997**, 151, 761-8 69
- 251 Transfection of rat ovarian surface epithelium with erb-B2/neu induces transformed phenotypes in vitro and the tumorigenic phenotype in vivo. **1998**, 152, 297-306 12
- 250 Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. **1996**, 148, 549-58 52
- 249 Neoplastic transformation of prostatic and urogenital epithelium by the polyoma virus middle T gene. **1996**, 149, 1177-91 18
- 248 Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. **1996**, 149, 1553-64 118
- 247 Expression of c-ErbB2 in human neuroblastoma tissues, adrenal medulla adjacent to tumor, and developing mouse neural crest cells. **1995**, 146, 660-72 8
- 246 Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. **1995**, 147, 905-11 191

245	C-myc proto-oncogene amplification detected by polymerase chain reaction in archival human ovarian carcinomas. 1990 , 137, 653-8	28
244	HER-2/neu oncogene expression and proliferation in breast cancers. 1990 , 137, 103-11	46
243	Immunodetection of the metastasis-associated laminin receptor in human breast cancer cells obtained by fine-needle aspiration biopsy. 1990 , 137, 1373-81	34
242	Study of neu-protein expression in mammary Paget's disease with and without underlying breast carcinoma and in extramammary Paget's disease. 1990 , 137, 1305-9	43
241	Oncogene amplification in breast cancer. 1991 , 138, 835-45	19
240	Transgenic oncogene mice. Tumor phenotype predicts genotype. 1991 , 139, 495-501	73
239	Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines. 1992 , 140, 23-31	29
238	K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. 1991 , 139, 777-85	128
237	Expression of neu protein, epidermal growth factor receptor, and transforming growth factor alpha in breast cancer. Correlation with clinicopathologic parameters. 1991 , 138, 1527-34	41
236	Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas. 1993 , 142, 733-41	34
235	Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. 1993 , 143, 1731-42	303
234	Does HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey. 2006 , 13, 2-7	
233	Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 2. 2006 , 13, 99-107	40
232	A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1. 1994 , 55, 666-77	52
231	Jeremiah Metzger Lecture. Targeted cancer therapy. 2000 , 111, 95-110; discussion 110-1	15
230	H-RYK, an unusual receptor kinase: isolation and analysis of expression in ovarian cancer. 1996 , 2, 189-203	8
229	A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer. 2007 , 3, 665-73	14
228	Oncogene expression in vivo by ovarian adenocarcinomas and mixed-mullerian tumors. 1989 , 62, 379-92	36

227	Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics. 2007 , 1, 367-76	16
226	Trastuzumab in the management of early and advanced stage breast cancer. 2007 , 1, 19-31	31
225	HER2 breast cancer therapies: a review. 2009 , 3, 289-301	43
224	EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. 2009 , 3, 215-24	24
223	Recent advances in the systemic therapy of breast cancer. 2000 , 2, 24-32	1
222	Systems approaches to molecular cancer diagnostics. 2010 , 10, 531-42	5
221	Translational research: current status, challenges and future strategies. 2011 , 3, 422-33	10
220	OVARIAN CANCER SUICIDE GENE THERAPY WITH GENETICALLY ENGINEERED, TRANSGENICALLY EXPRESSED, INTRACELLULAR scFv ANTIBODIES AGAINST ANTI-OXIDATIVE ENZYMES. 2008 , 87, 249-260	5
219	HER2/NEU GENE EXPRESSION PRODUCTS EVALUATED WITH SUPERPARAMAGNETIC, GENETICALLY ENGINEERED ANTIBODIES. 2007 , 86, 297-308	2
218	Mouse mammary gland is refractory to the effects of ethanol after natural lactation. 2013 , 63, 38-47	1
217	Overview of major classes of plant-derived anticancer drugs. 2009 , 5, 1-11	54
216	Dissecting GRB7-mediated signals for proliferation and migration in HER2 overexpressing breast tumor cells: GTP-ase rules. 2013 , 3, 173-95	25
215	HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer. 2006 , 26, 4235-43	47
214	Profiling serum HER-2/NEU in prostate cancer. 2013 , 17, 108-12	4
213	Production and Quality Control of [(67)Ga]-DOTA-trastuzumab for Radioimmunosintigraphy. 2013 , 12, 355-66	9
212	Clinicopathological factors associated to HER-2 status in a hospital-based sample of breast cancer patients in Puerto Rico. 2010 , 29, 265-71	2
211	Early Detection of Serum Levels of HER-2 in Patients with Head and Neck Squamous Cell Carcinoma. 2013 , 25, 161-8	2
210	Closing the personalized medicine information gap: HER2 test documentation practice. 2013 , 19, 838-44	5

209	Outcome prediction values of soluble human epidermal growth factor receptor-2 extracellular domain in metastatic breast cancer. 2014 , 7, 1108-13	3
208	Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer. 2013 , 1, 3-7	13
207	Investigating Molecular Mechanisms of Activation and Mutation of the HER2 Receptor Tyrosine Kinase through Computational Modeling and Simulation. 2011 , 4, 1-35	5
206	Preclinical characterization and validation of a dual-labeled trastuzumab-based imaging agent for diagnosing breast cancer. 2015 , 27, 74-82	3
205	Special suppressive role of miR-29b in HER2-positive breast cancer cells by targeting Stat3. 2015 , 7, 878-90	19
204	HER2 status in molecular apocrine breast cancer: associations with clinical, pathological, and molecular features. 2015 , 8, 8008-17	8
203	Internalization and Recycling of the HER2 Receptor on Human Breast Adenocarcinoma Cells Treated with Targeted Phototoxic Protein DARPiniSOG. 2015 , 7, 126-32	14
202	Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence. 2015 , 5, 2531-61	46
201	Synchronous primary breast cancer and hepatocellular carcinoma in a male patient: a case report. 2015 , 8, 11722-8	1
200	DC targeting DNA vaccines induce protective and therapeutic antitumor immunity in mice. 2015 , 8, 17565-77	8
199	Breast Cancer Immunotherapy. 2015 , 10, 185-191	5
198	Chromogenic in situ Hybridization Compared with Real time Quantitative Polymerase Chain Reaction to Evaluate HER2/neu Status in Breast Cancer. 2017 , 12, 128-134	1
197	Cancer Diagnosis Epigenomics Scientific Workflow Scheduling in the Cloud Computing Environment Using an Improved PSO Algorithm. 2018 , 19, 243-246	1
196	Boeravinone B a natural rotenoid exerts anticancer activity via inducing internalization and degradation of inactivated EGFR and ErbB2 in human colon cancer cells. 2018 , 10, 4183-4192	4
195	DE-ESCALATING TREATMENT FOR HER2-POSITIVE EARLY BREAST CANCER. 2020 , 131, 119-126	
194	Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials. 2020 , 10, e035802	1
193	Predictive Value of CD44 for Prognosis in Patients with Breast Cancer. 2020 , 21, 2561-2567	2
192	SOX12 expression is associated with progression and poor prognosis in human breast cancer. 2020 , 12, 8162-8174	3

191 Cytotoxicity effect of trastuzumab on canine peripheral blood mononuclear cells. **2020**, 21, 263-268

190 Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients. **2021**, 13, 17588359211006960 1

189 Impact of Using Median vs. Mean in Calculating ERBB2 FISH Results in Breast Cancer. **2021**, 4, 87-96

188 A tipping-point for apoptosis following dual inhibition of HER2 signaling network by T-DM1 plus GDC-0980 maximizes anti-tumor efficacy. **2021**, 11, 2867-2892 1

187 Identification and Characterization of a Homozygous Deletion Found in Ovarian Ascites by Representational Difference Analysis. **1999**, 9, 226-233 5

186 Cancer Vaccine in Solid Tumors: Where We Stand. **2021**, 42, 319-324

185 Diagnostic Potential of miR-30a and miR-200c in Invasive Breast Ductal Carcinoma. **2021**, 1,

184 Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. **2021**,

10

183 Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis. **2021**, 1 0

182 The tumor immune microenvironment of primary and metastatic HER2- positive breast cancers utilizing gene expression and spatial proteomic profiling. **2021**, 19, 480 1

181 Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study. **2021**, 14, 8775-8784 0

180 Periostin gene expression in neu-positive breast cancer cells is regulated by a FGFR signaling cross talk with TGF β /PI3K/AKT pathways. **2021**, 23, 107 0

179 Preparation of bimetal-polydopamine organic frameworks with core-shell structure and their application in HER2 detection.. **2022**,

0

178 Vaccination against Her-2/neu, with focus on peptide-based vaccines.. **2022**, 7, 100361 1

177 Trastuzumab (Herceptin) in the treatment of breast cancer with HER2 overexpression. **2001**, 3, 172-182 1

176 A comparative study of HER2/neu amplification and overexpression using fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in 101 breast cancer patients. **2002**, 4, 255-259 3

175 ErbB tyrosine kinase receptor inhibitors in breast cancer treatment. **2004**, 6, 12-21 1

174 Predictive Value of CD44 for Prognosis in Patients with Breast Cancer. **2020**, 21, 2561-2567 2

173	Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials. 2020 , 10, e035802	1
172	A pH-sensitive liposome formulation of a peptidomimetic-Dox conjugate for targeting HER2+ cancer.. 2021 , 612, 121364	2
171	ErbB2 promotes breast cancer metastatic potential via HSF1/LDHA axis-mediated glycolysis.. 2022 , 39, 45	0
170	Paraoxonase-1 Activity in Breast Cancer Patients Treated With Doxorubicin With or Without Trastuzumab.. 2022 , 7, 1-10	0
169	Development of intraoperative assessment of margins in breast conserving surgery: a narrative review.. 2022 , 11, 258-269	0
168	Determination of c-erbB-2/Her-2/Neu status in breast cancer: comparative analysis between immunoenzymatic assay (ELISA) and immunohistochemistry. 2003 , 5, 272-279	
167	Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective.. 2022 , 12, 780716	1
166	Phosphoproteome of signaling by ErbB2 in ovarian cancer cells.. 2022 , 140768	0
165	Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis.. 2021 ,	11
164	[Model systems for investigation of genetic factors in tumorigenesis]. 1995 , 82, 209-18	
163	Molecular imprinting of glycoproteins: From preparation to cancer theranostics.. 2022 , 12, 2406-2426	2
162	Tumor antigens for preventative cancer vaccines. 2022 , 51-74	
161	First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCG.. 2022 , 16, 11782234221086992	
160	Breast-conserving therapy is associated with better survival than mastectomy in Early-stage breast cancer: A propensity score analysis.. 2022 ,	2
159	Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib.. 2022 , 8, 22	0
158	Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors.. 2022 , 38, 110418	0
157	Efficacy of Disitamab Vedotin in Treating HER2 2+/FISH- Gastric Cancer.. 2022 , 15, 267-275	0
156	INHBA is a mediator of aggressive tumor behavior in HER2+ basal breast cancer.. 2022 , 24, 18	0

155	Margetuximab Versus Trastuzumab in Patients With Advanced Breast Cancer: A Cost-effectiveness Analysis.. 2022 ,	0
154	HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer.. 2022 , 9, 834651	7
153	EGFR Signaling in Lung Fibrosis.. 2022 , 11,	3
152	Synthesis of Multiple Bispecific Antibody Formats with Only One Single Enzyme Based on Enhanced Trypsinase.. 2022 , 23,	0
151	Regulation of a Novel Splice Variant of Early Growth Response 4 (EGR4-S) by HER+ Signalling and HSF1 in Breast Cancer.. 2022 , 14,	
150	HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.. 2022 , 20, 105	2
149	An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index.. 2022 , 15, 331-343	0
148	Cardioprotection for Anti-HER2 Therapy: Considerations for Primary Prevention and Use in Mildly Reduced Left Ventricular Ejection Fraction.. 2022 , 1	0
147	Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial.. 2022 , 165, 157-168	1
146	Template-Assisted Antibody Assembly: A Versatile Approach for Engineering Functional Antibody Nanoparticles.	1
145	Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model.. 2022 , 19, 101378	0
144	Exosomal-microRNA transcriptome profiling of Parental and CSC-like MDA-MB-231 cells in response to cisplatin treatment.. 2022 , 233, 153854	1
143	Development strategy of ENHERTU [®] (R) [®] (trastuzumab deruxtecan)â€”anti-HER2 antibodyâ€”drug conjugateâ€” 2021 , 36, 384-388	
142	Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer. 2021 , 100, e27632	0
141	Epitope Mapping of an Anti-HER2 Monoclonal Antibody (HMab-181) Using Enzyme-Linked Immunosorbent Assay.. 2021 , 40, 255-260	0
140	The efficacy and safety of pyrotinib in treating HER2-positive breast cancer patients with brain metastasis: A multicenter study.. 2021 ,	3
139	Meme kanseri subgruplar�n�n s�kl�� ve otoimm� tiroid hastal��n�n prognoz �zerine etkisi. 2021 , 2, 105-112	
138	Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile.. 2021 , 12,	10

- 137 . **2021**, 108, 11S1-11S7 o
- 136 Prostanoid Signaling in Cancers: Expression and Regulation Patterns of Enzymes and Receptors.. **2022**, 11, 1
- 135 Stimulatory role of nectin-4 and p95-ErbB2 in multilayered T47D cell proliferation.. **2022**, o
- 134 Prognosis of cancer. 473-498
- 133 Cancer Pharmacogenomics. **2005**, 339-357
- 132 Table_1.docx. **2020**,
- 131 Table_2.docx. **2020**,
- 130 table_1.PDF. **2018**,
- 129 Presentation_1.PDF. **2018**,
- 128 A phase III trial of alpelisib + trastuzumab + fulvestrant versus trastuzumab + chemotherapy in HER2+ -mutated breast cancer.. **2022**, o
- 127 Long-Term Prognostic Significance of HER2-Low and HER2-Zero in Node-Negative Breast Cancer.
- 126 N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer.. **2022**, 13, 2672 6
- 125 Targeting ErbB receptor signaling: A pan-ErbB approach to cancer. **2004**, 3, 1335-1342 17
- 124 A Survey on Various Combination of Breast Cancer Biomarkers. **2022**,
- 123 Clinical Dose Preparation of [Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [Lu]LuCl for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression.. **2022**,
- 122 Multifunctional Nanoplatfroms as a Novel Effective Approach in Photodynamic Therapy and Chemotherapy, to Overcome Multidrug Resistance in Cancer. **2022**, 14, 1075 1
- 121 Current status and future prospects of antibody-drug conjugates in urological malignancies.. **2022**, o
- 120 Overexpression of galectin2 (LGALS2) predicts a better prognosis in human breast cancer.. **2022**, 14, 2301-2316

- 119 Comparison of adverse effects of trastuzumab with other drug combinations for the treatment of breast cancer: A review. 66, 1-15
- 118 Evaluating the tumor immune profile based on a three-gene prognostic risk model in HER2 positive breast cancer. **2022**, 12, 0
- 117 Translational Epidemiology in Cancer Research: The Less Travelled Path. **2022**, 349-366
- 116 Potent anti-tumor immune response and tumor growth inhibition induced by HER2 subdomain fusion protein in a mouse tumor model. 0
- 115 Biomarker profile of invasive lobular carcinoma: pleomorphic versus classic subtypes, clinicopathological characteristics and prognosis analyses.
- 114 Recently approved treatment options for patients with metastatic triple-negative and HER2-neu-positive breast cancer. jim-2021-002298 2
- 113 Clinicopathologic significance of expression of Her-2 and P53 in gastric cancer. **2022**,
- 112 The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis. **2022**, 11, 1195 0
- 111 Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies. 12, 0
- 110 Novel applications of molecular imaging to guide breast cancer therapy. **2022**, 22, 1
- 109 Exploring chitosan-shelled nanobubbles to improve HER2 + immunotherapy via dendritic cell targeting. 0
- 108 Spontaneous Feline Mammary Carcinoma Is a Model of HER2 Overexpressing Poor Prognosis Human Breast Cancer. **2005**, 65, 907-912 31
- 107 Biological impediments to monoclonal antibody-based cancer immunotherapy. **2004**, 3, 1493-1501 40
- 106 Targeted Degradation of STAT3 via Chaperone-Mediated Autophagy by nanoCMATAC Platform.
- 105 Emerging Biosensors for Oral Cancer Detection and DiagnosisâA Review Unravelling Their Role in Past and Present Advancements in the Field of Early Diagnosis. **2022**, 12, 498
- 104 Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer. 0
- 103 DNA repair as a shared hallmark in cancer and ageing. 1
- 102 Advances and challenges of CAR-T therapy and suitability of animal models (Review). **2022**, 17, 0

101	Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer. 2022 , 173, 10-19	2
100	Ce-MOF/COF/carbon nanotube hybrid composite: Construction of efficient electrochemical immune platform for amplifying detection performance of CA125. 2022 , 147, 108201	0
99	Young Breast Cancer in a Specialised Breast Unit in Singapore: Clinical, Radiological and Pathological Factors. 2014 , 43, 79-85	8
98	Cyclooxygenase (COX)-2-dependent effects of the inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice. 2004 , 3, 417-424	6
97	Candidate Genes in Breast Cancer Revealed by Microarray-Based Comparative Genomic Hybridization of Archived Tissue. 2005 , 65, 439-447	26
96	Premature Senescence Is a Primary Fail-safe Mechanism of ERBB2-Driven Tumorigenesis in Breast Carcinoma Cells. 2005 , 65, 840-849	24
95	The Dual ErbB1/ErbB2 Inhibitor, Lapatinib (GW572016), Cooperates with Tamoxifen to Inhibit Both Cell Proliferation- and Estrogen-Dependent Gene Expression in Antiestrogen-Resistant Breast Cancer. 2005 , 65, 18-25	33
94	DESTINY-Changing Results for Advanced Breast Cancer. 2022 , 387, 75-76	0
93	Protocol for the murine antibody-dependent cellular phagocytosis assay. 2022 ,	
92	Cancer immunotherapy: diverse approaches and obstacles. 2022 , 28,	0
91	Antitumor Activities of Aqueous Cinnamon Extract on 5637 Cell Line of Bladder Cancer through Glycolytic Pathway. 2022 , 2022, 1-9	1
90	Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis.	1
89	A Causal Framework for Making Individualized Treatment Decisions in Oncology. 2022 , 14, 3923	0
88	Treatment Strategies for Residual Disease following Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer. 2022 , 29, 5810-5822	0
87	Advances of Epigenetic Biomarkers and Epigenome Editing for Early Diagnosis in Breast Cancer. 2022 , 23, 9521	2
86	Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers. 2022 ,	0
85	TUMOR IMAGING AND THERAPY. 1993 , 31, 859-879	2
84	Annexin A2 (AnxA2) association with the clinicopathological data in different breast cancer subtypes: A possible role for AnxA2 in tumor heterogeneity and cancer progression. 2022 , 308, 120967	0

83	Next-generation sequencing, should I use anti-HER2 therapy for HER2-amplified tumors off-label? Illustrating an extrapolation framework. 2022 , 14, 175883592211128	0
82	Neem Leaf Glycoprotein in immunoregulation of cancer. 2022 ,	0
81	Regulation of Signaling from the Epidermal Growth Factor Family.	0
80	Regulation of Signaling from the Epidermal Growth Factor Family. 2022 , 126, 7475-7485	0
79	Clinical-radiomics nomogram for identifying HER2 status in patients with breast cancer: A multicenter study. 12,	1
78	Pan-cancer gene expression analysis of tissue microarray using EdgeSeq oncology biomarker panel and a cross-comparison with HER2 and HER3 immunohistochemical analysis. 2022 , 17, e0274140	1
77	Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies. 13,	2
76	Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world. 9,	0
75	HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment. 10,	0
74	Emerging Targeted Therapies for Early Breast Cancer.	0
73	Cost-effectiveness analysis of neratinib plus capecitabine against lapatinib plus capecitabine for HER2-Positive metastatic breast cancer.	0
72	Molecular and clinicopathological characteristics of ERBB2 gene fusions in 32,131 Chinese patients with solid tumors. 12,	0
71	Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers. 2022 , 244, 114775	1
70	Preoperative Systemic Therapy for Breast Cancer. 2022 ,	0
69	Antitumor activity of the protein kinase inhibitor 1-(β -D-2'-deoxyribofuranosyl)-4,5,6,7-tetrabromo-1H-benzimidazole in breast cancer cell lines. 2022 , 22,	0
68	Squalamines in Blockade of Tumor-Associated Angiogenesis and Cancer Progression. 2022 , 14, 5154	0
67	Molecular Biology, Genetics, and Translational Models of Human Cancer. 1-34	0
66	Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine. 2022 , 10, 2654	0

65	Cancer Metabolism. 1-14	0
64	Aberrant Signaling Pathways in Cancer. 1-10	0
63	Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. 2022 , 10, e005119	1
62	Precision medicine: the precision gap in rheumatic disease.	2
61	Monoclonal Antibody and Targeted Toxin Therapy. 1-31	0
60	Screening, Docking, and Molecular Dynamics Study of Natural Compounds as an Anti-HER2 for the Management of Breast Cancer. 2022 , 12, 1729	0
59	A Randomized, Single-dose, Phase I Clinical Comparison of a Trastuzumab Biosimilar With a Reference Trastuzumab Formulation in Healthy Chinese Male Volunteers.	0
58	Genes and cancer: Genetic counselling and clinical management. 2023 , 521-559.e6	0
57	The potential of mRNA expression evaluation in predicting HER2 positivity in gastroesophageal cancer. 55,	0
56	Molecular Mechanisms of Breast Cancer Metastasis.	0
55	Netrin-4: Focus on Its Role in Axon Guidance, Tissue Stability, Angiogenesis and Tumors.	0
54	HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry. 2022 , 22,	0
53	Targeting HER2-positive breast cancer: advances and future directions.	3
52	Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population.	0
51	Spontaneous Transformation of a p53 and Rb-Defective Human Fallopian Tube Epithelial Cell Line after Long Passage with Features of High-Grade Serous Carcinoma. 2022 , 23, 13843	0
50	Prognostic Variables in Male Breast Cancer. 2000 , 66, 502-511	4
49	HER2-low breast cancer: Novel detections and treatment advances. 2023 , 181, 103883	0
48	Human proto-oncogene promoters. 2023 , 123-139	0

47	Synthesis and in vivo evaluation of [¹¹ C]tucatinib for HER2-targeted PET imaging. 2023 , 80, 129088	1
46	RNA biomarker discovery and validation. 2023 , 723-742	0
45	Pharmacogenomics and Cancer Treatment. 2022 , 1-16	0
44	Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer. 2022 , 14, 5678	0
43	Classification of breast cancer subtypes based on RNA profiling and immunohistochemical methods: clinical and biological aspects: A review. 2022 , 24, 351-354	0
42	Lateral Flow Assays for Detection of Disease Biomarkers. 2022 , 115206	0
41	A Novel Mechanism Underlying the Inhibitory Effects of Trastuzumab on the Growth of HER2-Positive Breast Cancer Cells. 2022 , 11, 4093	0
40	Current progress in the development of prophylactic and therapeutic vaccines.	1
39	Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases.	0
38	Translational Results of Zo-NANTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer. 2022 , 23, 15515	0
37	Novel Approaches for the Solid-Phase Synthesis of Dihydroquinazoline-2(1H)-One Derivatives and Biological Evaluation as Potential Anticancer Agents. 2022 , 27, 8577	0
36	Quantification of the growth suppression of HER2+ breast cancer colonies under the effect of trastuzumab and PD-1/PD-L1 inhibitor. 12,	1
35	Diastolic heart failure is a new clinical entity of trastuzumab-induced cardiotoxicity: a case report. 2022 , 7,	0
34	Upregulation of SCD1 by ErbB2 via LDHA promotes breast cancer cell migration and invasion. 2023 , 40,	0
33	Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. 2022 , 29, 9891-9895	0
32	Cancer Vaccines for Triple-Negative Breast Cancer: A Systematic Review. 2023 , 11, 146	1
31	A Single-Chain IL-12 IgG3 Antibody Fusion Protein Retains Antibody Specificity and IL-12 Bioactivity and Demonstrates Antitumor Activity. 1999 , 163, 250-258	12
30	Distinct Clinicopathological Features and Prognostic Values of High-, Low-, or Non-Expressing HER2 Status in Colorectal Cancer. 2023 , 15, 554	0

- 29 The Field-Dependent Nature of PageRank Values in Citation Networks. ○
- 28 Aptamers in Cancer Therapy: Problems and New Breakthroughs. ○
- 27 TDM-1 en c ncer de mama metast tico her2 positivo. **2022**, 21, ○
- 26 An Atypical Rash on the Chest. ○
- 25 Cardiac Tamponade in Patients With Breast Cancer: A Systematic Review. **2022**, ○
- 24 The HER2-low revolution in breast oncology: steps forward and emerging challenges. **2023**, 15, 175883592311528 ○
- 23 HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC. ○
- 22 Trastuzumab emtansina (T-DM1) en c ncer de mama HER2 positivo. **2013**, 18, ○
- 21 Breast Cancer Disease Exploitation to Recure a Healthy Lifestyle. **2022**, 2617-2635 ○
- 20 MULTIMODALITY TESTING OF HER2/NEU MARKER IN BREAST CANCER: A CORRELATIVE STUDY. 1413-1443 ○
- 19 Molecular Testing for Diagnostics, Prognostication, and Treatment Stratification in Cancers. **2023**, 29, 3-8 ○
- 18 HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study. **2023**, 30, 343-353 ○
- 17 HER2-low status may predict poor neoadjuvant chemotherapy response in HR-negative breast cancer: a real-world multicenter study. ○
- 16 HER2 Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review. **2023**, 24, 3590 ○
- 15 Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. ○
- 14 Cancer immunotherapies: A hope for the incurable?. 3, ○
- 13 CD98 regulates the phosphorylation of HER2 and a bispecific anti-HER2 / CD98 antibody inhibits the growth signal of human breast cancer cells. ○
- 12 Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer. **2023**, 15, 1413 ○

- 11 Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review. **2023**, 115, 102527 ○
- 10 Ex vivo expansion of circulating tumour cells (CTCs). **2023**, 13, ○
- 9 Special Studies. **2013**, 279-304 ○
- 8 Sauchinone inhibits breast cancer cell proliferation through regulating microRNA -148a-3p/ HER -2 axis. ○
- 7 The tumor-nerve circuit in breast cancer. ○
- 6 The Role of Genetic Mutations in Mitochondrial-Driven Cancer Growth in Selected Tumors: Breast and Gynecological Malignancies. **2023**, 13, 996 ○
- 5 Health-related quality of life in Her2-positive early breast cancer woman using trastuzumab: A systematic review and meta-analysis. 14, ○
- 4 Deep learning radiomics model based on breast ultrasound video to predict HER2 expression status. 14, ○
- 3 High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database. 1-12 ○
- 2 Understanding the activity of antibodyâdrug conjugates in primary and secondary brain tumours. ○
- 1 Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations. ○